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Chapter 1
Introduction
1.1 Barriers inhibiting drug delivery to the brain
Systemic drug delivery to the brain is a difficult challenge for modern drug development.
For an effective treatment of diseases in the CNS drugs have to overcome several barriers
including the blood-brain barrier and the blood-cerebrospinal fluid (CSF) barrier. If the
target of intracranial drug delivery is a CNS tumor an additional barrier, the blood-tumor
barrier has to be considered.
1.1.1 The Blood-Brain Barrier
The general concept of a restriction on the passage of dissolved substances out of the
blood into the brain was first postulated by Paul Ehrlich (Ehrlich 1902). Edwin Gold-
mann, a student of Paul Ehrlich, injected the dye trypan blue into the CSF and the
dye stained only the brain but not the other organs (Goldmann 1909). This experiment
together with the studies of Romanowsky, who used Prussians’ blue as a reagent in the
late 1890s (Brightman 1992), established the concept of the blood-brain barrier (BBB).
The cytoarchitecture of the BBB was discovered in the late 1960s by means of electron
microscopic studies (Miller 2002).
The BBB is build up by the endothelial cells of the brain capillaries (Fig. 1.1). Astro-
cytes, microglial cells, pericytes and nerve endings surrounding the capillaries are consid-
ered to be essential for the differentiation of the endothelial cells and the maintenance of
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the barrier (Abbott 2002, Brightman 1992, Rubin and Staddon 1999). Astrocytes are the
structural frame of the neurons and their adjoining foot processes fully encapsulate the
capillaries (Lo et al. 2001). Furthermore, they are necessary for the expression of vari-
ous growth factors and transport systems such as the glucose transporter GLUT1 (Janzer
and Raff 1987). Microglia and pericytes derived from mononuclear blood macrophages en-
hance the BBB function and are conducive to modulatory signaling (Zenker et al. 2003).
Axonal endings that are closely abutted to the endothelial cells, are considered to be
important for BBB permeability (Rennels et al. 1983).
pericyte
endothelial cell
extracellular matrix
axonal ending
astrocytic
foot process
microglial
cell
tight junction
Figure 1.1: Schematic diagram of the cells forming the BBB. Endothelial cells of brain capil-
laries are sealed by tight junctions. These cells are surrounded by pericytes and
foot processes of astrocytes responsible for the structural integrity of the barrier.
The microglial cells are part of the immune system due to their descent from
macrophages. Axonal endings provide vasoactive neurotransmitters which are im-
portant for BBB permeability (from Begley (2004)).
Brain capillaries have a total length of more than 600 kilometers through the human
brain, a total surface area of 12 m2 (Misra et al. 2003, Miller 2002) and are much smaller
in diameter as well as thinner walled compared to vessels in other organs. The typical
characteristics of blood vessels such as intercellular clefts, pinocytosis and fenestrae are
not found in brain capillaries. The endothelial cells form intercellular tight junctions
(zona occludes) that completely seal the capillaries and close the paracellular pathway
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(Brightman and Reese 1969, Saunders et al. 1999, Fenstermacher 2001). Several trans-
membrane proteins, particulary occludin and claudin, are responsible for the formation of
the junctions by complex interactions with each other (Kniesel and Wolburg 2000). The
high seclusiveness of the brain to the other organs and the blood circulation results in an
extremely high trans-endothelial electrical resistance of 1500 to 2000 Ω·cm2 (Butt et al.
1990). Moreover, the brain capillaries are identified by limited paracellular transport due
to the low endocytic activity and the absence of fenestration (Kemper et al. 2004a).
All these properties of the endothelial cells contribute to a strongly restricted per-
meability of the BBB, which is required to protect the brain against foreign and toxic
substances as well as neurotransmitters and hormones (van Asperen et al. 1997). Ad-
ditionally, the relative impermeability supports the maintenance of a constant internal
environment, which is very important for proper neuronal function in the brain. Also, the
composition of the resulting extracellular fluid of the brain parenchyma can be precisely
controlled (Begley 2004). Due to the limited access of substances to the brain, only small
lipid soluble compounds can cross the BBB by passive diffusion. To enable the uptake
of essential polar substances into the brain, a lot of different transport proteins are ex-
pressed at the BBB (Begley 2003). These active transporters include carriers for glucose
and amino acids as well as receptor mediated systems for certain peptides such as insulin
or transferrin (Begley 1996). Fig. 1.2 shows different possible pathways through the BBB.
Apart from the transporters that are responsible for substance uptake into the brain,
two specific mechanisms exist at the BBB. which are concerned with the protection of
the brain. In order to degrade unwanted crossing substances the endothelial cells con-
tain a large number of degrading enzymes and a high density of mitochondria, which
are metabolically highly active organelles (Misra et al. 2003, Brownlees and Williams
1993). The high ability of the BBB to detoxify and transform compounds has been un-
derestimated in the past. Furthermore, active efflux transport proteins are expressed
at high concentrations at the luminal or basolateral membrane of the endothelial cells
such as ABCB1 (p-glycoprotein 170), ABCC1 (MRP1) and ABCG2 (BCRP) and are
able to transport a broad variety of compounds against a concentration gradient from the
endothelial cytoplasm back to the lumen of the brain capillaries (Ramakrishnan 2003).
These efflux transporters are described in detail in chapter 1.3.
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Figure 1.2: Possible routes for transport across the BBB. (A) Cells, particularly leukocytes,
cross the BBB adjacent to tight junctions or directly. (B) The most common
pathway for compounds is passive diffusion. (C) However, passively transported
substances may be carried out by active efflux pumps. (D) Carrier mediated influx
is used by essential polar solutes such as glucose. (E) Macromolecules, e.g. insulin,
are transported by specific receptors. (F) Alternatively, adsorptive mediated trans-
cytosis may occur induced by negatively charged macromolecules (from Begley
(2004) with modifications).
1.1.2 The Blood-CSF Barrier
The most important function of the choroid plexus is the secretion of CSF. To produce
this fluid, a broad variety of nutrients and other blood borne solutes are necessary. Since,
however, molecules can be exchanged between the CSF and the interstitial fluid of the
brain parenchyma (Misra et al. 2003), the uptake of these solutes into the CSF has to
be controlled in order to restrict the penetration of cytotoxic agents or other unwanted
substances into the brain. This is done by the blood-CSF barrier (BCB) which is formed
by the epithelia of the choroid plexus and the circumventricular organs (CVO) (Wolburg
et al. 2001). Furthermore, the arachnoid membrane is also involved in the function of the
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BCB (Siegal 2001). The arachnoid membrane consists of a double layer of ependymal
cells between dura and pia mater. Tight junctions between the ependymal cells seal the
arachnoid membrane against the paracellular pathway. Also, the epithelial cells of the
choroid plexus, arranged in a close sheet, form tight junctions to prevent macromolecular
diffusion into further brain regions. However, these epithelial-like cells show a lower
resistance of approximately 200 Ω·cm2 compared to the endothelial cells of the BBB
(Misra et al. 2003). Moreover, paracellular diffusion is impeded at the CVO due to
the occurrence of tight junctions between the ependymal cells surrounding the CVO. To
enable the passage of peptides, ions and further nutrients from blood into the CSF, the
capillaries of the choroid plexus and the CVO are fenestrated and non-continuous. Due
to the sealed paracellular pathways at the surrounding epithelia, exchange of molecules
can only occur in a small restricted area of the extracellular fluid immediately around the
CVO. Within this limited volume, the activity of dendritic processes and neuron receptors
can be influenced by blood borne compounds leading to certain neural impulses in distant
brain areas (Begley 2004).
However, the surface area of the BCB is approximately 1,000 fold smaller compared
to the BBB surface area (Pardridge 1997). Hence, drug entry to the brain via the BCB
plays a secondary role in brain drug uptake (Rautio and Chikhale 2004).
1.1.3 The Blood-Tumor-Barrier
Although in brain tumors the BBB is at least partly disrupted, other barriers together
with the physiological conditions in the brain tumor tissue such as abnormal blood capil-
laries, hamper effective drug delivery to the tumor. In contrast to brain capillaries, the
blood capillaries within different regions of the tumor tissue show significantly different
morphology (Schlageter et al. 1999, Siegal 2001). These changes include alterations in
the tight junction structure and the irregular appearance of endothelial cells with either
many fenestrations, increased pinocytosis or a totally irregular basal membrane (Bart
et al. 2000). The inconsistent spatial density of the capillaries together with the decreased
vascular surface compared to the tumor volume contribute to an insufficient brain tumor
drug delivery. Furthermore, tumor blood capillaries are sometimes leaky, leading to an
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accumulation of interstitial fluid and hence, an increase of the interstitial tumor pressure
(Jain 1994). The high intratumoral pressure limits drug penetration into the tumor tissue
and could effect the drug permeability of capillaries in tumor adjacent regions of normal
brain, resulting in low extratumoral interstitial drug concentrations (Cornford et al. 1982).
The term blood-tumor barrier includes all aforementioned aspects of drug delivery to brain
tumors.
1.2 Drug delivery into the brain: different approaches
to overcome the BBB
Drug delivery to the brain is a major challenge in brain disease treatment nowadays. There
are various strategies to circumvent the aforementioned barriers in order to increase drug
concentrations in the brain. Generally, the majority of these strategies can be classified
in four categories: direct manipulation of the drug itself, disruption of the BBB, direct
brain delivery, and alternative drug delivery routes.
1.2.1 Improvement of the physicochemical properties
The common requirements to a compound for penetration through the BBB are a low
molecular mass between 150 and 500 Da and an optimal log Po/w between 1.5 and 2.5
(Madrid et al. 1991). Furthermore, the compound has to be uncharged at physiological
pH 7.4. Due to the clear relationship between lipophilicity and CNS penetration (Levin
1980), small chemical modifications to compounds that normally do not cross the BBB
should lead to lipophilic analogs with the desired characteristics for penetrating the BBB.
Besides the increased log Po/w values, the circulatory half life of such compounds may be
prolonged and the plasma AUC may be increased, resulting in higher drug concentrations
that are available for brain uptake.
However, increasing the lipid solubility often achieves reversed effects on drug uptake
into the brain. Improvement of the lipophilicity leads to decreased solubility and unavail-
ability. Moreover, the plasma protein binding of such modified compounds is increased,
resulting in lower drug concentrations in the brain and in enhanced systemic toxicity. In
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addition, the activity of the drug is influenced by its poor solubility in the interstitial
fluid. This was demonstrated with BCNU analogs (reviewed by Pardridge (1988)). The
antineoplastic activity of the different derivatives was inversely proportional to their lipid
solubility.
Although a compound is sufficiently lipophilic to penetrate the BBB, sometimes no
enhanced brain accumulation is observed. Then, the compound is a substrate of an efflux
transporter located at the BBB (see 1.2.6 and 1.3). Today it is possible to predict the
permeability of compounds and their lipophilic analogs by use of computation techniques.
However, these programs provide no information about the affinity of the compounds to
certain efflux transporters.
1.2.2 Prodrugs
An alternative approach to improve the delivery to the brain is the preparation of pro-
drugs, e.g. by esterification of carboxylic acid containing drugs. These prodrugs contain
the drug in pharmacologically inactive or only weakly active form, but show improved
physicochemical properties such as increased lipophilicity for an enhanced BBB penetra-
tion of the drug. The transformation of the prodrug in its active form requires a transient
chemical or biochemical modification that should take effect solely in the desired organs
(Stella et al. 1985). In case of drug delivery to the brain, the active compound is more
polar compared to the prodrug and thus, trapped inside the brain after conversion. Then,
the brain concentrations of the compound remain high although the prodrug levels in the
blood significantly decrease. The brain delivery of heroin is a good and well known ex-
ample for the prodrug approach. The structure of heroin is similar to morphine as heroin
contains two further acetyl groups leading to an enhanced lipid solubility compared to
morphine. The brain accumulation of morphine is about 30 times lower compared to that
of heroin (Begley 2004). Inside the brain, however, heroin is transformed to 6-acetyl mor-
phine and subsequently metabolized to morphine which is trapped in the brain because
of its hydrophilicity. Morphine is the active form that interacts with the opioid receptors.
Hence, heroin is a prodrug form of morphine.
However, the use of prodrugs for brain delivery has its limitations. Besides an en-
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hanced brain uptake the prodrug accumulates in other tissues resulting in an increased
tissue burden. This loss of selective drug delivery is critical, particularly in case of steroids
and cytotoxic agents. Furthermore, the prodrug could be metabolized into other active
compounds than the desired one, which may enhance the toxicity of the compound. There-
fore, the required metabolic transformations to produce the active compound have to be
seriously considered.
1.2.3 Chemical drug delivery systems
The concept of a chemical drug delivery system was developed from the prodrug approach.
The drugs used for this system consist of several additionally attached moieties that are
introduced into the molecule to improve lipid solubility, protect certain functions of the
molecule, and prevent premature metabolic degradation. Furthermore, another moiety is
attached to the molecule to target the drug to a specific tissue. This targeting aspect is
the major difference to the prodrug concept. Drug modifying and targeting functions can
be fulfilled by the same moiety. Once at the targeted tissue, the active drug is released
from the system by several enzymatic processes. Bodor and Brewster (1991) developed
a chemical delivery system that can be used for brain drug delivery (see Fig. 1.3). 1-
Methyl-1,4-dihydronicotinic acid was covalently linked to a drug by esterification. Due to
the enhanced lipophilicity by the attachment of the nicotinic acid derivative, the drug is
able to penetrate the BBB and accumulate in the brain. Inside the brain parenchyma,
the dihydronicotinic acid moiety of the drug is enzymatically oxidized to the quaternary
salt by the NAD+/NADH coenzyme system. The charged drug is locked in the CNS and
subsequently, the active form is released slowly from the attached moiety by hydrolysis.
However, the modified drug distributes not only in the brain, but also in various other
organs. Since the conversion to the salt form takes place ubiquitously in the body, the
oxidized salt that is present outside the brain will be rapidly eliminated from the body
by liver and kidney. Hence, the use of this chemical delivery system leads to a sustained
and brain-specific drug accumulation. Due to the accelerated systemic elimination of the
charged drug in the periphery, the systemic toxicity is reduced. Furthermore, since the
majority of the drug in the brain is present in the inactive form, the central toxicity of
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and accelerated elimination in the periphery (adopted from Bodor and Brewster
(1991)).
the drug is lowered as well. During the last decade, variations of chemical drug delivery
systems were developed such as anionic or redox chemical delivery systems. This approach
to brain drug delivery is established for various drug classes such as chemotherapeutic
agents (Bodor and Buchwald 1999) or estrogens (Bodor and Buchwald 2002).
1.2.4 Carrier- and receptor mediated transport
A broad variety of transporters, carriers, and certain receptors is localized at the BBB.
They all are responsible for the uptake of polar metabolites and nutrients that normally
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have no access to the brain (Begley and Brightman 2003). These transport pathways
through the BBB can be utilized to enhance the brain concentration of certain com-
pounds. Therefore, the stereochemical transport requirements for transport by these
carrier systems has to be known in order to use this pathway for compounds that can act
as pseudosubstrates (Tamai and Tsuji 2000).
The carrier systems at the BBB include hexose transporters (Pardridge et al. 1990a),
the large neutral amino acid transporter (LAT) (Boado et al. 1999), acidic and basic amino
acid transporters (Smith 2000), tricarboxylic acid transporters (Walker et al. 1994), nucle-
oside transporters (Schaddelee et al. 2003), and peptide transporters (Tsuji 2000). There
are transport systems with a very high substrate selectivity such as the hexose trans-
porter GLUT1 or the nucleoside transporter, that accept only a very restricted amount
of compounds. In contrast, the LAT is less specific for its substrates and accepts the
widest variety of pseudosubstrates (Begley 2004). The substrates of the LAT require only
a carboxylic acid group and an amino group covalently linked to the same carbon atom,
or a conformation that is similar to this grouping. Furthermore, a LAT substrate needs a
large hydrophobic side to ensure the correct alignment of the compound to the active site
of the transporter (Smith and Stoll 1999). The anticancer drug melphalan, a derivative
of L-phenylalanine, shows only low affinity for the LAT. Taken the structure transport
relationships of LAT into account for the synthesis of a melphalan derivative with higher
affinity to LAT, the compound D,L-2-amino-7-bis[(chloroethyl)amino]-1,2,3,4-tetrahydro-
2-naphthoic acid (D,L-NAM) was developed which had a 100-fold greater affinity for LAT
compared to melphalan (Takada et al. 1992). The affinity of D,L-NAM for LAT is even
higher than that of endogenous substrates, leading to preferred transport into the brain.
In addition to the described transporters and carriers, certain receptor systems are
present at the BBB such as transferrin and insulin receptors. Also by means of transcytosis
mediated by these receptors, several proteins, peptides, and drugs can gain access to the
brain (see also chapter 8). BBB transcytosis can be mediated by either a receptor (RMT)
or by absorption (AMT) (Bickel et al. 1994). In case of RMT the compound has to bind
directly to the receptor at the luminal site of the capillary endothelial cells. The binding
induces internalization of the compound-receptor complex and leads to the formation of
a vesicle containing the complex. The vesicle can enter several pathways that carry it
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either to the abluminal site of the cell, where exocytosis of the compound takes place, or
to a lysosome to fuse forming a secondary lysosome. The latter pathway describes a dead
end and may lead to the degradation of the compound. If direct binding of a drug to
the receptor is not possible, the drug can be conjugated to a vector by chemical linkers
such as Traut’s reagent, polyethylene glycol (PEG) linkers or the avidin-biotin technique.
The effectiveness of this delivery approach was demonstrated for several peptide based
pharmaceuticals, such as vasoactive peptides (Pardridge 1999). Monoclonal antibodies
(MAb) that are directed to a certain receptor at the BBB are used as BBB transport
vectors. The most common MAb used in experimental studies is the OX26 MAb directed
to the rat transferrin receptor (Broadwell et al. 1996). Using the OX26 as a BBB transport
vector, specific accumulation of neuropeptides in the brain of rats was shown (Bickel et al.
1993). However, the capacity of RMT systems is very low as only one molecule can bind
to the receptor or the vector. Furthermore, the competition with endogenous substrates
for the receptors is a major drawback of this strategy particularly in case of direct binding
to the receptor.
The concept of absorption mediated transcytosis (AMT) is based on electrostatic in-
teractions between peptides or proteins and the luminal surface of the endothelial cells.
These charge interactions induce vesicle formation and internalization. This approach is
applicable for compounds with high positive charge as for example cationized albumin
(Pardridge et al. 1990b). Furthermore, the structure of the C-terminus and the basicity
of the molecule are important for brain uptake via AMT (Tamai et al. 1997).
1.2.5 Disruption of the BBB
Interference with the cytoarchitecture of the BBB is another approach that was developed
especially for the treatment of rapidly growing high grade glioma. Here, the function of
the tight junctions is disturbed and the BBB is transiently disrupted to open a paracellular
transport pathway for the enhanced access of systemically administered drugs. There are
several ways to open the BBB. The first attempts were done by infusion of dimethyl sulf-
oxide or ethanol. Also pathological conditions such as hypertension, hypoxia or ischemia
were induced at which disruption of the BBB was observed (Misra et al. 2003). However,
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all these techniques have unacceptable side effects.
In the 1970s Rapport et al. demonstrated the osmotic opening of the BBB which is
still applied in the treatment of human brain tumors (Rapoport et al. 1972, Rapoport
2000). An inert hypertonic solution is injected via the carotid artery. Generally, a 25 %
solution of mannitol is used for the BBB opening that is infused at a rate of 4 to 8 ml/sec
over a period of 30 min (Begley 2004). The hypertonic solution initiates shrinkage of the
endothelial cells, resulting in the disruption of the tight junctions and the opening of a
paracellular pathway for a few hours. Subsequently after the injection of the BBB opener,
the chemotherapeutic drug is administered by intraarterial injection. This method was
very successful in patients who failed systemic chemotherapy (Rautio and Chikhale 2004).
However, the opening of the BBB is nonselective and potentially neurotoxic compounds
can easily reach the brain leading to sometimes unreasonable toxicity. Furthermore, the
osmotic disruption enhanced the permeability of the tumor capillaries only by 25 %, in
contrast to a 10 fold increase in the permeability of normal brain capillaries (Neuwelt et al.
1994). The toxic vs. therapeutic ratio has to be carefully considered for the individual
patient.
The opening of the BBB using biochemical techniques is a more reliable alternative to
hypertonic solutions. This was demonstrated with an intracarotid infusion of leukotriene
C4 (Chio et al. 1992). Here, a selective opening of the tumor capillaries was observed. The
adjacent normal brain capillaries were not affected. An explanation of this phenomenon
may be the abundant expression of γ-glutamyl transpeptidase in normal brain capillaries,
which inactivates leukotriene C4 to leukotriene D4 (Black et al. 1994). This enzyme
is downregulated in damaged capillaries or brain tumor capillaries leading to elevated
vascular permeability mediated by leukotriene C4 in these regions. Further BBB openers
are bradykinin (Cloughesy and Black 1995) and the synthetic bradykinin analog RMP-7
(receptor mediated permeability; cereport; Emerich et al. (2001)). These substances act
on the B2 receptors that are expressed in the luminal membrane of the endothelial cells.
The stimulated receptors initiate an increase in intracellular free calcium, which leads to
an activation of the actin/myosin system within the cells. This activation influences the
scaffolding proteins (ZO1-3) that are attached to the tight junction proteins occludin and
claudin, resulting in a remove from the cell membrane and thus, modify the functionality of
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the tight junctions (Begley 2004). First promising results were obtained in the treatment
of glioma bearing rats with carboplatin and RMP-7 (Matsukado et al. 1996). In contrast
to leukotriene C4, this opening is unselective due to the overall distribution of B2 receptors
in the body which may again result in unwanted toxic side effects. Hence, phase II trials
on combination treatment of anticancer drugs with RMP-7 were aborted due to toxicity
concerns (Misra et al. 2003, Prados et al. 2003).
Also, allylglyceroles, particularly monoacetyl and diacetyl glycerols, are able to modu-
late the permeability of the BBB (Erdlenbruch et al. 2003a, Lee et al. 2002). They cause
a rapid opening of BBB that remains for up to 120 min. The most effective compound
is 1-O-hexyldiglycerol. A possible mechanism for this substance class is the formation of
vesicles at the cell membrane due to the detergent properties. Thus, pores are formed
through the plasma membrane leading to enhanced access of polar compounds to the
brain. Using this approach, Erdlenbruch et al. (2003b) were able to increase the delivery
of methotrexate to the rat brain without any signs of toxicity. However, this kind of BBB
opening is again unselective as both normal and tumor brain capillaries are affected.
1.2.6 Modulation of efflux transporters
Brain tumor therapy with cytostatic drugs that should be able to penetrate the BBB often
failed due to the extremely low drug concentrations in the brain. This is explainable by
the high affinity of these compounds to efflux transport systems that are localized at the
luminal membrane of the brain capillary endothelial cells, at newly formed capillaries of
brain tumors, and in the tumor cells themselves (Bendayan et al. 2002, Toth et al. 1996,
Matsumoto et al. 1991). These efflux transport proteins belong to the ABC transporter
class including ABCB1, ABCC1 and ABCG2. They are described in detail in chapter 1.3.
The major strategies to overcome the ABC transporter mediated efflux are the appli-
cation of specific inhibitors in addition to the effluxed compound, and the synthesis of
new drugs that lack the affinity to the ABC transport proteins. It is essential for both
approaches to know the detailed structure activity relationships of the ABC transport
mechanism. As these proteins do not show interactions with their substrates in a clas-
sic enzyme-substrate or lock-and-key manner, the determination of these relationships is
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hampered. Research effort was mostly directed to the inhibition of the ABCB1 transport
protein. Several ABCB1 inhibitors were developed in the past (Tan et al. 2000) that have
been shown to successfully enhance CNS concentrations of ABC transporter substrates
such as the anticancer agent paclitaxel (see Fig. 1.4). These inhibitors include the second
generation inhibitor valspodar (SDZ PSC 833, Fellner et al. (2002)) as well as the third
generation inhibitors elacridar (GF 120918, Kemper et al. (2003)) and zosuquidar (LY
335979, Kemper et al. (2004b)). One major problem of ABCB1 inhibitors, especially
of first and second generation compounds, is the lack of organ specificity. Valspodar,
for example, inhibits ABCB1 not only at the BBB but also in liver and kidney leading
to altered drug metabolism and excretion, and hence, to an increased systemic toxicity
of the co-administered drug. Furthermore, it influences the cytochrome P450 3A4 drug
metabolism, which contributes to the enhanced drug toxicity. Third generation inhibitors
have only a slight influence on this metabolism. Chemotherapy in combination with third
generation modulators should therefore be better tolerated by patients.
In case of the other two ABC transporters mentioned above, ABCC1 and ABCG2,
only a few specific inhibitory compounds are known so far. The leukotriene LTD4 re-
ceptor antagonist MK571 modulates the ABCC1 mediated drug efflux (Gekeler et al.
1995). The ABCG2 transporter is inhibited specifically by fumitremorgine C (Rabindran
et al. 2000). Some ABC transporter compounds show affinity to more than one transport
protein. Biricodar blocks both ABCB1 and ABCC1 drug transport (Litman et al. 2001),
whereas elacridar affects the transport activity of the ABCB1 and the ABCG2 transporter
(Kruijtzer et al. 2002). In contrast, valspodar and zosuquidar are specific inhibitors of the
ABCB1 efflux pump (Shepard et al. 2003). The difference between the efficacy of mul-
tispecific and single specific ABC transporter inhibitors in chemotherapeutic treatment
studies is part of ongoing research (Bardelmeijer et al. 2004, Kemper et al. 2004c).
Another approach to overcome the drug efflux mediated by the ABCB1 transporter is
the use of excipients such as pluronic block copolymers. Two mechanisms are suggested
to be involved in the interaction with the ABCB1 protein: depletion of cellular ATP
and alteration of physicochemical properties of the lipid membrane (Kabanov et al. 2003,
Fricker and Miller 2004). Pluronic P85 block copolymer was shown to be at least in part
responsible for the increase in opioid peptide analgesia in the mouse brain (Witt et al.
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Figure 1.4: Structures of different ABC transporter inhibitors.
2002). However, the inhibition of the ABC transporter mediated efflux that is counted
in the self-defense mechanisms of an organism, may lead to an enhanced access to the
brain for other toxic substrates resulting in neurotoxic effects. Hence, blockade of these
transport mechanisms should only be used for short term treatments.
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1.2.7 Liposomes and nanoparticles as carrier systems
The use of liposomes as a drug carrier system to increase brain drug concentrations is a
further development of the lipid analog approach. The drug is incorporated in a liposome
that is sufficiently lipophilic to cross the BBB. Liposomes have a size of up to 500 nm in
diameter and can incorporate large amounts of drug (up to 10,000 molecules). The drug is
released from the liposome at the desired tissue by degradation of the liposome. However,
to transport drugs into the brain using liposomes, the surface of the liposome has to be
modified with brain targeting vectors such as MAbs. Huwyler et al. (2002) demonstrate
the specific brain delivery of digoxin incorporated in modified immunoliposomes with the
OX26 MAb as brain targeting vector. As digoxin is a substrate of the efflux transporter p-
glycoprotein 170 (p-gp), incorporation in an immunoliposome is a possibility of bypassing
this efflux mechanism and enhancing brain concentrations of drugs that are normally
effluxed from the brain by p-gp. Further modification of the surface with PEG side
chains lead to a prolonged half life of the liposomes in the blood stream.
Nanoparticles were developed for the improvement of the stability of liposomes (Benoit
et al. 2000). They mostly consist of poly(butyl)cyanoacrylate (PBCA) and are normally
250 nm in diameter, which is a suitable size for intravenous injection. Nanoparticles
can be loaded by two different methods: the drug can be incorporated during the initial
particle polymerization or it can be absorbed on the nanoparticle surface (Begley 2004).
After drug loading, the nanoparticles are coated with Tween 80 (Ramge et al. 2000). The
coated particles preferentially absorb the plasma protein ApoE from blood plasma after
intravenous injection. With the attached ApoE, the nanoparticles appear to imitate LDL
particles and are recognize by LDL-receptors at the BBB, leading to internalization of the
nanoparticles (Kreuter et al. 2002; 2003). Using this approach, drugs such as doxorubicin
or dalargin are successfully delivered to the brain (Gulyaev et al. 1999, Alyautdin et al.
1995). Moreover, chemotherapy of glioma bearing rats with nanoparticles containing
doxorubicin led to 40 % cure (Steiniger et al. 2004). Two requirements for the design of
appropriate nanoparticles are deducible from the published experiments. The carrier has
to provide long lasting circulation of the particle in the blood stream. Also the surface
has to be modified with certain characteristics that enable specific interactions with the
targeted cells.
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1.2.8 Direct intracerebral delivery
The most obvious way of increasing drug concentrations inside the brain is the direct
injection of the drug into the brain or in case of a solid tumor into the brain tumor
parenchyma. Several methods including infusion of active agents or implantation of drug
loaded polymer wafers are available. The advantages of these techniques are the cir-
cumvention of the BBB and the low systemic toxicity. Furthermore, direct intracerebral
delivery is the sole method by which 100 % of the administered dose of a drug is delivered
to the targeted tissue.
Direct injection into the brain could be done intraventricularly, intrathecally or directly
into the brain parenchyma. These highly invasive approaches of brain drug delivery are
suitable for the treatment of primary brain tumors at best as these tumors rarely develop
systemic metastases. Intraventricular and intrathecal drug injection is performed into the
lumbar subarachnoid space or the cerebral ventricles. This kind of intracerebral injection
is used for patients with tumors developed at the CSF spaces or adjacent brain regions.
Of course, the injection of certain drug volumes damage the brain at least in an extension
of the administered volume. Moreover, the distribution of the drug in the brain is hardly
predictable due to interstitial pressure gradients, and the convection and diffusion of the
drug itself. Although the initial drug concentration is very high at the injection site after
the injection, it decreases very fast due to the steady turnover of newly secreted brain
extracellular fluid (Cserr and Patlak 1992). Even after intraventricular injection, the drug
is carried away by the continuous production of CSF by the choroid plexus (Begley et al.
2000). Hence, the administered drug volume has to be given via long term infusion.
Several infusion systems have been developed, the first in the late 1960s. This system is
called Ommaya reservoir (Ratcheson and Ommaya 1968). Here, an inert plastic reservoir
is implanted subcutaneously in the scalp and can be refilled by subcutaneous injection
of drug solutions. The drug is delivered from the reservoir to the targeted brain tumor
region through an outlet catheter by manual compression. Further infusion systems were
designed working with different pump mechanisms. The Infusaid pump (Chandler et al.
1988) uses compressed vapor pressure. A solenoid pump is part of the MiniMed PIMS
system (Lord et al. 1988) and in case of the Medtronic SynchroMed system (Heruth 1988),
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a peristaltic mechanism delivers the drug to the brain tissue. All mentioned infusion sys-
tems have successfully shown to provide high intratumoral drug concentrations of certain
anticancer agents such as doxorubicin or cisplatin (Walter et al. 1995) with only mild
side effects. However, infection and damage of brain parenchyma along the catheter, en-
hanced neurotoxicity and high discomfort for the patient limit the applicability of brain
drug delivery by infusion techniques.
Continuous drug delivery can also be achieved with implanted polymer matrices. Par-
ticularly after brain tumor surgery, the remaining space is packed with a drug loaded
implant that slowly releases chemotherapeutic agents for the treatment of remaining tu-
mor cells. The implants are based on lipid or polymeric materials such as polyanhydrides
that deliver the containing molecules at defined rates for specific periods of time. Also,
biodegradable polymeric implants such as the BCNU loaded Gliadel™ are introduced in
the chemotherapy of glioma. The use of Gliadel™ resulted in prolonged survival in pa-
tients with recurrent glioblastoma multiforma (Brem and Gabikian 2001). Despite this
encouraging improvement of brain drug delivery, brain implants are only useful in a very
limited number of patients due to diffusion problems. The chemotherapeutic agent that
is released by the polymer implant is only effective in the brain parenchyma directly
surrounding the implant. Krewson et al. (1995) proved this by examination of the con-
centration of a nerve growth factor adsorbed on a plastic disk in the rat brain. Even in
a distance of 1 mm from the disk the brain concentrations of the nerve growth factor are
undetectably low. Furthermore, interstitial therapy with implanted polymers may result
in an increased risk of local neurotoxicity. Also, once implanted in the brain, the release
of the drug from the matrix can not be controlled and breakdowns of polymer structures
followed by a complete release of drug may occur.
1.2.9 Brain drug uptake using the olfactory pathway
An alternative and interesting approach to deliver drugs to the brain is the use of the
olfactory pathway (Illum 2002). The intranasal route is based on the fact that olfactory
neurons that penetrate the cribriform plate are surrounded by a part of the arachnoid
membrane. A fraction of the CSF inside the arachnoid membrane flows into the local
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lymphatic system, but an other part of the CSF seems to be recirculated back into the
subarachnoid CSF. Compounds that are attached to the olfactory mucosa may be trans-
ported via this CSF fraction into the subarachnoid space (Begley and Brightman 2003,
Begley 2004). Besides this extraneuronal route, an intraneuronal pathway is postulated
by Illum (2003). According to this, the olfactory nerves themselves may carry drugs
by the retrograde axonal cytoplasmic flow into the brain. The intranasal approach is
a non-invasive and very fast transport way to the brain, as compounds administered to
the nose are detected in the brain within a few minutes (Sakane et al. 1991). Various
drugs have been transported to the brain using the olfactory pathway including sulfon-
amides (Sakane et al. 1991) and polypeptides such as insulin and hyaluronidase (Fehm
et al. 2000). Lipophilicity of a compound increases the intranasal transport indicating
the participation of a transmembrane movement in the drug transport process (Sakane
et al. 1991). Further investigations are required to elucidate the exact delivery process.
However, it is questionable, if the achieved brain concentrations are sufficient to achieve
therapeutic effects.
1.2.10 Alternative routes
Cell penetrating peptides. A relatively new research field regarding drug delivery to
the brain is the development of cell penetrating peptides. These peptides seem to wind
directly through the cell membrane without damaging the cell, similar to signal peptides.
The mechanism of this cell penetration is for the most part unknown. Several hypotheses
are described in the literature. According to Torchilin et al. (2001), the peptides initiate
the formation of reverse micelles in an energy independent process. In contrast, Richard
et al. (2003) suggest, that endocytic events are induced at the plasma membrane similar
to the interactions observed at AMT.
Cell penetrating peptides include TAT (transactivating-transduction) peptide that pen-
etrates the nuclear membrane by the process of replication of the HIV virus, and pen-
etratin. They characteristically consist of an amphiphatic α-helix as well as repeating
sequences of positively charged and lipophilic amino acids (Begley 1996). Schwarze et al.
(1999) demonstrate the transport of biologically active proteins such as the β-galactosidase
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protein across the BBB mediated by TAT in the mouse. When doxorubicin is linked to
penetratin, the doxorubicin brain concentrations are 3 to 8 times higher compared to
doxorubicin alone as shown in a rat in situ brain perfusion model (Rousselle et al. 2000).
Implanted biological tissue as drug distributor. This invasive technique uses the
naturally ability of certain tissues to produce the desired therapeutic agent. This tissue is
implanted in the brain to provide the required compounds. The success of this approach
was shown in the treatment of Parkinson’s disease (Madrid et al. 1991). However, a
major drawback is the low vascularization of the implanted foreign tissue resulting in a
reduced supply with nutrients and consequently in the decay of the transplanted tissue.
The survival of the implanted tissue may be improved by co-cultivation of certain cells.
Thus, two different types of cells are implanted in the brain, one for the expression of
the therapeutic agent and the second for the secretion of tissue stabilizing factors. Since
it is difficult to find cells that release appropriate compounds for the therapy of brain
diseases, an alternative method was developed. The cells are genetically modified to
express specifically active compounds. The success of the genetically modified tissue was
demonstrated in the treatment of gliomas (Lal et al. 1994).
1.2.11 Conclusion
The presented approaches to overcome the BBB and enhance intracranial drug concen-
trations are summarized with respect to their advantages and drawbacks in table 1.2.11.
The variety of the methods listed above reveals the current opinion about the BBB.
The BBB is no longer thought to be a static barrier between blood and CNS. In light of
the enormous knowledge about the BBB that was collected in recent years, the BBB is
considered a highly complex structure with bidirectional transport properties. The barrier
function and the activity can be modified by several factors and signals from CNS and
the blood.
Nowadays, the research for CNS active drugs as well as the development of brain drug
delivery systems is changing away from the mere synthesis of compounds and the direct
delivery of drugs irrespective of the applicability in the human body. Using the knowledge
from modelling techniques and modern cell biology methods, highly potent CNS active
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Table 1.1: Advantages and drawbacks of various invasive and non-invasive approaches for cir-
cumvention of the BBB.
Approach Advantages Drawbacks
invasive
direct bypass of BBB, immediate brain damage; neuronal
intracerebral high drug concentrations; toxicity; restricted
delivery controlled drug delivery to local therapy
non-invasive
improvement of increased lipophilicity leads to poor aqueous solubility;
physicochemical enhanced brain uptake peripheral distribution;
properties reduced therapeutic activity
prodrug trapping of active drug inside poor selectivity, poor
the brain after transformation retention; risk of toxic
of the prodrug metabolites
chemical drug site specific drug delivery; oxidative and hydrolytic
delivery systems slow and constant release of instability
active drug at targeted site
carrier- and utilization of endogenous similar structure to natural
receptor-mediated transport pathways; great substrate is needed;
transport variety of brain transport attachment of transport
vectors vectors alters drug activity
BBB disruption promising strategy for high unfavorable toxic/therapeutic
grade glioma therapy; ratio; breakdown of self-
selective BBB opening with defense mechanism of the brain
LTC4 derivatives
modulation of no modification of therapeutic opening not specific for
efflux transport agent; reduced side effects therapeutic agent;
proteins by third generation breakdown of self-defense
modulators mechanism
liposomes and capable for receptor-mediated modified surface required
nanoparticles transport through BBB (vectors, coating) for specific
brain delivery
agents may be developed. Furthermore, new or improved drug delivery systems based
on immunoliposomes and nanoparticles approaches as well as on RMT pathways, might
provide specific transport systems for brain drug delivery and thus, the treatment of brain
diseases in the future.
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1.3 ABC transporters
ABC transporters were first discovered in tumor cells in the 1970s when Dane demon-
strated the active outward transport of daunorubicin in drug resistant Ehrlich ascites
tumor cells (Dano 1973). The family of the ABC transporters is widely distributed from
bacteria to man (Holland et al. 2003). An ATP binding cassette (ABC) is characteristic
for these proteins. They transport a broad variety of compounds including amino acids,
peptides, and xenobiotics against a concentration gradient enabled by ATP hydrolysis
across biological membranes. ABC transporters are typically composed of two hydropho-
bic halves, each comprising six transmembrane domains, and two ATP binding domains.
The ATP binding domains are also termed as nucleotide binding domains (NBD) and
contain four motifs: Walker A, Walker B, Q-loop and H-loop (Higgins 1995, Linton et al.
2003). A diagnostic signature sequence called LSGGQmotif is located between the Walker
A and the Walker B region. It is unique for ABC transporters and highly specific for each
family. The transport proteins are clustered according to their LSGGQ motif by the hu-
man genome nomenclature committee (HUGO) creating the ABC nomenclature (Klein
et al. 1999). Table 1.2 provides an overview of three subfamilies of ABC transporters
(ABCB, ABCC and ABCG) and their most important members with respect to their lo-
calization in the human body, their substrate specificity, and the diseases that are linked
to these proteins.
P-glycoprotein 170 (p-gp, ABCB1), MRP1 (ABCC1) and a recently discovered protein,
called ABCG2 (MXR, BCRP), are the most important proteins of the three subfamilies
regarding the involvement in MDR. They are discussed concerning their predicted struc-
ture, their localization, their mode of action and their physiological role.
Structural data of these transport proteins were obtained from single-particle analysis
and electron crystallography leading to low-to-medium resolution structures with a reso-
lution of 10 to 25 Å (Rosenberg et al. 1997; 2001a). However, these structures are only
estimations. X-ray crystallographic data for a complete ABC transporter exist only for
the lipid transporter MsbA both from Escherichia coli (Chang and Roth 2001) and from
Vibrio cholera (Chang 2003), and for the Escherichia coli vitamin B12 transporter BtuCD
(Locher et al. 2002). As these proteins are homologous to the multidrug resistance ABC
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Table 1.2: Overview of the most important members of the ABC transporter subfamilies
ABCB, ABCC and ABCG.
member HUGO further main tissue substrates linked
term names localization disease
MDR1 ABCB1 PGY1, BBB, adrenal hydrophobic, MDR
p-gp cortex, kidney, amphiphilic drugs, resistance
liver, placenta, cationic organic in cancer
intestine compounds
MDR3 ABCB4 PGY3, liver phosphatidyl progressive
MDR2/ choline familial
MDR3 intrahepatic
cholestasis
MRP1 ABCC1 MRP, ubiquitous organic anions, MDR
GS-X glutathione resistance
conjugates in cancer
MRP2 ABCC2 COAT liver, similar to MRP1, Dubin-
intestine, non-bile salt Johnson
kidney organic anions syndrome
MRP3 ABCC3 cMOAT2, intestine, liver, glucuronide
MOAT-D, pancreas, bile salts
MLP2 kidney
MRP4 ABCC4 MOAT-B prostate, lung organic anions,
pancreas, testis, nucleoside
ovary, intestine analogs
MRP5 ABCC5 SMRP, ubiquitous similar to MRP4
MOAT-C
MRP6 ABCC6 ARA, liver, kidney, anionic peptides pseudo-
MLP1, xanthoma
MOAT-E elasticum
MRP7 ABCC10 liver, heart, glutathione
kidney conjugates
MXR ABCG2 BCRP, placenta, liver, mitoxantrone MDR
ABCP intestine, BBB, hydrophobic, resistance
breast amphiphilic drugs in cancer
transporters these structures are used for the elucidation of transport processes and sub-
strate recognition. Moreover, most research effort was done on p-gp. Therefore, the mode
of action and the transport of substrates by ABC transporters are discussed for p-gp.
24 Introduction
1.3.1 ABCB1 - P-glycoprotein 170
P-gp was first described by Juliano et al. in 1976, who found that chinese hamster ovary
cells selected for resistance to colchicine showed cross resistance to a broad range of drugs
(Juliano and Ling 1976). The authors detected a transport protein in the cell membranes
of the resistant cells that was not found in wild type cells and named it P-glycoprotein
170. Besides this localization at tumor cell membranes, where p-gp is responsible for the
development of multi drug resistance in chemotherapy, p-gp was found in several tissues
of the human body. It is expressed at the biliary canalicular membrane of hepatocytes as
well as at the brush border membrane of the intestinal epithelium (Thiebaut et al. 1987).
In kidney, abundant p-gp is found at the luminal membrane of the proximal tubules. In
liver, kidney and intestine, p-gp has excretory and detoxifying functions. Moreover, p-gp
is expressed in the brain. It was detected both in the choroid plexus (Rao et al. 1999)
and at the BBB (Thiebaut et al. 1989). The precise localization of p-gp at the BBB
is a topic of controversy. On the one hand, there is evidence for the expression of p-gp
at the luminal membranes of endothelial cells of the brain capillaries. Beaulieu et al.
(1997) detected strong enrichment of p-gp by Western blotting in brain capillary luminal
membranes, compared with brain capillaries (17-fold) and whole membranes (400-500-
fold). On the other hand, other work groups used the MRK-16 MAb against human p-gp
for the detection of the transport protein. According to their findings p-gp expression at
the BBB is similar to the localization of glial fibrillary acidic protein (GFAP) which is
found in astrocytes. Hence, they postulated that p-gp is localized at the astrocyte foot
processes (Pardridge et al. 1997). In the meantime several studies have demonstrated
that p-gp is co-localized at the astrocytes as well as at the luminal membrane of the
endothelial cells (Decleves et al. 2000). However, much more p-gp is expressed at the
endothelial cell membrane compared to astrocytes foot processes. Furthermore, the co-
cultivation of astrocytes and brain capillary endothelial cells (BCEC) in in vitro models
of the BBB led to an increased p-gp expression compared to BCEC monolayer models
indicating an important role of the astrocytes regarding the expression of p-gp (Gaillard
et al. 2000). Due to the localization of p-gp at the endothelial membrane of the capillaries
the role of p-gp is the protection of the brain from foreign and toxic compounds.
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Figure 1.5: Predicted membrane topology of human p-gp. The ABC transport protein p-gp is
thought to be organized in two hydrophobic halves, each half consisting of six TMDs
and one cytoplasmic ATP-binding domain (NBD). The protein is glycosylated at
three sites on the first extracellular loop.
A model for the predicted structure of p-gp is presented in Fig. 1.5. P-gp is a 170
kDa transmembrane protein that is encoded by the MDR1 gene. This gene consists of 27
exons distributed over 100 kb and is located on the long arm of chromosome 7 (Fardel
et al. 1996). The human p-gp is composed of 1280 amino acids. They are organized in two
halves each containing 610 amino acids in 6 hydrophobic transmembrane domains (TMD)
and one hydrophilic NBD. The protein is N-glycosylated on the first extracellular loop in
three different locations. This glycosylation appears to be necessary for the effectiveness
of the protein (Ramakrishnan 2003). The TMDs play an important role for the substrate
recognition as single mutations in all transmembrane regions affect the transport function
of the protein either directly through alteration of the binding site or by interference
in the conformational changes (Litman et al. 2001). Therefore, the binding sites are
broad interaction regions. Using photoaffinity labelling studies and epitope mapping with
iodomycin (Demmer et al. 1997) two major regions were identified within the TMDs: TMD
5 and 6 in the N-terminal half, and TMD 11 and 12 in the C-terminal half. However,
there are much more interaction points between substrates and amino acids. These are
particularly localized at TMD 4 and 10 and have been discovered by means of cysteine
scanning mutagenesis of all TMDs combined with thiol modification (Loo and Clarke
2000; 2001, Van Veem and Callaghan 2003). Within these TMDs, specific amino acids
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are responsible for substrate recognition. For example, charged substrates are able to
interact with the pi face of aromatic residues in tyrosine, phenylalanine and tryptophan.
This binding is as strong as electrostatic interactions between ion pairs (Dougherty 1996,
Kwan et al. 2000). Until now, at least four binding sites are identified by several work
groups (Martin et al. 2000, Ekins et al. 2002, Wang et al. 2003). These binding sites are
in part transport sites, but regulatory sites also exist. Both site types appear to switch
between high and low affinity conformations (Martin et al. 2000).
In contrast to the TMDs, the NBDs are not integrated in the process of substrate
recognition. NBDs are involved in the transport mechanism of ABC transporters. Liu
and Sharom (1996) demonstrated by 2-(4-maleimidoanilino)naphthalene-6-sulfonic acid
(MIANS) labelling of cysteine residues located within the Walker A motif of the NBD
that the NBDs change their positions relative to the cell membrane in the presence of p-gp
substrates. MIANS is fluorescent in an aqueous environment, but in lipophilic solutions
the fluorescence is quenched. Therefore, the quenching of the MIANS fluorescence during
the efflux process indicates conformational changes of the transporter including the NBDs.
These changes can be seen directly by cryo-electron microscopy of p-gp trapped in different
stages of the transport cycle (Rosenberg et al. 2001b). The energy for these changes which
are essential for the releasing of a compound, is provided by hydrolysis of ATP at the
NBDs. The binding and hydrolysis of ATP are crucial steps in the transport process,
which can be divided in four steps (see Fig. 1.6). First, the substrate has to be recognized
and bound by p-gp. ATP binds to one NBD in this first step. In the second step, ATP
hydrolysis at the NBD leads to the aforementioned conformational changes. The affinity of
the binding site is switched to the low affinity status and the drug binding site is oriented
to the extracellular site to release the substrate. Uptake of a second ATP molecule in
the third step results in a further conformational change at the NBD, whereas the drug
binding site remains in the low affinity status. In the last step after hydrolysis of the
second ATP molecule the protein returns to the original conformation with high affinity
status of the binding site to recognize a new substrate. ATP hydrolysis takes place during
the second and the fourth step. To supply the energy for the conformational changes of
the TMDs, the NBDs have to be in contact with the TMDs. This exchange takes places
via the intracellular loops (Van Veem and Callaghan 2003).
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Figure 1.6: Proposed mechanism of p-gp function. The ellipses represent the substrate-binding
face of the protein, the extra- and the intracellular location. The square describes
the intracellular site with reduced affinity. The NBDs are represented by two over-
lapping circles indicating that both sites are required for ATP hydrolysis (according
to Druley et al. (2001), Sauna and Ambudkar (2001)).
It is important to note that both NBDs are required for the efflux process. For a
complete transport cycle, both NBDs have to be activated by the binding of ATP, but
it is indifferent which NBD binds to ATP first. Sauna and Ambudkar (2000) proved
this by investigation of the affinity of [I125]iodoarylazidoprazosin for p-gp in the presence
of the nonhydrolyzable nucleotide 5’-adenylylimidodiphosphate and vanadate, as well as
for p-gp that is trapped in transition-state conformation by ADP and vanadate. The
affinity is clearly reduced (> 30-fold) to low affinity state if p-gp is trapped, whereas it is
not influenced by the nonhydrolyzable compounds. Furthermore, they found an inverse
correlation between ADP release and the recovery of substrate binding. Therefore, Sauna
et al. summarized that one ATP molecule is necessary for the efflux of a bound substrate
resulting in the aforementioned change to the low affinity status. In addition, a second
ATP molecule is required to reset the status of the binding sites to the high affinity
conformation in order to prepare the next catalytic cycle.
Three different models are described in the literature concerning the mechanism of
transport at the multiple drug binding sites of ABC transporters. The "altering ac-
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cess/single site model" (Bruggemann et al. 1992, Martin et al. 2000) suggests that the
sites are localized within a single binding region which is alternately oriented to the ex-
tracellular or to the intracellular site. Dey et al. (1997) postulated in the "fixed two side
model" the existence of two static binding regions. The high affinity "on"-site is located
in the C-terminal half of the protein, whereas the low affinity "off"-site is found in the
N-terminal half. The bound substrate moves from the "on" to the "off" site during the
first ATP hydrolysis. This model agrees well with the process of ATP hydrolysis described
by Sauna and Ambudkar (2000) mentioned above. Furthermore, the "altering two-site
(two-cylinder engine) model" is a combination of the aforementioned models; two distinct
binding regions are alternately exposed to the inner and outer membrane. Here, ATP
hydrolysis leads to simultaneous or sequential movement of the two regions (van Veen
et al. 2000). The differences between the three models may be related to the different
localization of the substrate binding sites.
The establishment of a complete transport model is difficult since many factors that
influence the transport function both directly and indirectly have to be taken into ac-
count. These factors include conformational changes, the existence of multiple binding
sites, the role of NBDs, as well as the variable effects of p-gp inhibitors (Litman et al.
2001). Nowadays, there is more knowledge about the number of binding sites, their in-
teractions among each other, and various pharmacophores of substrates. However, only
little research is focused on the reactions of the protein caused by substrate binding which
is important for the design of new modulators and for the development of agents with low
p-gp affinity.
1.3.2 ABCC1 - MRP1
MRP1 is a member of the largest subfamily of the ABC transporters. It was discovered
in HL60/ADR cells which did not overexpress p-gp, but showed a MDR phenotype (Mc-
Grath and Center 1987). The resistance was attributed to a 190 kDa protein and was
classified in the family of the ABC transporters due to its immunoreactivity with peptide
antisera directed at the conserved NBD of p-gp (Marquardt et al. 1990). The cDNA
of the new transport protein was isolated in 1992 by Cole et al. in the MDR resistant
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doxorubicin-selected human lung cancer cell line H69AR and was then designated as mul-
tidrug resistance-associated protein (Cole et al. 1992). In addition to the expression at the
cell membrane of tumor cells, MRP1 is localized at the basolateral membrane of epithelial
cells in all tissues in the human body (Ambudkar et al. 2003). It is also expressed at the
BBB together with MRP3 and MRP5 (Bart et al. 2000). However, MRP1 has only 15 %
homology to p-gp, but a higher relation to the cystic fibrosis transmembrane regulator
gene (CFTR). Also, within the MRP subfamily the sequence identity of MRP1 compared
to MRP2-6 ranges between 35 and 58 %, although the overall membrane topology appears
to be similar in this subfamily (Litman et al. 2001).
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Figure 1.7: Predicted structure model of the ABC transport protein MRP1. The protein con-
sists of 17 transmembrane domains that are organized in three groups. The orien-
tation of the two NBDs and the TMD 6 to 17 is similar to p-gp. Compared to the
p-gp structure five TMDs (1-5) are added resulting in an extracellular N-terminus.
The predicted structure of MRP1 consists of 1531 amino acids and 17 TMDs. These
are divided into three membrane spanning domains (MSD) in the following organization:
MSD1 (5 TMDs), MSD2 (6 TMDs), NBD1, MSD3 (6 TMDs), NBD2 (see Fig. 1.7). The
structure of MSD2 and MSD3 together with the NBDs is similar to p-gp. The additional
5 TMDs are attached to the N-terminus of this p-gp similar structure by a linker region
that seems to be necessary for the MRP1 mediated transport of organic anions (Bakos
et al. 1998). Hence, in contrast to p-gp, the N-terminus of MRP1 is oriented to the
extracellular site. MRP1 transports hydrophobic anions and drugs that are conjugated
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to glutathione, glucuronic acid or sulfate as well as exogenous compounds. MRP1 is
one of the best characterized proteins of this subfamily regarding its physiological role.
In tumor cells it is involved in the development of MDR. Due to its expression in liver,
kidney and at the BBB it is part of the self defense system of the human body against toxic
xenobiotics, particularly against anthracyclins, epipodophyllotoxins, vinca alkaloids and
camptothecins. These compounds are also substrates of p-gp, indicating a large overlap of
the resistance profiles of these transport proteins. Exceptions from this overlap are taxanes
which are specific substrates of p-gp. Glutathione and glucuronate conjugates are products
of the phase II metabolism. The role of MRP1 as an efflux pump which is responsible
for the cellular extrusion of these conjugates in phase II underlines the MRP1 function
as a cellular detoxifying factor (Kruh and Belinsky 2003). P-gp transports exogenous
compounds to the bile and intestine for elimination out of the body due to its luminal
localization. In contrast, MRP1 is expressed at the basolateral membrane resulting in the
transport into tissues beneath the basement membrane. Recently, a further key function
of MRP1 was discovered by Wijnholds et al. (1997). As mice lacking MRP1 show a
decreased inflammatory response and leukotriene C4 is a MRP1 substrate, MRP1 may
play a major role in the leukotriene depending inflammatory response.
The clinical relevance of MRP1 mediated efflux in cancer chemotherapy has not been
determined yet due to the broad variety of resistance factors that are found in tumor cells
and tissues with barrier functions in the human body (Kruh and Belinsky 2003). The
lack of specific MRP1 inhibitors contributes to this issue. Development of such inhibitors
and their application to clinical studies may help to elucidate the importance of MRP1
in MDR.
1.3.3 ABCG2 - BCRP
ABCG2 belongs to the "white subfamily" that is named after the white ABC transporter
gene in Drosophila melanogaster. This protein was discovered by three different work
groups in the late 1990s. Doyle et al. (1998) detected cross resistance to other anthracy-
clins than doxorubicin in multidrug-resistant human breast cancer MCF-7/AdrVp cells.
They postulated the existence of another efflux pump as the cells did not overexpress
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p-gp or MRP1 and contributed the observed resistance to a certain gene that was subse-
quently designated as breast cancer resistance protein (BCRP) gene. At the same time
this gene was cloned from human DNA sequences by searching for novel human ABC
transporter (Allikmets et al. 1998). Since the identified sequence is highly expressed in
placenta, the gene was named ABCP (ABC transporter highly expressed in placenta).
Also, a third work group was able to clone this gene from mitoxantrone-resistant S1-M1-
80 human colon carcinoma cells which lack the overexpression of p-gp and MRP1 (Miyake
et al. 1999). Due to the used anticancer drug for resistance, Miyake et al. called the gene
mitoxantrone resistance (MXR). In the following, the transport protein is designated as
ABGC2 according to the HUGO nomenclature.
ABCG2 is frequently observed in plasma membranes of tumor cells especially breast,
colon, gastric, lung and ovarian cancer cells (Maliepaard et al. 1999, Ross et al. 1999, Lit-
man et al. 2000). Inside the human body, the protein is found with the highest expression
levels in placenta and at lower levels in breast, liver, intestines, prostate and at the BBB
(Litman et al. 2001). The physiological role of ABCG2 is similar to that of p-gp and
MRP1. Due to its detection in multidrug resistant tumor cells, a part of the low response
rate to chemotherapy is attributable to this protein. ABCG2 plays an important role in
the natural defense mechanism against xenobiotic compounds because it is expressed in
tissues that are involved in excretion processes or have certain barrier functions like liver,
placenta and BBB (Cooray et al. 2002). The localization of ABCG2 in stem cells again
shows a protective function of this protein (Zhou et al. 2002).
ABCG2 is a 72 kDa half ABC transporter that consists of 655 amino acids. In contrast
to full length ABC transporters of other subfamilies, the domain orientation is reversed.
ABCG2 has one NBD located at the N-terminal site followed by six TMDs at the C-
terminal site (see Fig. 1.8). The largest extracellular loop is located between TMD 5 and
TMD 6 and is therefore a potential target for antibody recognition (Han and Zhang 2004).
The protein is heavily glycosylated. However, in contrast to p-gp, the glycosylation has
no influence on the transport function of ABCG2 since recombinant ABCG2 generated
in insect and bacterial cell is functional although it is unglycosylated (Janvilisri et al.
2003). In some cell lines expressing ABCG2 after selection with various anticancer drugs,
different substrate specificities were observed particularly concerning the transport of the
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Figure 1.8: Predicted membrane orientation of TMDs of human ABCG2. This half transporter
consists of six TMDs and one NBD. In contrast to the other ABC transporters, the
NBD is at the N-terminal end of ABCG2 leading to a reverse orientation of the
protein. ABCG2 is thought to act as a homodimer.
fluorescent dye rhodamine 123. This finding led to the detection of the mutation hot spot
Arg482 which is located at the start of TMD 3 and significantly affects the transport profile
of ABCG2 (Honjo et al. 2001). If this amino acid is replaced with glycine, threonine,
methionine or serine, the cells show higher resistance to anthracyclins, relatively lower
resistance to topotecan, and an enhanced efflux of rhodamine 123 (Han and Zhang 2004).
Honjo et al. (2001) suggested that the exchange of the amino acid at position 482 results
in an altered position of the TMD 3.
As ABCG2 is a half transporter, it must have a dimerization partner to fully achieve
effectiveness. There are several studies indicating that ABCG2 works as a homodimer
(Kage et al. 2002, Janvilisri et al. 2003). Janvilisri et al. expressed human ABCG2 in
the gram-positive bacterium Lactococcus lactis and were able to generate a functional
transport protein that could be inhibited by the potent ABCG2 specific modulator fu-
mitremorgine C. Therefore, the human protein has to function by itself inside the bac-
terium. Litman et al. (2002) used immunoblot analysis performed after treatment with
cross-linking reagents to demonstrate a molecular mass shift from 72 kDa to several bands
of 180 kDa and higher molecular mass. They postulated from these results that higher
forms of oligomerization may exist. Also, the possibility of the formation of heterodimers
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can not be excluded. This may also be possible with other members of the subfamily
such as ABCG1, a protein that is mostly expressed in lung, placenta and liver (Han and
Zhang 2004).
The clinical relevance of ABCG2 in cancer chemotherapy was proven in studies by
temporal inhibition of the ABCG2 function in patients in order to increase the availability
of orally administered anticancer drugs (Malingre et al. 2001). However, these studies
were conducted with the nonspecific modulator elacridar. Hence, development of new and
specific ABCG2 inhibitors may lead to an improvement of cancer chemotherapy regarding
higher bioavailabilities of anticancer drugs as well as the overcoming of MDR caused by
ABCG2. The elucidation of the drug binding sites and the dimerization domain will be
necessary for a more precise understanding of the function of the ABCG2 transporter.
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Chapter 2
Objectives
Up to now, the therapy of primary and secondary brain tumors still remains a major
problem in cancer chemotherapy. Although surgery and radiotherapy are becoming even
more effective and precise, cancer treatment with chemotherapeutic agents offers inter-
esting therapeutic approaches with a broad range of applications concerning brain drug
delivery (see introduction). However, an important obstacle in brain cancer chemother-
apy is the BBB, limiting the brain access of several highly potent anticancer drugs such
as paclitaxel or vinblastine by efflux transport proteins such as the P-glycoprotein 170
(p-gp). Very recently successful treatment studies on glioblastoma multiforma were done
by Fellner (2001) with a combination of the cytostatic agent paclitaxel and the p-gp in-
hibitor valspodar. In continuation of these investigations, the main goal of this thesis
was the further development of this treatment strategy, particularly with respect to sec-
ondary brain tumors from different lung cancer types due to the higher incidence of lung
carcinomas compared to primary brain tumors, and newly developed p-gp inhibitors.
Lung cancer cell lines had to be characterized in view of the establishment of tumor
models in animals. The examinations comprise the determination of cell proliferation
characteristics and chemosensitivity of the lung cancer cell lines against several cytostatic
agents (see chapter 3).
To determine the potency of p-gp inhibitors and the p-gp activity of cells, a fluorescence
assay based on calcein-AM can be used. The establishment of this assay system is part
of preliminary investigations of this thesis (see chapter 4).
The lung cancer cells had to be investigated with respect to their suitability for sim-
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ulating brain metastases in nude mice. Subsequently, the aforementioned combinatory
approach should be applied to the resulting tumor models using the well established p-gp
inhibitor valspodar and appropriate anticancer drugs due to the chemosensitivity deter-
mined in the first part of the project (see chapter 5).
Recently, new p-gp inhibitors were developed, designated as elacridar and tariquidar,
which are described as more selective for p-gp at the BBB and should lead to better
tolerated treatment in combination with anticancer drugs. The two compounds had to be
characterized in vitro with respect to their p-gp inhibition activity and their selectivity
for other efflux transporters and had to be compared to valspodar (see chapter 6). In case
of higher potency of the two new modulators regarding the inhibition of p-gp activity
in vitro, the ability of elacridar and tariquidar to block p-gp at the BBB resulting in
higher cytostatic drug concentrations in the brain should be examined in comparison to
valspodar in order to get information about a possible improvement of the therapy by a
combination treatment with the new modulators (see chapter 7).
In addition to the investigation of the inhibition of efflux transporters at the BBB, an-
other part of the thesis was concerned with the transferrin receptor mediated transcytosis
at the BBB as a method to increase intracerebral drug concentrations. For this purpose,
a model of primary brain tumors in nude rats had to be established that should enable
treatment studies with immunoliposomes targeted to the transferrin receptor both at the
BBB and in tumor cells (see chapter 8).
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Chapter 3
Characterization of human lung cancer
cell lines
3.1 Introduction
Malignant tumors of the lung were the most common form of cancer and the most common
cause of cancer death in the world in the year 2000 in the male population according to
the WHO (Globocan 2000). These tumors are subdivided into two classes, the small cell
lung cancers (SCLC) and the non-small cell lung cancers (N-SCLC) comprising adenocar-
cinoma, squamous cell carcinoma and large cell carcinoma (Travis et al. 1999, Mitsuuchi
and Testa 2002). N-SCLC, which amounts to 80 % of the cases includes various histo-
logical subtypes depending on the origin in the lung, whereas SCLC is relatively undif-
ferentiated. The latter tumors, except for the bronchial carcinoids, a rare form of SCLC,
are characterized by a rapid growth, the ability to metastasize early and the expression
of neuroendocrine markers, e.g. adrenocorticotropin (ACTH), bombesin and calcitonin
(Hay et al. 1994). The prognosis to recover from lung cancer, irrespective of histological
classification, is very poor as the 5 year survival amounts to 15 % (Van Houtte and Albain
1999). Nowadays the therapy of lung cancer is based on three modalities of treatment:
surgery, radiation and chemotherapy.
For chemotherapy various cytostatic drugs, e.g. cisplatin and vinorelbin for the treat-
ment of advanced N-SCLC (Wozniak et al. 1998), are combined and radiation is often
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added to polychemotherapy (Eberhardt et al. 1998). However, combination therapies
often prolong the patient’s life for several months only. The tendency of the tumor to
metastasize to the brain is another problem of the therapy as 50 % of all brain metas-
tases derive from lung cancer (Staab and Drlicek 1988). The treatment of these brain
metastases is additionally hampered because many cytostatic drugs are substrates of the
P-glycoprotein (p-gp), an efflux pump located in the blood-brain barrier, and thus cannot
reach the brain and the brain metastases. To solve this problem Fellner et al. (2002)
investigated the treatment of nude mice bearing human brain tumors by co-application
of the cytostatic paclitaxel, a p-gp substrate, with the p-gp inhibitor valspodar. By this
combination the paclitaxel level in the mouse brain was significantly increased and the
tumor volume was reduced by 90 % (for details see chapter 5). Stimulated by these
results human lung cancer cell lines were selected to investigate the application of the
aforementioned combination therapy to the treatment of secondary brain tumors. First
of all the cell lines were characterized with regard to their in vitro and in vivo morphol-
ogy, their growth characteristics and their chemosensitivity to select cell lines which are
representative for the broad variety of lung tumors.
3.2 Materials and methods
3.2.1 Drugs and chemicals
Cisplatin, doxorubicin, etoposide, paclitaxel and vinblastine were purchased from Sigma
(München, Germany). Docetaxel (Taxotere®) was obtained from Aventis (Bad Soden,
Germany), topotecan (Hycamtin®) from GlaxoSmithKline (München, Germany), vin-
cristine (Vincristine 1mg/ml®) from Rhone-Poulenc (Strasbourg, France) and vinorelbin
(Navelbine®) from Pierre Fabre Pharma (Freiburg, Germany). Stock solutions of all
drugs were prepared in 70 % ethanol with exception of cisplatin (DMSO), docetaxel
(pure ethanol) and vinorelbin (sterile deionized water). The stock solutions of topote-
can and vinorelbin were stored at 4 ℃, all other stock solutions were stored at -80 ℃.
Fetal calf serum (FCS) was obtained from Biochrom. All other chemicals and reagents
were procured either from Merck or from Serva. Water was de-ionized by Milli Q wa-
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ter system (Millipore). Phosphate buffered saline (PBS) contained 8.0 g/l NaCl, 1.0 g/l
Na2HPO4x2H2O, 0.2 g/l KCl, 0.2 g/l KH2PO4 and 0.15 g/l NaH2PO4xH2O. Bouin’s
solution consisted of 300 ml of aqueous saturated picric acid, 100 ml of formaldehyde and
20 ml of glacial acetic acid.
3.2.2 Culture conditions
Lung cancer cell lines were obtained from the ATCC (Rockville, USA). The tumor cells
were cultured as "monolayer cultures" in 75 cm2 flasks (Nunc, Wiesbaden, Germany).
The cell cultures were maintained at 37 ℃/5 % CO2 in different culture media. For
the NCI-H460 cell line RPMI 1640 culture medium (Sigma) was used containing 10 mM
HEPES, 1 mM sodium pyruvate, 2.5 g/l glucose, 1.5 g/l sodium hydrogen carbonate and
10 % FCS. The small cell lung cancer cell lines DMS 53, DMS 114 and DMS 153 were
cultivated first in Waymouth’s MB 752/1 culture medium (Sigma, München, Germany)
supplemented with 2.24 g/l sodium hydrogen carbonate and 10 % FCS, and then adapted
to EMEM culture medium (Sigma, München, Germany) supplemented with 110 mg/l
sodium pyruvate, 2.2 g/l sodium hydrogen carbonate and 5 % FCS. All culture media
were adjusted to pH 7.4. Subculturing was carried out with 0.2 % trypsin/EDTA (Viralex,
Paa Laboratories, Pasching, Austria) in PBS once a week. Mycoplasm contamination was
monitored by a mycoplasma PCR detection kit (Venor Dem, Minerva Labs, Worcester,
USA) periodically. A tumor bank according to the seed stock concept (Hay 1988) was
created to have suitable cell material available at any time. For that purpose, the cells
were expanded in lower passages and frozen in culture medium with an addition of 10 %
DMSO in an ampule for storage in liquid nitrogen. To thaw a sample the ampule was
put into water (40 ℃) and afterwards, the cells were cultivated in the appropriate culture
medium.
3.2.3 Cytological and histological staining
For cytological staining cells were cultivated on microscopic slides that were prepared
in accordance to the chromosome preparation. The cells were fixed for 30 min with
Carnoy’s solution (ethanol:chloroform:glacial acetic acid 6:3:1) and stained by the method
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of Papanicolaou (Takahashi 1987). Harris’ haematoxylin, orange G6 and eosin azure 31
were utilized as dye reagents to stain plasma turquoise, nuclei blue and nucleoli deep blue.
For histological sections of the tumor tissue NMRI(nu/nu) nude mice with subcutaneous
solid tumors were killed, and the tumor and part of the dermal tissue were removed and
fixed for at least three days in Bouin’s solution. The tissues were embedded in paraffin
by a standard procedure in a Histokinette (Shandon, Frankfurt/Main, Germany), cut by
a Microtome Leitz 1516 (Leitz, Wetzlar, Germany) in sections with a thickness of 6 µm
and put on object slides prepared with poly-L-lysin. Prior to each staining procedure
the sections were deparaffinized with xylol and various ethanol solutions with descending
concentrations. For the haematoxylin-eosin (HE) staining the method described elsewhere
(Romeis 1989) was used with Mayer’s haematoxylin and eosin. With these dye reagents
the nuclei appear blue, whereas the rest of the section is stained pink or red. The Masson-
Goldner (MG) staining was also carried out according to Romeis in consideration of the
modification of Jerusalem. Here, Weigert’s haematoxylin, acid fuchsin-ponceau, orange
G and light green were used to stain nuclei violet, erythrocytes red and connective tissue
green. All stained sections were evaluated with a BH2 microscope (Olympus, Hamburg,
Germany) mounted with a CCD-camera for digital imaging.
3.2.4 In vitro growth determination
For the in vitro growth characterization the lung cancer cells were cultured in 96 well
(100 µl/well) flat-bottomed microtitration plates (Greiner, Frickenhausen, Germany) at
an appropriate density of 10 to 20 cells per microscopic field (320x, Diavert microscope,
Leitz, Wetzlar, Germany) depending on the cell line. After an incubation at 37 ℃/5 %
CO2 for 24 h another 100 µl/well culture medium were added. Cell growth was stopped at
various periods of incubation time and the cell density was determined by a crystal violet
staining as described in chapter 3.2.6. The absorbance of the cells was measured by a
BioTek EL 309 Autoreader (Bad Friedrichshall, Germany) and the average and standard
deviation values were calculated. Absorbance values outside of the confidence interval
(95 %) were not considered for the calculation. The incubation time was plotted against
the absorbance. The doubling time was computed using a computer analysis program
(Reile et al. 1990) and plotted against the incubation time.
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3.2.5 Metaphase chromosomes preparation
Metaphase chromosomes of the tumor cell lines were prepared by the following procedure.
Microscopic slides were prepared according to the method of Rooney and Czepulkowski
(1986). For that purpose the slides were degreased for 24 h in ethanol hydrochloric acid
(6 ml of concentrated hydrochloric acid in 200 ml 70 % ethanol), rinsed with de-ionized
water and dried. Before culturing the cells the slides were autoclaved. Cells were cultured
on the prepared slides in Quadriperm 4-well lux-multiplates up to a confluence of 50 %.
Metaphase cells were arrested with colcemide (0.04 mg/ml). After an incubation time of
3 h at 37 ℃/5 % CO2, the culture medium was removed by suction and replaced with
37 ℃ warm hypotonic potassium chloride solution (75 mM) for 30 min to lyse the cells.
Afterwards, an equal volume of icecold fixative (methanol/glacial acetic acid 3:1) was
added and removed at once. This step was repeated twice and after the last fixation the
slides were stored at 4 ℃ for 10 min. The fixative was removed and the slides were dried.
Chromosomes were stained with a Giemsa dye solution (10 ml filtered Giemsa solution
+ 90 ml 0.025 M KH2PO4 , pH 6.8) for 8 min. After washing and drying the slides were
mounted with DePex. The chromosome numbers were determined by an Olympus BH-2
microscope (Olympus, Hamburg, Germany) with 60x and 100x SPlanApo oil immersion
objective. For each cell line 50 metaphases were counted. In addition, digital imaging
was performed by means of an Axiovent 200 M microscope (Zeiss, Jena, Germany) and
LSM 510 imaging software.
3.2.6 Chemosensitivity assay
The chemosensitivity of the tumor cells was quantified by the crystal violet assay described
elsewhere (Bernhardt et al. 1992, Reile et al. 1990). In brief: tumor cells were seeded
(100 µl/well) in 96 well flat-bottomed microtitration plates (Nunc, Wiesbaden, Germany)
at an appropriate density of 10 to 20 cells per microscopic field (320x, Diavert microscope,
Leitz, Wetzlar, Germany) depending on the cell line. After incubation at 37 ℃/5 % CO2
for 48 h to 72 h according to the cell growth characteristics, the medium was carefully
removed by suction and replaced with fresh medium (200 µl/well) containing either drug
or pure solvent. The drug solutions were diluted 1:1,000 with culture medium. In 16
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wells on every plate culture medium with vehicle was given, so that these wells served
as control. For every drug concentration 16 wells were used. After various periods of
incubation at 37 ℃/5 % CO2 the culture medium was shaken off and the cells were fixed
with 100 µl 1 % glutardialdehyde in PBS per well for 30 min. The fixative was replaced
by 180 µl PBS per well, and the plates were stored at 4 ℃. At the end of the experiment
the cells were simultaneously stained with 100 µl of 0.02 % crystal violet solution (N-
hexamethylpararosanilin · HCl in water) per well for 20 min. To remove excess dye the
plates were rinsed with demineralized water for 20 min and dried. The stain bound by the
cells was redissolved in 70 % ethanol (180 µl/well) while shaking the microplates for about
3 h on a Köttermann 4010 shaker. Absorbance was measured at 578 nm using a BioTek EL
309 Autoreader (Bad Friedrichshall, Germany) and the average and standard deviation
values were calculated. Absorbance values outside of the confidence interval (95 %) were
not considered for the calculations. The drug effects were expressed as corrected T/C
values according to
T/Ccorr.[%] =
T − C0
C − C0 · 100%
where T is the mean absorbance of the treated cells, C the mean absorbance of the
control and C0 the mean absorbance of the cells at the time when the drug was added
(t=0). When the absorbance of the treated cells T is less than that of the culture at t=0
(C0) the extent of cell killing must be calculated as
cytocidal effect[%] =
T − C0
C0
· 100%
3.2.7 In vivo experiments
For the characterization of the in vivo growth of the lung cancer cells NMRI(nu/nu)
nude mice obtained from the nude mice laboratory of the department were used. The
mice were allowed to take water and food, a combined breed and maintenance nutrition
(Altromin), ad libitum. The water was supplemented with 1.33 g/l of potassium sorbate,
2 g/l of chloramphenicol and 1 g/l of hydrochloric acid leading in a pH value of 2.5. The
animals were housed under specific pathogen free conditions at a 12 h light/dark cycle at a
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temperature of 25 ℃ and a relative humidity of 70 %. At an age of 6 weeks the mice were
used for studies. For the subcutaneous injection cell suspensions of the corresponding cells
were prepared in vitro. Cells were detached from the culture flask with trypsin/EDTA
and FCS free medium and washed twice with FCS free medium. To adjust the appropriate
cell quantity (2 mill. cells/100 µl in case of the NCI-H460 cell line and 4 mill. cells/100
µl for DMS 53 and DMS 114 cell lines, respectively) cells were resuspended in FCS free
medium. Under aseptic conditions 100 µl of the cell suspensions were injected under the
thoracic dermis. To maintain the subcutaneous tumors in the mice the solid tumor was
excised when the tumor growth reached an area of about 150 mm2. Pieces of 2 mm3
were prepared in sterile PBS and transplanted into new mice. The NCI-H460 tumor
was grafted every three weeks whereas the other tumors were transplanted at an average
period of seven weeks.
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3.3 Results
The selected four lung cancer cell lines NCI-H460 (N-SCLC), DMS 53, DMS 114 and
DMS 153 (all SCLC) were examined with respect to their suitability for establishing a
lung cancer tumor model. The tumor cell lines were obtained from the American Type
Culture Collection (ATCC) and characterized with respect to their in vitro and in vivo
morphology and growth as well as their chemosensitivity against various cytostatic drugs.
3.3.1 Origin and morphology of selected lung cancer cell lines
The large cell carcinoma cell line NCI-H460 (ATCC HTB 177) was isolated by A.F. Gadzar
et al. from the pleural fluid of a male patient with large cell carcinoma in 1982 prior to
therapy. NCI-H460 cells were obtained in the 140th passage and grew as a monolayer
culture with epithelial morphology and easily distinguishable cells. When cultured in
flasks over 5 days multilayered cell clusters were observed.
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Figure 3.1: In vitro morphology of human NCI-H460 lung cancer cells (Papanicolaou staining).
The highly vacuolated round cells (a) form adherent cell aggregates and show a
high mitotic activity (a,b). Cells are of the same size, occasionally large cells are
observed (a). Two cells in metaphase exhibit abnormal mitotic figures (b).
The round to oval large cells displayed in Fig. 3.1 form tight adherent cell sheets and
are of different sizes. The cell cytoplasm is highly vacuolated and the round nuclei, that
fill a major portion of the cells, contain multiple prominent nucleoli scattered within the
nuclei. A high mitotic activity of the cells is observed. The aggressiveness of NCI-H460
tumors is clearly deducible from the abnormal mitotic figures (tetrapolar spindles) in cell
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metaphases shown in Fig. 3.1b (indicated by arrows).
The small cell lung cancer cell line DMS 53 (ATCC CRL 2062) was isolated from a
mediastinal biopsy at the time of diagnosis by O.S. Pettengill et al. from a 54-year old
male Caucasian in 1974 prior to treatment (Pettengill et al. 1980b). DMS 53 cells were
purchased in the 34th passage. The DMS 53 cell line is an example of a SCLC cell line
with a well differentiated neuroendocrine phenotype (Mabry et al. 1989).
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Figure 3.2: In vitro morphology of human DMS 53 lung cancer cells (Papanicolaou staining).
The oval cells have small appendages and are slightly vacuolated. The tumor cells
grow as tight adherent cell cluster (b) with less mitotic activity (a,b). Cells with
more than one nucleus are observed (a).
The DMS 53 cell line is a typical SCLC cell line because of its oval cells with scant
cytoplasm that are small to moderate in size in contrast to NCI-H460 tumor cells. The
cells have short appendages and are slightly vacuolated (Fig. 3.2). The majority of the
cells have one oval nucleus and mostly one prominent, round nucleolus. Cells with two
nuclei and multiple nucleoli are observed, too. The mitotic activity was not as high as in
the case of the NCI-H460 cell line.
The human small cell lung cancer cell line DMS 114 (ATCC CRL 2066) was established
from a mediastinal biopsy by O.S. Pettengill and associates from a 68-year old male
Caucasian at the time of diagnosis prior to therapy in 1975 (Pettengill et al. 1980b).
DMS 114 cells were obtained in the 36th passage and were described as tumorigenic in
athymic mice (Pettengill et al. 1980a). DMS 114 cells as well as the DMS 53 cell line are
classified to SCLC type IV as both cell lines grew attached to the culture flask (Carney
et al. 1985)
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Figure 3.3: In vitro morphology of human DMS 114 lung cancer cells (Papanicolaou staining).
The oval to polymorphic cells with appendages form loose cell aggregates (b).
Multinucleated cells are frequently observed, that are sometimes of giant size (a).
The cells show relatively high mitotic activity (a,b).
The irregularly formed cells shown in Fig. 3.3 have appendages and form loose cell
clusters without vacuolization. The oval nuclei have two or more prominent nucleoli. The
nucleocytoplasmic ratio is nearly 3:1. Multinucleated giant cells are frequently observed.
The high malignancy of SCLC tumors is clearly deducible from the relatively high mitotic
activity of the cells.
The human small cell lung cancer cell line DMS 153 (ATCC CRL 2064) was isolated
from liver tissue taken at an autopsy of a patient with small cell carcinoma in the lung,
who received therapy with cyclophosphamide and methotrexate (Pettengill et al. 1980b).
DMS 153 cells were obtained in the 26th passage. Unfortunately, the cell line is a mixture
of adherent cells and cells growing in suspension. Therefore, the cultivation of DMS 153
cells was stopped as the planned assays are unsuitable for suspension cells.
3.3.2 In vitro growth and doubling time
In permanent in vitro cultivation it is important to monitor growth parameters like dura-
tion of G0- and M-phase and minimal doubling time. Modifications of these parameters
could affect chemosensitivity, as the antiproliferative effect of cytostatic agents is heavily
depending on the growth kinetics of the examined cell line. Therefore, the selected cell
lines were incubated for at least 250 hours. At various time points the cell proliferation
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was stopped by fixation with glutardialdehyde. The cells were stained with crystal violet
solution and the absorbance was measured. The absorbance is an indication of the cell
density: the higher the absorbance, the higher is the cell density. The absorbance was
plotted against the incubation time to assess the growth of the different lung cancer cell
lines.
All three curves are characterized by a steep increase at the beginning followed by
a plateau phase with constant absorbance values (Fig. 3.4). The NCI-H460 cell line is
the fastest growing cell line of the selected human lung cancer cell lines. The growth
curves of the SCLC cell lines DMS 53 and DMS 114 are similar in their characteristics in
consideration of the different cell densities at the beginning of the measurements. Both
SCLC cell lines grew slower in comparison to the NCI-H460 cell line. Confluently grown
NCI-H460 and DMS 53 cells reached a higher absorption level compared to confluently
grown DMS 114 cells.
Figure 3.4: Representative growth curves of NCI-H460, DMS 53 and DMS 114 human lung
cancer cell lines in lower passages. Absorbance as a parameter for cell growth is
plotted against the incubation time.
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Figure 3.5: Long time cultivation of NCI-H460 (a), DMS 53 (b) and DMS 114 (c) lung cancer
cells. Doubling times in various passages are plotted against the incubation time.
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To determine the minimal doubling times of the cell lines the doubling time was plotted
against the incubation time (Fig. 3.5). NCI-H460 cells exhibited the shortest minimal
doubling times (about 9 h), so the cell line was the most rapidly growing cell line among
the selected ones. DMS 53 and DMS 114 cells had similar minimal doubling times of 34 h
and 28 h, respectively, indicating a slower cell growth in comparison to NCI-H460 cells.
The doubling time curves are used to indicate logarithmic cell growth, which is char-
acterized by constant doubling times. At logarithmic growth, a characteristic for normal
growing cells, the doubling time curve results in a parallel line to the x-axis. This curve
progression was not observed in any of the three selected cell lines.
The minimal doubling times did not alter during long term cultivation in the case of the
NCI-H460 and DMS 114 cell lines. In contrast, the minimal doubling time of DMS 53 cells
determined in the 168th passage was three times less compared to the minimal doubling
time examined in the 151st passage. This marked decrease of the doubling times indicates
a rapid cell growth with increasing cultivation period. Therefore, the DMS 53 cell line is
unsuited for a stable long term cultivation, which is necessary for the establishment of a
tumor model.
3.3.3 Chromosome distribution
Genetic alterations play a decisive role in genesis and progression of cancer (Kaye 2001).
For lung cancer multiple molecular genetic changes are known concerning oncogenes and
tumor suppressor genes, which are typical for SCLC. Prevalent expression of oncogenes
is mainly existent in N-SCLC (Mitsuuchi and Testa 2002). The most common genetic
modification (SCLC >90 %, N-SCLC >50 %) is the loss of heterozygosity at chromosome
3p (Whang-Peng et al. 1982, Sekido et al. 2001) and this change is one of the first alter-
ations in the development of lung cancer. In comparison to SCLC the modifications of
N-SCLC karyotypes are more complex. Depending on the N-SCLC tumor species vari-
ous alterations and imbalances take place at the chromosomes and certain chromosomal
aberrations show evidence for the tumor malignancy, e.g. gain of 7q and 8q. Therefore,
it is of great importance to examine the chromosome distribution and the karyotype of
cell lines to estimate genetic stability and the aggressiveness of lung cancer cell lines.
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Figure 3.6: Effect of long term cultivation on the chromosome distribution of human lung
cancer cell line NCI-H460. The chromosome distribution of the 144th (a), the 164th
(b) and the 210th (c) passage is shown.
Figure 3.7: Representative metaphase chromosomes of NCI-H460 cell line. Chromosomes were
stained with Giemsa solution.
The results of the chromosome distribution for NCI-H460 cells during several passages
are shown in Fig. 3.6. The modal chromosome number of 57 specified in the ATCC manual
remained nearly unchanged. At higher passages it was only reduced by two chromosomes
to 55 chromosomes. The chromosome number was distributed in a close range during
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the cultivation period (overall range: 44-69 chromosomes per cell), so the majority of the
NCI-H460 cells possessed a hypotriploid set of chromosome.
The chromosome distribution of DMS 53 cells during different passages are described
in Fig. 3.8. Here the modal chromosome number of 58 remained constant. In long time
Figure 3.8: Effect of long term cultivation on the chromosome distribution of human small cell
lung cancer cell line DMS 53. The chromosome distribution of the 45th (a), the
107th (b) and the 156th (c) passage is shown.
Figure 3.9: Representative metaphase chromosomes of DMS 53 cell line. Chromosomes were
stained with Giemsa solution.
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cell cultures several nuclei with 80 and more chromosomes per cell were observed. Apart
from these nuclei the chromosome number ranged from 49 to 65 chromosomes per cell.
Figure 3.10: Effect of long term cultivation on the chromosome distribution of human small
cell lung cancer cell line DMS 114. The chromosome distribution of the 44th (a),
the 82nd (b) and the 145th (c) passage is shown.
a b
Figure 3.11: Representative metaphase chromosomes of DMS 114 cell line. Chromosomes were
stained with Giemsa solution. Metaphase chromosomes of a multinucleated giant
cell (b).
The chromosome distributions of cell line DMS 114 are presented in Fig. 3.10. Two
metaphase chromosomes are shown in Fig. 3.11, whereas in Fig. 3.11 b the chromosome
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set of a multinucleated giant cell mentioned in chapter 3.3.1 is depicted. Such chromosome
sets were excluded from the chromosome number determination, but they represent about
10 % of all cells in the examined passages. Modal chromosome numbers of 62 in the 44th
passage, 66 in the 82nd passage and 61 in the 145th passage were determined showing
nearly no alteration in the modal chromosome number. The range of the chromosome
number was similar over the cultivation period (52 to 74 chromosomes per cell).
Thus all three human lung cancer cell lines had a relatively constant number of chro-
mosomes during the cultivation period and are suitable for the establishment of a lung
cancer model.
3.3.4 Chemosensitivity against selected cytostatic drugs
Many cytostatic drugs which are utilized for the treatment of lung cancer and its metas-
tases cannot cross the blood-brain barrier because they are substrates of p-gp. One aim
of this work was the development of a treatment for brain metastases of lung cancer
by analogy with the combination therapy investigated by Fellner et al. (2002) (see 3.1).
Therefore, only those chemotherapeutics were selected, which are p-gp substrates (Fisher
et al. 1996, Van Veem and Callaghan 2003) and established in clinical lung cancer ther-
apy (Thomas et al. 2002). In addition, the modes of action of the substances should be
different. The following classes of substances were chosen (Fig. 3.12): mitotic inhibitors
(paclitaxel, docetaxel, vincristine, vinblastine and vinorelbin), topoisomerase inhibitors
(etoposide and topotecan), and anthracyclins (doxorubicin). Additionally, cisplatin was
used as a chemotherapeutic agent which is not a p-gp substrate.
A screening of the antiproliferative activities of the selected cytostatic drugs was per-
formed by a chemosensitivity assay using the three human lung cancer cell lines NCI-H460,
DMS 53 and DMS 114. In Figs. 3.13 to 3.24 the proliferation kinetics of the correspond-
ing controls are shown, and the corrected T/C values, calculated from the proliferation
kinetics are plotted against the incubation time. The correction for the initial cell number
allows discrimination between cytotoxic, cytostatic and cytocidal drug action at any time
of incubation. Clear dose-response relationships were obtained for all selected cytostatic
substances and specific effects were derived from these relationships.
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Figure 3.12: Structures of the selected chemotherapeutic agents
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Figure 3.13: Chemosensitivity of NCI-H460 cells against the mitotic inhibitors paclitaxel (a)
and docetaxel (b)
Figure 3.14: Chemosensitivity of DMS 53 cells against the mitotic inhibitors paclitaxel (a) and
docetaxel (b)
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Figure 3.15: Chemosensitivity of DMS 114 cells against the mitotic inhibitors paclitaxel (a)
and docetaxel (b)
Mitotic inhibitors paclitaxel and docetaxel. In Fig. 3.13, Fig. 3.14 and Fig. 3.15
the results of the chemosensitivity of the respective cell lines to the taxanes paclitaxel
and docetaxel are presented. Paclitaxel and docetaxel, two mitotic inhibitors, prevent
the deaggregation of the spindle in G2 phase by binding to microtubules. Effects on the
growth of the lung cancer cell lines were already achieved at low concentrations for both
substances. In the case of paclitaxel (a) the cell proliferation of NCI-H460 and DMS 53
cells was transiently inhibited at 10 nM paclitaxel. DMS 114 cell growth was already
inhibited at a paclitaxel concentration of 2 nM. A cytocidal effect on DMS 114 cells was
observed at 5 nM paclitaxel. Compared to the impact of paclitaxel a more powerful
cytostatic effect on the cell proliferation was noticed for docetaxel, the semi-synthetical
paclitaxel analogue. For example DMS 114 cells disintegrated at 1 nM docetaxel (b).
The sensitivity of the selected lung cancer cell lines against the taxanes paclitaxel and
docetaxel may be summarized according to the following order:
DMS 114 cells > NCI-H460 cells > DMS 53 cells
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Figure 3.16: Chemosensitivity of NCI-H460 cells against the mitotic inhibitors vinblastine (a),
vincristine (b) and vinorelbin (c)
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Figure 3.17: Chemosensitivity of DMS 53 cells against the mitotic inhibitors vinblastine (a),
vincristine (b) and vinorelbin (c)
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Figure 3.18: Chemosensitivity of DMS 114 cells against the mitotic inhibitors vinblastine (a),
vincristine (b) and vinorelbin (c)
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Vinca alkaloids vinblastine and vincristine, vinorelbin. Fig. 3.16, Fig. 3.17 and
Fig. 3.18 illustrate the effects of the vinca alkaloids vinblastine (a), vincristine (b) and
vinorelbin (c) on the growth of the lung cancer cell lines. Vinblastine and vincristine
are genuine products of the Madagascar periwinkle leaves and vinorelbin is the semi-
synthetical derivative of vinblastine. In contrast to taxanes, vinca alkaloids inhibit the
assembly of microtubules. Vinblastine affected the growth of the lung cancer cells similar
to docetaxel in case of DMS 53 and DMS 114 cells (cytocidal effect at 10 nM and 1 nM,
respectively), whereas a concentration of 50 nM vinblastine is required for a cytocidal
effect on NCI-H460 cells (10 nM with docetaxel). Compared to vinblastine higher con-
centrations of vincristine were needed to inhibit the growth of DMS 53 cells (cytotoxic
effect at 30 nM and cytocidal effect at 50 nM). The effect of vincristine on NCI-H460
and DMS 114 cells was comparable to that of vinblastine. Vinorelbin was expected to
be more efficient than the genuine vinca alkaloids. However, there was no increase in
chemosensitivity compared to vincristine and vinblastine in case of NCI-H460 and DMS
53 cells. The DMS 114 cell line was even less sensitive to vinorelbin than to the other
vinca alkaloids. Here, with 1 nM vinorelbin only a cytotoxic effect was achieved compared
to a cytocidal effect at 1 nM vinblastine and vincristine, respectively. Hence, vinorelbin
was not superior to the genuine vinca alkaloids in inhibiting the investigated lung cancer
cell lines. The sensitivity of the human lung cancer cells may be summarized according
to the following ranking:
Vinblastine: DMS 114 cells > DMS 53 cells > NCI-H460 cells
Vincristine: DMS 114 cells > NCI-H460 cells > DMS 53 cells
Vinorelbin: DMS 114 cells > DMS 53 cells > NCI-H460 cells
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Figure 3.19: Chemosensitivity of NCI-H460 cells against the topoisomerase inhibitors topote-
can (a) and etoposide (b)
Figure 3.20: Chemosensitivity of DMS 53 cells against the topoisomerase inhibitors topotecan
(a) and etoposide (b)
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Figure 3.21: Chemosensitivity of DMS 114 cells against the topoisomerase inhibitors topotecan
(a) and etoposide (b)
Topoisomerase inhibitors etoposide and topotecan. The chemosensitivities of the
selected cell lines against topotecan and etoposide are represented in Fig. 3.19, Fig. 3.20
and Fig. 3.21. Both substances act as topoisomerase inhibitors, inducing DNA strand
breaks and cell apoptosis. Topotecan inhibits the type I and etoposide the type II topoi-
somerase. All three cell lines were much more sensitive against topotecan than against
etoposide. A concentration of 50 nM topotecan was required to induce a cytocidal effect
on NCI-H460 and DMS 114 cells. In case of etoposide concentrations of 5 µM and 1 µM
were necessary to produce comparable effects on NCI-H460 and DMS 114 cells respec-
tively. Topotecan had already a cytocidal effect on DMS 53 cells at 10 nM. At this low
concentration the growth of the other cell lines was not effected at all. In case of etoposide
the DMS 53 cell line was similar in its sensitivity to the NCI-H460 cell line and thus about
200 times less sensitive compared to the results received with topotecan. The following
list summarizes the rank order of sensitivity of the human lung cancer cell lines against
the topoisomerase inhibitors topotecan and etoposide:
Topotecan: DMS 53 cells > DMS 114 cells > NCI-H460 cells
Etoposide: DMS 114 cells > DMS 53 cells > NCI-H460 cells
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Figure 3.22: Chemosensitivity of NCI-H460 cells against the anthracyclin doxorubicin (a) and
cisplatin (b)
Figure 3.23: Chemosensitivity of DMS 53 cells against the anthracyclin doxorubicin (a) and
cisplatin (b)
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Figure 3.24: Chemosensitivity of DMS 114 cells against the anthracyclin doxorubicin (a) and
cisplatin (b)
Doxorubicin and cisplatin. The chemosensitivity of the three lung cancer cell lines
against doxorubicin and cisplatin is shown in Fig. 3.22, Fig. 3.23 and Fig. 3.24. At least
two mechanisms of action account to the cytotoxic effect of the anthracyclin doxorubicin:
on the one hand it intercalates with DNA by wedging between the DNA bases thereby
blocking DNA replication and transcription, and on the other hand it inhibits topoiso-
merase type II. Cisplatin arrests the DNA synthesis mainly by formation of intrastrand
crosslinks. Compared to the mitotic inhibitors, doxorubicin is a moderately active cyto-
static agent as concentrations of 10 nM in case of DMS 114 or higher (50 nM and 100 nM
for DMS 53 and NCI-H460 respectively) were needed to achieve a cytotoxic or cytostatic
effect. The cell lines were less sensitive to cisplatin than to doxorubicin. This becomes
evident from the comparison of doxorubicin and cisplatin effects on the cell growth of
NCI-H460 and DMS 53 cell lines: 10 times higher concentrations were required to induce
similar effects on the cell proliferation of the NCI-H460 and DMS 53 cell lines. The sensi-
tivity of the investigated cell lines against doxorubicin and cisplatin may be summarized
as follows:
DMS 114 cells > DMS 53 cells > NCI-H460 cells
3.3 Results 65
In summary, the DMS 114 cells were most sensitive to all cytostatic drugs except
topotecan, which was most effective against DMS 53 cells. In general, the chemosensitiv-
ities of NCI-H460 and DMS 53 cells were comparable. Generally, all lung cancer cell lines
responded excellently to mitotic inhibitors. Compared to the other investigated drugs
the topoisomerase inhibitor etoposide required the highest concentrations to achieve a
cytostatic effect, whereas topotecan affected the cell growth at moderate concentrations.
Among the mitotic inhibitors the taxanes, especially docetaxel, were the most potent
antitumor agents in this assay.
3.3.5 In vivo growth characteristics
The lung cancer cell lines NCI-H460, DMS 53 and DMS 114 were established in vivo as
subcutaneous and intracerebral tumor models, respectively. The intracerebral model is
described in detail in chapter 5. In the literature the SCLC cells are described as tumori-
genic in athymic mice (Pettengill et al. 1980a). To study new tumor treatment approaches
in animals it is indispensable to have a stable tumor growth which is reproducible over
several passages. Therefore, the size of the established tumor has to be measured and the
growth had to be compared in different passages by plotting the tumor area against the
time after tumor implantation.
In Fig. 3.25 the in vivo growth of the selected cell lines in the nude mouse is illustrated
during various passages. The implantation of NCI-H460 and DMS 114 cells produced
stably growing subcutaneous tumors of sufficient size in different passages (about 140 mm2
for NCI-H460 tumors, Fig. 3.25 a, and 200 mm2 in case of DMS 114 tumors, Fig. 3.25
c). In contrast, DMS 53 tumors (Fig. 3.25 b) were growing slower and were smaller.
Furthermore, the DMS 53 cells were poorly tumorigenic in mice: only two of five mice
developed a subcutaneous tumor after DMS 53 cell injection. The NCI-H460 and DMS
114 tumors were well tolerated by mice. A rapidly growing subcutaneous tumor model
was established using the NCI-H460 cell line; this tumor was passaged every 30 days. The
DMS 114 cell line should be used for a slowly growing subcutaneous tumor model, that
requires a duration greater than 40 days.
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Figure 3.25: In vivo growth curves of subcutaneously growing human lung cancer cell lines
NCI-H460 (a), DMS 53 (b) and DMS 114 (c) in mice during various passages
When tumors were passaged tissue samples were taken from the tumor for histological
characterization by HE- and MG-staining. MG-stained sections of subcutaneously grown
NCI-H460 cells in the 3rd passage are displayed in Fig. 3.26. The subcutaneously growing
NCI-H460 cells form a heterogenous tumor with large undifferentiated cells. The cells have
round to oval nuclei with large irregularly formed nucleoli and the nucleocytoplasmic ratio
is approximately 1 : 2. The high malignancy of the tumor is deducible from the intense
mitotic activity and abnormal mitotic figures (tripolar spindle, Fig. 3.26 b). Infiltration of
blood vessels is clearly visible in Fig. 3.26 a. The tumor is pervaded with necrotic areas.
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Figure 3.26: MG-staining of subcutaneously growing NCI-H460 tumor. The large undifferenti-
ated cells have irregularly formed nucleoli. Abundant mitosis (a,b) and abnormal
mitotic figures (b) are observed. The tumor tissue is necrotic (a) and blood vessels
are infiltrated by the tumor cells (b).
In Fig. 3.27 the MG-stained sections of subcutaneously grown DMS 53 tumor in the
1st passage are presented. The homogenous DMS 53 tumor consists of round to oval cells
with dense nuclei, prominent round nucleoli and scanty cytoplasm. The tumor is more
differentiated in comparison to the NCI-H460 tumor, i.e. a glandular cell formation is
observed (Fig. 3.27 b). The tumor tissue is well provided with blood vessels and shows
only a few cells in metaphase indicating a lower mitotic activity.
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Figure 3.27: MG-staining of subcutaneously growing DMS 53 tumor. Large blood vessels are
observed in the tissue (a). The round to oval cells with dense nuclei and scanty
cytoplasm are less undifferentiated compared to NCI-H460 tumors as glandular
structures are observed (b).
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Figure 3.28: MG-staining of subcutaneously growing DMS 114 tumor. The inhomogeneous
tumor consists of oval cells with indistinct cytoplasm and polymorphic nuclei. In-
filtration of smooth muscles (a) and blood vessels (b) is observed. Multinucleated
giant cells are seen as well (b).
MG-stained sections of subcutaneous grown DMS 114 tumor in the 1st passage are de-
picted in Fig. 3.28. The DMS 114 cells produce xenografts consisting of inhomogeneously
formed cells with round to oval nuclei and indistinct cytoplasm. The majority of the cells
has one prominent, commonly central nucleolus. The cell density of the tumor is very
high. The mitotic activity is lower in mice than in vitro (see page 46). In addition, the
malignancy of the DMS 114 tumor is obvious from the infiltration of smooth muscles and
blood vessels. Multinucleated giant cells are observed, too.
In summary, all three human lung cancer cell lines were tumorigenic in athymic mice.
The DMS 53 cell line is poorly tumorigenic, and hence, unsuited for the establishment of
a tumor model in animals as mentioned on page 65. Subcutaneously growing NCI-H460
tumors are highly malignant, rapidly growing tumors, which could be used to produce a
stable xenograft model in athymic mice. A subcutaneous tumor model was established
with DMS 114, too, but this model is more suitable for experiments of longer duration.
The in vivo results confirmed the in vitro morphology and the growth characterization:
NCI-H460 was the fastest growing cell line in vitro and in vivo. Moreover, this tumor was
found to have the highest malignancy among the investigated lung cancers, indicated by
the intense mitotic activity both in vitro and in vivo.
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3.4 Summary and conclusion
Three human lung cancer cell lines obtained from the ATCC were characterized with the
objective to establish a subcutaneous and an intracerebral tumor model in nude mice for in
vivo treatment experiments. Therefore, the cell lines were examined with respect to their
in vitro and in vivo morphology and growth, respectively, their number of chromosomes,
and their chemosensitivity against several selected cytostatic agents. The NCI-H460, a
N-SCLC cell line, and the SCLC cell line DMS 114 proved to be particularly suited.
NCI-H460 was identified as a highly malignant cell line both in vitro and in vivo. The
cells were tumorigenic in athymic mice and generated solid subcutaneous tumors. The
growth of the NCI-H460 cells in vitro and the subcutaneous tumors in vivo was stable
and reproducible. The cell proliferation was significantly effected by various cytostatic
drugs, particularly by taxanes such as docetaxel. The cell line NCI-H460 is suitable for
the establishment of a tumor model in nude mice with an aggressively and rapidly growth
as a human lung cancer.
The DMS 114 cell line showed the well-known characteristics of tumor cells such as
intense mitotic activity both in vitro and in vivo. The chromosome distribution of the
DMS 114 cells remained constant during the cultivation period. Giant multinucleated
cells were visible in Papanicolaou stained cells as well as in MG-stained tumor sections.
The portion of the giant cells remained unchanged during the cultivation period. DMS
114 cells grew slower compared to NCI-H460 cells. Furthermore, they were most sensitive
to the selected cytostatic drugs. The cell growth was affected already at nanomolar
concentrations of the drugs. Therefore, a subcutaneous model in mice was established
with the DMS 114 lung cancer cell line as well, which was very suitable for long time
studies.
In contrast to NCI-H460 and DMS 114, the minimal doubling time of the third lung
cancer cell line, DMS 53, decreased with higher passages, and the cells were poorly tumori-
genic in nude mice. Thus, the DMS 53 cell line was excluded from further investigations.
In summary, subcutaneous tumor models were established in nude mice using the
human lung cancer cell lines NCI-H460 and DMS 114.
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Chapter 4
Establishment and application of a
calcein-AM efflux assay
4.1 Introduction
P-glycoprotein 170 (p-gp) is an unusual member of the highly conserved superfamily of
ATP-binding cassette (ABC) transport proteins as it recognizes a broad variety of struc-
turally and mechanistically unrelated agents in comparison to other transport proteins
(Seelig 1998). The literature describes three different drug transport models: the classical
pump, the vacuum cleaner and the flippase model (Sharom 2003). In case of the pump
model p-gp interacts with its substrate at the cytosolic side of the plasma membrane
and pumps the substrate across the membrane to the extracellular site via a transport
channel. The vacuum cleaner model suggests that hydrophobic substrates are delivered
by p-gp to the extracellular side after interaction with p-gp within the lipid bilayer of
the plasma membrane. In the flippase model it is assumed that the hydrophobic p-gp
substrates interact with p-gp within the inner leaflet of the cytoplasmic membrane lead-
ing to a translocation into the outer leaflet (Higgins and Gottesman 1992). However, the
exact transport mechanism seems to be very complex and is still unclear. Hence, the
determination of p-gp transport activity as well as the identification and classification of
p-gp substrates is difficult.
Various in vitro screening assays have been developed to examine p-gp activity by
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quantification of ATPase activity or by means of radioactively labelled ligands or fluores-
cent dyes using isolated cells, cell monolayer cultures or isolated tissues (Bauer et al. 2003,
Schwab et al. 2003). Cell monolayer cultures are routinely used in industry to investigate
the effect of p-gp mediated efflux on the penetration of different drugs across the mono-
layer. The assays are mainly performed with the p-gp overexpressing cell lines Caco-2
and MDKC (Horio et al. 1989, Kim et al. 1998). For compounds, which are studied in
this monolayer system, low to moderate passive permeability is required to detect the
influence of p-gp on their transport across the cell monolayer (Lentz et al. 2000).
In the ATPase assay the high-capacity ATP hydrolytic activity of p-gp is measured
by monitoring the release of inorganic phosphate with a colorimetric reaction (Urbatsch
et al. 1994). Since the ATPase activity is drug dependent, it directly reflects the drug
transport capability of p-gp and can be used to identify high-affinity substrates of p-gp
(Scarborough 1995). However, several well known p-gp substrates such as vincristine or
ivermectine show no stimulation of the ATPase activity (Schwab et al. 2003) and thus,
are not identified as p-gp substrates by the ATPase assay.
Another approach to determine the transport activity of p-gp are micro-pH measure-
ments presented by Landwojtowicz et al. (2002). This method is based on the observation
that p-gp ATPase activation causes a cytosolic alkalinization in p-gp overexpressing cells
(Roepe et al. 1993). The increased cytosolic pH results in an acidification of the cell cul-
ture medium which can be detected by pH microsensors (McConnell et al. 1992). However,
the mechanism of proton translocation is still unknown.
Assays with radioactively labelled compounds such as [3H]colchicine or [3H]vinblastine
are another possibility to identify p-gp substrates and to examine p-gp activity. Begley
et al. (1996) used this method to prove the expression of p-gp in the immortalized cell line
RBE4, derived from rat cerebral capillary endothelial cells. However, the separation of cell
associated radioactivity from unbound radiolabeled ligands in the surrounding medium
is a major obstacle of this method. In addition, screening assays should be performed
without the use of radioactivity due to safety and environment protection aspects.
Fluorescence assays, which are mostly performed with rhodamine 123 or calcein-acetoxy-
methylester (calcein-AM) present an alternative to the aforementioned radiochemical as-
says. They allow a rapid screening of both cell lines and compounds concerning p-gp
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expression and affinity, respectively, in a relatively short time. Before these two com-
pounds were used for detecting p-gp substrates, transport studies were mostly carried out
on the basis of doxorubicine (Wall et al. 1993). As rhodamine 123 is a substrate of p-gp,
the rhodamine 123 uptake in p-gp expressing cells is decreased compared to the rhodamine
123 uptake in cells without a MDR1 phenotype. There is an inverse correlation between
expression of p-gp and cellular uptake of rhodamine 123. The use of rhodamine 123 in
such a fluorescence screening assay to identify p-gp substrates or inhibitors is hampered
by the mitochondrial trapping of the dye (Scaduto and Grotyohann 1999). Furthermore,
rhodamine 123 is a fluorescent substance, which leads to similar problems as in radio-
chemical experiments with respect to the separation of rhodamine 123 loaded cells from
free rhodamine. The separation step may affect the integrity of the cells and may cause
leakage of the dye (Bauer et al. 2003). On the contrary, calcein-AM is most suitable for
the use in a fluorescence assay to identify either p-gp expression in cells or p-gp substrates
and p-gp inhibitors (Schwab et al. 2003). Non-fluorescent calcein-AM is transformed into
calcein, which is strongly fluorescent and trapped inside the cells (see chapter 4.3). Hence,
in contrast to the fluorescent rhodamine 123, high concentrations of calcein-AM located
in buffer do not interfere with the measurements of cell associated fluorescence. More-
over, additional preparation steps are not required and the adulterations of the measured
fluorescence due to dye leakage are minimized. In contrast to micro-pH measurements the
mechanism of calcein-AM efflux is well-known (see chapter 4.3). The calcein-AM efflux
assay can be performed within a few hours compared to one day in case of radiochemical
assays. Nowadays, calcein-AM is widely used in cell biology studies of intracellular ion
activities.
In this chapter a calcein-AM efflux assay is described and different applications of the
assay such as the determination of p-gp expression in tumor cells or identification of p-gp
substrates are exemplified. Additionally, the feasibility of the calcein-AM efflux assay in
common cuvette measurement and at the flow cytometer is compared.
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4.2 Materials and methods
4.2.1 Drugs and reagents
Calcein-AM was obtained from Molecular Probes (Eugene, OR, United States). Calcein-
AM was dissolved in DMSO (Merck, Darmstadt, Germany) to achieve a final concentra-
tion of 1 mM and aliquoted into stock solutions that were stored at -20 ℃. Calcein was
prepared by cleaving the ester bonds of calcein-AM with 0.2 % porcine esterase (Sigma,
München, Germany) in phosphate buffer, pH 7.4, at 37 ℃ for 1 hour. Vinblastine and R-
verapamil were received from Sigma. SDZ PSC 833 (Valspodar®) was a gift from Novartis
(Nürnberg, Germany). Rapamycin (Sirolimus®) was kindly provided by Wyeth Pharma
(Nürnberg, Germany). The suppliers of the other chemicals are mentioned in chapter
3. Loading buffer consisted of 120 mM NaCl, 5 mM KCl, 2 mM MgCl2 · 6H2O, 1.5 mM
CaCl2 · 2H2O, 25 mM HEPES and 10 mM glucose and was adjusted to pH 7.4. Loading
suspension contained loading buffer supplemented with 20 mg/ml of bovine serum albu-
min (Serva, Heidelberg, Germany) and 5 µl/ml of Pluronic F127 (20 % in DMSO). PBS
composition is specified in chapter 3.
4.2.2 Cell culture
All cell lines were purchased from the American Type Culture Collection (ATCC, Rock-
ville, MD, USA) and cultured as monolayers in 75 cm2 flasks (Nunc, Wiesbaden, Ger-
many). The cell cultures were maintained at 37 ℃/5 % CO2 in different culture media.
Kb-V1 cells (wildtype) were cultivated in DMEM culture medium (Sigma) supplemented
with 3.7 g/l of sodium hydrogen carbonate, 110 mg of sodium pyruvate and 10 % of
FCS and adjusted to pH 7.4. The cultivation of NCI-H460 is described in chapter 3.
Subculturing was carried out with 0.2 % trypsin/EDTA (Viralex, Paa Laboratories) in
PBS once a week. The p-gp overexpressing subclones of Kb-V1 and NCI-H460 cells,
termed Kb-V1/VBL and NCI-H460/VBL, respectively, were obtained by adding increas-
ing amounts of a vinblastine solution after subculturing to achieve a vinblastine concen-
tration of 300 ng/ml culture medium within a period of about 90 days (66.7 µl of 10−4M
vinblastine in 70 % ethanol). After 3 passages the modified cell lines expressed sufficient
quantities of p-gp. New cells were thawed after Kb-V1/VBL cell line was cultivated for
about 15 weeks.
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4.2.3 Calcein-AM efflux assay
Flow cytometry The assay was carried out with slight modifications according to Hollo
et al. (1994), Homolya et al. (1993) and Homolya et al. (1996). Cells were trypsinized 3
or 4 days after the passaging and washed with PBS at 25 ℃. To 0.75 ml cell suspension
containing 1·106 cells in loading buffer 0.25 ml loading suspension was added. The samples
were mixed with different concentrations of test compounds and vortexed. After 15 min
calcein-AM solution (1 mM in DMSO) was added to achieve a concentration of 1 µM.
If cells were examined regarding their p-gp functionality, calcein-AM was given directly
to the samples. After an incubation for 10 min at 37 ℃/5 % CO2 the supernatant was
discarded after centrifugation for 7 min at 4 ℃ and 1100 rpm. The cell pellet was rinsed
once with ice cold PBS and resuspended in 0.5 ml of loading buffer per 1 · 106 cells.
Calcein fluorescence was measured by a FACS Calibur™ (Becton Dickinson, Heidelberg,
Germany) flow cytometer in the FL1-H channel. In each measurement 30,000 gated events
were evaluated. The photomultiplier settings were as follows: E-1 for FSC, 270 for SSC
and 300 for FL1-H. Data were analyzed by the WinMDI 2.8 software.
Conventional fluorimetry Cells were seeded in black 96-well plates with transparent
bottom (Nunc) at a density of 10 and 25 cells per well in case of the Kb-V1 and Kb-
V1/VBL cell line, respectively. After an incubation of 4 days at 37 ℃/5 % CO2, the
subconfluent cells were washed with PBS and preincubated for 15 min at room tempera-
ture with 50 µl loading buffer which contained test compounds in various concentrations.
Then, 50 µl of 2 µM calcein-AM in loading buffer were added so that the final calcein-AM
concentration amount to 1 µM. The cells were incubated for 10 min at 37 ℃/5 % CO2
and rinsed three times with ice cold PBS. PBS was carefully removed by suction and re-
placed with 200 µl of Triton-X-100 solution per well to lyse the cells. Subsequently, plates
were gently shaken on a Köttermann 4010 shaker for 30 min. Calcein fluorescence was
measured by Fluoroskan Askent Labsystem™ microplate reader (Franklin, MA, Unites
States) with an excitation wavelength of 485 nm and an emission wavelength of 538 nm.
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4.2.4 Time-resolved measurements on the flow cytometer
Cells were prepared as described in the calcein-AM-efflux assay for the flow cytometer.
Each sample contained 3 · 106 cells in 3 ml of loading buffer. After preincubation with
the test compounds, the samples were measured with a FACS Calibur™ flow cytometer
at the same parameter as used for the calcein-AM efflux assay. Calcein-AM addition was
carried out after 30 s with a Hamilton syringe. Care was taken that the sample tubes
were at a stable temperature of 37 ℃ during the experiment. The fluorescence intensity
increase at FL1-H channel was recorded over a period of 7.5 min. Data were analyzed
by the WinMDI 2.8 software and the fluorescence events in channel FL1-H were plotted
against the time.
4.3 Principle of the calcein-AM efflux assay
Calcein-AM is a non-fluorescent, lipophilic ester, that rapidly penetrates the plasma mem-
brane of cells (Fig. 4.1 a). Inside the cells the ester bonds are cleaved by nonspecific
esterases and highly fluorescent calcein is generated (Fig. 4.2 a). Calcein (Fig. 4.1 b) is
hydrophilic and thus, trapped inside the cells, so that intracellular fluorescence can be
measured. Calcein-AM is a substrate of p-gp. In cells of the MDR1 phenotype calcein-AM
is extruded by p-gp before esterases can cleave the ester bonds and calcein is not accu-
mulated (Fig. 4.2 b).
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Figure 4.1: Structures of calcein-AM (a) and calcein (b)
4.3 Principle of the calcein-AM efflux assay 77
calcein
esterase
calcein-AM
cell membrane
cell without MDR1 phenotypea
calcein-AM
cell with MDR1 phenotypeb
calcein
calcein-AM
cell with MDR1 phenotype
plusp-gp inhibitor
calcein
c
Figure 4.2: Principle of the calcein-AM efflux assay: in cells without MDR1 phenotype the
fluorescence dye calcein is formed by intracellular hydrolysis of non-fluorescent
calcein-AM, a p-gp substrate, by esterases (a). In MDR positive cells overexpression
of p-gp increases extrusion of calcein-AM from the cell membrane before hydrolysis
takes place, leading to a reduced accumulation of calcein (b). The calcein-AM
efflux is blocked by addition of a p-gp inhibitor (c).(from Bauer et al. (2003) with
modifications)
Thus, the intracellular fluorescence is significantly higher in cells with low or no p-gp
expression than in multidrug resistant cells. Inhibition of p-gp mediated calcein-AM trans-
port by certain modulators decreases the calcein-AM efflux. Depending on the modulator
concentration this results in an intracellular calcein fluorescence comparable with cells
without a MDR1 phenotype. Therefore, intracellular fluorescence is indicative for either
an inhibition of p-gp by an added p-gp inhibitor or of cells expressing non-functional p-gp.
The intracellular calcein fluorescence can be detected by means of conventional fluo-
rimetry, flow cytometry and laser-scanning microscopy (Hollo et al. 1994). The fluores-
cence excitation and emission maxima of calcein are 496 and 517 nm, respectively (Fig.
4.3).
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Figure 4.3: Excitation (λem=517 nm) and emission (λex=496 nm) spectrum of calcein in phos-
phate buffer pH 9.
Preceding investigations such as examination of the autohydrolysis of calcein-AM and
the photostability of calcein proved the high stability of the compounds (data not shown)
and confirmed the suitability of this fluorescent dye system for the investigation of p-gp
efflux in cells.
4.4 Optimization of the calcein-AM efflux assay for flow
cytometry
Various experimental procedures for the calcein-AM efflux assay are described in literature
(Homolya et al. 1993, Hollo et al. 1994, Feller et al. 1995, Liminga et al. 1994, Legrand
et al. 1998). They differ in several parameters such as incubation time, incubation temper-
ature, calcein-AM concentration and cell number in the sample. The calcein-AM loading
concentration of the cells is depending on the used calcein-AM concentration and the
number of cells per sample. Homolya et al. (1996) examined the appropriate conditions
for the calcein-AM efflux assay in great detail and found that at calcein-AM concentra-
tions between 0.1 to 1 µM and cell numbers between 5 · 104 ml−1 and 1 · 106 ml−1, clearly
distinguishable fluorescence differences between p-gp expressing cells and cells without a
MDR1 phenotype can be detected.
In our department a fluorescence assay was established for the determination of intra-
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cellular calcium using fluo-4 at the flow cytometer (Schneider et al. 2002). Calcein-AM
is analogous to fluo-4. Fluo-4, an acetoxymethylester, can easily penetrate the cell mem-
brane. Inside the cell the ester bonds of fluo-4 are cleaved by intracellular esterases and
the resulting fluo-4 can complex intracellular calcium. Due to the similar uptake and
transformation mechanism of both fluo-4 and calcein-AM the loading procedure of the
fluo-4 assay can be adapted to the calcein assay using Pluronics F-127 to improve the
solubility of calcein-AM and its penetration into the cells (Granados et al. 1997).
To optimize the aforementioned assay conditions for the calcein-AM efflux assay several
experiments were carried out using Kb-V1 cells (wildtype) which are negative for the
MDR1 phenotype. In a first series of experiments the incubation time and the incubation
temperature were altered (Fig. 4.4 and Fig. 4.5). Subsequently, the optimal calcein-AM
loading concentration was determined by incubation of cells with different calcein-AM
concentrations ranging from 0.5 to 2.0 µM under the optimized conditions described
above (Fig. 4.6).
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Figure 4.4: Optimization of calcein-AM efflux assay conditions by variation of incubation times
using Kb-V1 wildtype cells (10 min - solid line, 30 min - dashed line, 60 min - dotted
line). All experiments were carried out at 25 ℃ using a cell number of 1 · 106 ml−1
and a calcein-AM concentration of 1.25 µM.
In Fig. 4.4 the results of the calcein-AM assay carried out at 10, 30 and 60 min,
respectively, are displayed in histograms. The cell associated fluorescence increased with
longer incubation times. However, the fluorescence intensity measured after an incubation
time of 10 min is even high enough for p-gp activity measurements compared to that after
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Figure 4.5: Optimization of calcein-AM efflux assay conditions by variation of incubation tem-
peratures using Kb-V1 wildtype cells (37 ℃ - solid line, 25 ℃ - dashed line). All
experiments were carried out using a cell number of 1 · 106 ml−1, a calcein-AM
concentration of 1.25 µM and an incubation time of 10 min.
a 60 min incubation. Therefore, the calcein-AM efflux assay can be performed with an
incubation time of 10 min. In a next step, the incubation temperature was varied (Fig.
4.5). The cell associated fluorescence after an incubation at 37 ℃ was similar compared
to the fluorescence intensity after an incubation at 25 ℃. As with an incubation at 37 ℃
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Figure 4.6: Optimization of calcein-AM efflux assay conditions by variation of calcein-AM load-
ing concentrations using Kb-V1 wildtype cells. All experiments were carried out
at the optimized incubation conditions using a cell number of 1 · 106 ml−1.
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physiological conditions can be simulated, this temperature was chosen for the calcein-AM
incubation.
After the optimization of the incubation conditions the appropriate calcein-AM concen-
tration was determined (Fig. 4.6). The fluorescence intensities increased with increasing
calcein-AM concentrations. The maximum fluorescence intensities did not differ very
much. However, the distribution of the fluorescence intensities after an incubation with
0.5 and 0.75 µM, respectively were relatively broad compared to incubation with higher
calcein-AM concentrations. Thus, in order to get a narrow distribution of fluorescence in-
tensities and to use only a minimum of calcein-AM, the optimal calcein-AM concentration
was determined to 1.0 µM.
Analyzing the calcein-AM efflux in Kb-V1/VBL cells, that are a p-gp overexpressing
subclone of the Kb-V1 cell line, a much lower cell assiciated fluorescence intensity was
detected compared to the fluorescence intensity of calcein loaded Kb-V1 cells due to the
p-gp mediated efflux of calcein-AM before its transformation into calcein. Both signals
were well separated from each other (Fig. 4.7). Hence, Kb-V1/VBL cells provide a system
that can be used for the examination of substances with respect to their influence on p-gp
mediated efflux. Kb-V1 wildtype cells serve as a positive control for the p-gp mediated
calcein-AM efflux. Using the determined parameters for the calcein-AM assay MDR1
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Figure 4.7: Calcein-AM efflux assay with Kb-V1 (dotted line) and Kb-V1/VBL (dashed line)
cells carried out at the optimized assay parameters (mixed population - solid line;
10 min, 37 ℃, 1 µM calcein-AM, 1 · 106 ml−1 cells)
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positive and MDR1 negative Kb-V1 cells could be even detected with this assay if they
are examined in a mixed cell population (Fig. 4.7).
In summary, the appropriate conditions for the calcein-AM efflux assay to identify p-gp
expression in cells and to investigate p-gp substrates and inhibitors are an incubation
temperature of 37 ℃, an incubation time of 10 min and a calcein-AM concentration of
1 µM using 1 · 106 cells ml−1 in each sample.
4.5 Applications of the calcein-AM efflux assay
4.5.1 Identification of p-glycoprotein expressing cells
In order to identify expression of functional p-gp in cell lines, it is not sufficient to examine
the transcription of p-gp encoding mRNA by PCR or the p-gp expression with immuno-
histochemistry. Using these methods no further information can be obtained concerning
the functionality of p-gp in the cells (Krishan et al. 1997). In contrast, the calcein-AM
efflux assay provides an analytical system for the determination of functional p-gp. For
this purpose, cells were incubated with calcein-AM according to the method described in
chapter 4.3. The lower the intensity of the intracellular calcein fluorescence, the greater
is the activity and therefore, the expression of functional p-gp.
In Fig. 4.8 the results of the calcein-AM efflux assay of wildtype and MDR resistant
NCI-H460 cells are illustrated. Although the NCI-H460 cell line characterized in chapter 1
possessed the mRNA encoding p-gp (Fig. 4.8 b), it showed an intense intracellular fluores-
cence in the calcein-AM efflux assay (Fig. 4.8 a). This leads to the assumption that p-gp is
not or at least not functionally expressed in this cell line. Different cell subclones of NCI-
H460/VBL were prepared by cultivation of the NCI-H460 wildtype cells with increasing
vinblastin concentrations. After 3 weeks of cultivation the subclones expressed functional
p-gp resulting in significantly lower intracellular fluorescence of the NCI-H460/VBL cells
compared to the wildtype. The intensity of the intracellular fluorescence decreased with
increasing p-gp expression.
In conclusion, the calcein-AM efflux assay is a suitable method to determine the p-gp
activity of a cell line in a very short time. Results are available in a few hours rather
than in more than one day in the case of using PCR or immunohistochemistry methods.
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Figure 4.8: (a) Induction of MDR1 phenotype in NCI-H460 cells by cultivation with increas-
ing vinblastine concentrations over 90 days quantificated by the calcein-AM efflux
assay. (b) Qualitative determination of mRNA encoding p-gp in wildtype NCI-
H460 cells (ethidiumbromide stained agarose gel after RT-PCR (34 cycles); β-actin
served as a control)
Additionally, a close relationship between the intracellular fluorescence intensity and the
quantity of expressed p-gp is obvious.
4.5.2 Characterization of p-glycoprotein substrates and modula-
tors
Ineffectivity of tumor chemotherapy is often caused by the multidrug resistance of malig-
nant cells and by the localization of multidrug transporters such as p-gp at several barriers
inside the body. Various substances are developed which are not transported by p-gp but
modulate the p-gp mediated efflux of p-gp substrates. The efficacy of these modulators
was studied in p-gp overexpressing Kb-V1/VBL cells using the calcein-AM efflux assay.
Cells were preincubated with the test compound for 15 min, and the assay was carried out
subsequently according to the procedure described in chapter 4.3. If the test compound
interacts with p-gp as a modulator, the intracellular fluorescence intensity increases be-
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cause p-gp transport of calcein-AM is blocked and calcein is formed and accumulates in
the cells (see Fig. 4.2 c). As a representative of 1st generation modulators, R-verapamil
(Fig. 4.9 a) and of 2nd generation modulators, valspodar (Fig. 4.9 b), were examined.
Both are well known as p-gp modulators in the literature (Holland et al. 2003).
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Figure 4.9: Structures of the 1st generation p-gp modulator verapamil (a) and the 2nd genera-
tion p-gp modulator valspodar (b)
Increasing concentrations of either verapamil or valspodar led to an elevated intracel-
lular calcein fluorescence (Fig. 4.10 a and Fig. 4.11 a). This is explained by the increasing
inhibition of the p-gp activity mediated by the two p-gp modulators. Concentration-
response profiles were acquired by incubation with various concentrations of the respec-
tive modulator. For that purpose, the geometric means of the obtained histograms were
plotted against the modulator concentrations (Fig. 4.10 b and Fig. 4.11 b) and the IC50
values were determined. An IC50 value of 248 µM was calculated using the Hill equation
for the p-gp modulation by verapamil. In case of valspodar an IC50 value of 1.63 µM was
determined. The intensity shift caused by the inhibition of the p-gp mediated efflux is dif-
ferent for the two modulators. In the case of valspodar the fluorescence intensity abruptly
increased at valspodar concentrations higher than 0.3 µM. However, when verapamil was
used to inhibit p-gp, the fluorescence intensity increased gradually (for further investiga-
tions see chapter 4.5.3). Moreover, the p-gp modulation by verapamil was not maximal
as the fluorescence intensity was still increasing at 300 µM of verapamil. Verapamil con-
centrations higher than 300 µM were not used due to solubility problems. Therefore, the
half maximum inhibitory concentration of 248 µM represents only an estimation.
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Figure 4.10: Modulation of p-gp activity by increasing concentrations of R-verapamil. Fluores-
cence intensity increased with increasing R-verapamil concentrations (a). Plotting
of geometric means against the R-verapamil concentration leads to concentration
response curves (b).
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Figure 4.11: Modulation of p-gp activity by increasing concentrations of valspodar. Fluores-
cence intensity increased with increasing valspodar concentrations (a). Plotting
of geometric means against the valspodar concentration leads to concentration
response curves. The calculated IC50 value is 1.63 µM. (b).
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In addition to a complete inhibition of the p-gp activity, it is important to regard the
limited solubility of the test compounds in the aqueous assay system to calculate precise
IC50 values. The results of the p-gp modulation by the immunosuppressant rapamycin in
the calcein-AM efflux assay are shown in Fig. 4.12. A correlation between the shift of the
fluorescence intensity in channel FL1-H and the added rapamycin could not be established.
The fluorescence intensities decreased at high amounts of rapamycin. Considering the
solubility of rapamycin in water (Fig. 4.13), it becomes obvious that rapamycin is only
partially soluble in aqueous systems at concentrations higher than 30 µM. In literature
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Figure 4.12: Modulation of p-gp activity by increasing amounts of rapamycin. There is no cor-
relation between the shift of the fluorescence intensity and the added rapamycin.
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Figure 4.13: Solubility of rapamycin in loading buffer determined by turbidimetric analysis at
λ600nm. Rapamycin is not soluble in aqueous solutions in concentrations higher
than 30 µM.
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the solubility of rapamycin in water is even given as low as 0.3 µM. Hence, conclusions
about the exact concentration of the drug responsible for the p-gp modulation in the
calcein-AM efflux assay cannot be drawn.
It becomes clear that accurate results in the calcein-AM efflux assay can only be ob-
tained for those substances that are sufficiently soluble in aqueous systems. Furthermore,
false negative results are achieved if the affinity of a test compound for p-gp is lower com-
pared to the p-gp affinity of calcein-AM (Homolya et al. 1993). In that case calcein-AM
is the preferred substrate of p-gp and is being effluxed by p-gp.
In summary, the distinction between p-gp substrates and inhibitors is difficult. Using
the calcein-AM efflux assay, the potency of p-gp modulation can be assessed. However,
only interactions of p-gp substrates with a higher affinity to p-gp compared to calcein-AM
can be detected.
4.5.3 Investigation of transport mechanisms by time-resolved mea-
surements
The 1st generation modulator verapamil and the 2nd generation modulator valspodar
significantly differ regarding the steepness of the corresponding concentration-response
curves (Fig. 4.10 b and Fig. 4.11 b). This could be a hint to different inhibition mechanisms
of the p-gp mediated efflux and was investigated by means of time-resolved measurements
based on the calcein-AM efflux assay during the incubation period. Flow cytometry offers
the possibility to observe changes in the fluorescence over an arbitrary period of time.
In Fig. 4.14 the results of the time resolved measurements are shown. An increase in
fluorescence intensity during the incubation period was observed as expected.
Calcein-AM was added after 30 s, and the experiment was aborted after 7.5 min when
the fluorescence intensity of the control cells (Kb-V1 wildtype cells) was nearly constant.
The diagrams show the measurements with the most pronounced changes of the slope of
the concentration response curves. Immediately after calcein-AM addition, fluorescence
rises irrespective of the modulator. The higher the modulator concentration, the faster
is the increase in calcein fluorescence. Fluorescence intensities in channel FL1-H reached
after 7.5 min correspond to the results depicted in Fig. 4.10 and Fig. 4.11. In conclusion,
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Figure 4.14: Time-resolved measurements of calcein fluorescence during incubation with dif-
ferent concentrations of verapamil (VP, a) and valspodar (PSC, b)
with respect to the explanation of the different slopes of the concentrations response
curves no additional information could be obtained by this approach. Calculations of
typical kinetic parameters (i.e. Michaelis constant Km and maximum velocity vmax) based
on the fluorescence intensity increase were impossible as well. Therefore, insight into the
kinetic processes could not be gained. It is difficult to assess the transport procedures
with respect to kinetic aspects, as the formation of calcein is controlled by two subsequent
steps. First, calcein-AM has to be incorporated into the cells and in the second step the
ester bonds have to be cleaved to form calcein. The first step is the more interesting
one when characterizing the p-gp transport process. However, the separation of the two
processes for a calculation is difficult and additional assays have to be carried out to
clarify the transport processes.
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4.6 Comparison of flow cytometry and fluorimetry with
respect to the calcein-AM efflux assay
The calcein-AM efflux assay was adapted to the fluorimeter to confirm the reliability of
the method. Advantages and drawbacks of the newly developed flow cytometric method
in comparison to the conventional fluorimetric procedure are explained in the following.
The assay was carried out in microtiter plates. As with conventional fluorimetry the
fluorescence of a number of cells is measured at once, it is important to ensure the same
cell density in each well. This aspect is negligible, if the assay is performed with the
flow cytometer, since the fluorescence signals of single cells are detected in this case. To
determine the intracellular calcein fluorescence with the fluorimeter cells were washed
several times after loading with calcein-AM and then lysed to release the calcein.
Figure 4.15: Calibration curve of calcein at the conventional fluorimeter. The framed data in
(a) is presented in detail in (b) (λex = 485 nm, λem = 538 nm)
As the sensibility of the fluorimeter for calcein fluorescence is a crucial point, a cali-
bration curve was recorded (Fig. 4.15 a). As shown in Fig. 4.15 b even in low fluorescence
intensity ranges the linearity of the calcein calibration was maintained.
To assess the reliability of the calcein-AM efflux assay, p-gp modulation experiments
with valspodar were performed both with the fluorimeter and the flow cytometer using
Kb-V1/VBL cells (Fig. 4.16). The curve shape was similar in both cases. The curves
showed similar steepness and the IC50 values of 1.63 µM and 1.80 µM determined by flow
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Figure 4.16: Comparison of p-gp activity modulation by valspodar with the flow cytometer and
the fluorimeter using Kb-V1/VBL cells (10 min, 37 ℃, 1 µM calcein-AM). The
measurements at the fluorimeter are performed at lysed cells with λex = 485 nm
and λem = 538 nm. The fluorescence intensity at the flow cytometer is recorded
in channel FL1-H.
cytometry and fluorimetric measurements, respectively, are in good agreement. Thus, the
measurements of the p-gp activity in cells using the calcein-AM efflux assay, give reliable
results.
The KB-V1 cells and the corresponding chemoresistant subclones grew irregularly lead-
ing to different cell concentrations in microtiter plates used in fluorimetry. In contrast,
flow cytometry measurements are independent of cell growth due to the aforementioned
single cell measurement principle. Moreover, the lysis of the cells, that is necessary to
release the intracellular calcein for the measurements with the conventional fluorimeter,
leads to an intensive light scattering. This results in a low signal-to-noise ratio that impairs
the fluorescence intensity measurements up to valspodar concentrations of 1 µM. Exact
fluorescence intensities can not be determined in this concentration range. In contrast, the
flow cytometric determination of the calcein fluorescence intensities in dependence of p-
gp modulation by valspodar resulted in significant concentration-response curves. Hence,
the flow cytometric measurement is superior to the conventional fluorimetric procedures.
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Therefore, all further calcein-AM efflux assay measurements were carried out with the
flow cytometer.
4.7 Conclusions and summary
The calcein-AM efflux assay represents a convenient method to characterize the MDR1
phenotype with respect to the activity of expressed p-gp in cells. The method is useful for
the investigation of p-gp modulators. However, the assay is not able to distinguish between
transported substrates of p-gp and compounds with inhibitory properties. The prediction
of the p-gp interaction is important for the screening of drug candidates. Furthermore,
the characterization of the kinetics of the p-gp transport process has to be investigated
for the development of potent p-gp inhibitors. This is especially true for agents with
CNS activity. Further efforts have to be made to elucidate p-gp binding sites and the
complex allosteric interactions (Martin et al. 2000) as well as to develop new assays for
differentiation between inhibitors, transported substrates and non-transported substances.
Today it is difficult to perform this classification with only one assay (Schwab et al. 2003)
and the characteristics of substances in different assays must be considered to obtain
information about the site of interaction for the tested compound (Polli et al. 2001).
Computer based models are also used as computational filters to select drugs lacking the
interaction with p-gp (Penzotti et al. 2002). However, the calcein-AM efflux assay is most
suitable for primary screening of drug candidates and should be confirmed by transport
assays and in vivo experiments.
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Chapter 5
In vivo models of human lung cancer
brain metastases
5.1 Introduction
Multidrug resistance (MDR) is one of the major obstacles to successful tumor therapy.
The overexpression of P-glycoprotein 170 (p-gp) is the best characterized phenotype of
MDR, although this is not the only mechanism involved (Gottesman and Pastan 1993).
P-gp is not only expressed in chemoresistant tumor cells but also within normal cells of
the human body, particularly in liver, kidney and the blood-brain-barrier (BBB). The
localization of p-gp at the BBB is one of the drawbacks in the chemotherapy of primary
and secondary brain tumors because of the protective function of p-gp that results in
efflux transport of chemotherapeutic agents (Schinkel et al. 1995). A further problem in
the treatment of brain metastases is the primary chemoresistance of tumors preferably
metastasizing to the brain (Sawaya and Bindal 1995). However, in case of secondary brain
tumors chemotherapy is preferred to locally acting methods such as radiation therapy and
surgery because the whole brain is treated. In addition, the cytostatic drugs can act on
the primary tumor as well as on metastases in organs other than the brain.
Secondary brain tumors represent approximately 40 % of intracranial neoplasms. In the
United States annually approximately 170,000 cancer patients develop brain metastases.
In adults, primary tumors that often metastasize to brain are lung cancer (50 %), breast
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cancer (15 - 20 %), unknown primary neoplasms (10 - 15 %), melanoma (10 %), renal and
colon cancer (both 5 %) (Kaye and Laws 1995). Brain metastases from unknown primary
tumors are most likely from lung cancer (72 %). Furthermore, breast, renal and colon
cancer produce single metastases, whereas metastases from lung cancer and melanoma
are normally multiple (Wen and Loeffler 1999, Khosla 2004). Brain metastases contribute
to cancer morbidity and mortality, and are responsible for the neurologic breakdown in
cancer. As mentioned before the majority of secondary brain tumors originate from lung
cancer which is characterized by a high fatality rate due to the advanced stage of disease
at time of diagnosis and its aggressive biologic nature (Tuveson and Jacks 1999). Hence,
need for new approaches to the treatment of lung tumor brain metastases is obvious.
Possible new treatment strategies, e.g. the combination of anticancer drugs with ABC
efflux transporter modulators, have to be examined first regarding their effectiveness
in preclinical studies. For that purpose animal models are required that simulate the
situation in the human body. At present, various mouse models are established including
mice, which develop lung tumors spontaneously or after chemical induction, as well as
transgenic mice, which express viral and cellular oncogenes (Tuveson and Jacks 1999).
However, none of these models account for the development of brain metastases.
At our department an orthotopic tumor model, using nude mice bearing intracerebral
human gliobalstoma, was developed to study the therapy of primary brain tumors (Fellner
et al. 2002). For that purpose, human glioblastoma cells were injected intracerebrally into
nude mice according to Altenschöpfer (1998). The anticancer agent paclitaxel was co-
administered intravenously with valspodar, an inhibitor of the efflux transporter p-gp, to
increase the paclitaxel concentration in the brain. The paclitaxel dose had to be reduced
from 3 to 2 mg paclitaxel per kg body weight within the experiment due to the body
weight reduction that is an indication of the toxicity of the combination with valspodar.
In this study a significant increase in the brain paclitaxel concentration and a reduction
of the tumor volume by 90 % was achieved with the combination treatment. Since the
glioblastoma cells expressed no p-gp, the observed effect could only be explained by the
p-gp inhibition at the BBB.
The aforementioned model was very useful to demonstrate that the combination stra-
tegy is a promising approach to the treatment of primary brain tumors. In principle, this
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animal model can be adapted to study secondary brain tumors from lung cancer, and to
investigate the therapeutic benefit of a treatment with a cytostatic in combination with
p-gp modulators. Hence, this study was focussed on the treatment of secondary brain
tumors originating from the lung. After an extensive characterization of selected human
lung cancer cell lines (see chapter 3) the suitability of these cell lines for the presented brain
tumor model was examined. In addition, the simulation of lung cancer brain metastases
and their response to a combination treatment with valspodar was investigated.
5.2 Material and methods
5.2.1 Drugs and chemicals
SDZ PSC 833 (Valspodar®) was a gift from Novartis (Nürnberg, Germany). Paclitaxel
and vinblastine used for the in vitro tests were purchased from Sigma (München, Ger-
many). Stock solutions of all drugs were prepared in 70 % ethanol. For the treatment
experiments Cellblastin® (Cellpharm, Hannover, Germany) and Taxol® (Bristol-Myers-
Squibb, München, Germany) were used. All other chemicals and reagents were purchased
either from Merck (Darmstadt, Germany) or from Serva (Heidelberg, Germany). The
valspodar vehicle consisted of 52.2 g of cremophor RH40 (Caelo, Hilden, Germany), 15 g
of absolute ethanol (Merck), 0.1 g of DL-α-tocopherol (Sigma), 7.5 g of propylene glycol
(Merck) and 15 g of Labrafil M2125CS (Gattefosse, Weil am Rhein, Germany). The PCR
primers were purchased from MWG Biotech (Ebersberg, Germany). Solution D contained
250 g guanidine thiocyanate (Merck), 293 ml demineralized water with DEPC, 17.6 ml
sodium citrate (0.1 M, pH 7) and 26.4 ml 0.5 % N-lauryl sarcosine sodium salt (sacrosyl,
Merck). All ingredients were dissolved at 64 ℃. The composition of PBS and Bouin’s
solution is specified in chapter 3.
5.2.2 RNA-Isolation and RT-PCR
The isolation of total RNA was carried out according to the procedure of Chomczynski
and Sacchi (1987). Human lung cancer cells were grown in 75 cm2 flasks. When the
cells were confluent, the culture medium was removed, and 5 ml of solution D was added
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to lyse the cells. The solution was mixed with 0.5 ml of sodium acetate (pH 4, 2 M),
5 ml of water-saturated phenol and 1 ml of chloroform, and was vortexed for 20 s. After
incubation on ice for 15 min and centrifugation at 10,000 g for 15 min at 4 ℃, the two
phases were separated and isopropyl alcohol p.a. (Merck, Darmstadt, Germany) was
added to the upper phase to yield a 1:1 mixture. RNA was precipitated by incubation for
1 h at -20 ℃ followed by centrifugation at 15,000 g for 15 min at 4 ℃. The supernatant
was removed by suction, and the RNA pellet was resuspended in 1 ml of solution D.
After the addition of 1 ml of isopropyl alcohol p.a., the RNA was precipitated for a
second time by incubation for 1 h at -20 ℃ followed by centrifugation at 13,000 g for
30 min at 4 ℃. Again, the supernatant was removed and the pellet was washed with 70 %
ethanol. After centrifugation at 15,000 g for 15 min at 4 ℃ the pellet was dried at room
temperature, dissolved in water containing DEPC (DEPC water), and stored at -80 ℃.
The concentration and purity of the isolated RNA were measured using an ultraviolet
spectrophotometer, confirming A260/280 ratio values between 1.6 and 1.8.
The reverse transcription (RT) reaction was carried out with 1 µg of total RNA and
1 µl of oligo(dT12−18) primer (Invitrogen, Karlsruhe, Germany) in DEPC water. The
mixture was heated at 70 ℃ for 5 minutes and afterwards cooled on ice. To 10 µl of
the mixture the following reagents were added: 200 U of M-MLV reverse transcriptase
(Invitrogen, Karlsruhe, Germany), 0.5 µl of RNAsin (Promega, Mannheim, Germany),
10 mM dNTP (MBI Fermentas, St. Leon-Rot, Germany), 2 µl of dithiothreitol (DTT,
Roche, Basel, Germany) and 4 µl of first strand buffer (Invitrogen, Karlsruhe , Germany).
cDNA was synthesized at 37 ℃ for 1 h followed by incubation at 95 ℃ for 2 min. cDNA
samples were stored at -20 ℃.
The polymerase chain reaction (PCR) was performed according to standard procedures.
2 µl of cDNA solution were mixed with 1 U of Taq (Roche, Mannheim, Germany), 2 µl
of 10x PCR buffer, 2 µl of 10 mM dNTPs, 1 µl of sense and anti-sense primer and DEPC
water to yield a volume of 20 µl. The used primer sequences are displayed in table 5.1.
The PCR encompassed 34 cycles at a denaturation temperature of 95 ℃ for 30 s,
an annealing temperature of 60 ℃ for 60 s, and an extension temperature of 72 ℃ for
30 s. The last cycle contained a 2 min extension step at 72 ℃. Following PCR, 10 µl
of PCR reaction mixture was subjected to electrophoresis on 1.5 % agarose gels. The
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Table 5.1: Primer sequences used for RT-PCR
Primer Sequence bp
β-actin sense 5’-CGGGATCCCCAACTGGGAC-3’ 304
antisense 5’-GGAATTCTGGCGTGAGGGA-3’
MDR1 sense 5’-CGGGATCCCCCATCATTGCAATAGCAGG-3’ 167
antisense 5’-GGAATTCGTTCAAACTTCTGCTCCTGA-3’
PCR products were visualized by staining with ethidium bromide (2 %) and analyzed by
a GelDoc imaging system (BioRad, München, Germany).
5.2.3 Immunocyto- and Immunohistochemistry
Subconfluent tumor cells, cultured on chambers slides, were fixed in 4 % phosphate
buffered paraformaldehyde, pH 7.4, for 30 minutes and washed three times with PBS.
The deparaffinizing of paraffine embedded tumor tissue sections is described in chapter
3.2.3. The staining procedure was similar for cells and tissue sections.
Endogenous peroxidase was blocked by incubation in PBS containing 3 % H2O2 and
10 % methanol for 30 min, followed by two incubations in PBS with 0.04 % Triton-X-
100 (PBST) for 5 min. Nonspecific binding was prevented by incubation for 30 min in
10 % natural goat serum (NGS, Sigma, München, Germany), 2.5 % skimmed milk pow-
der (Milupa, Friedrichsdorf, Germany), and 0.3 % Triton-X-100 in PBS. Subsequently,
cells were washed three times with PBST. Primary antibody AB-1 (PC03) (polyclonal
anti-human/mouse p-gp, Dianova) was diluted 1:10 (1:50 in case of immunocytochem-
istry) with washing buffer consisting of 10 ml of PBST, 100 µl of 1 % NGS, and 0.3 %
Triton-X-100. After incubation with AB-1 over night at room temperature, the slides
were washed three times with PBST and treated with biotinylated goat anti-rabbit an-
tibody as secondary antibody (1:200, Dianova, Hamburg, Germany) for 2 hours at room
temperature in a humid chamber. Afterwards, slides were washed three times in PBST
and incubated for 1 hour with horseradish-conjugated avidin-biotin complex (Vectastain
Elite Kit ABC, Vectorlabs, Burlingame, United Kingdom) in PBST. Slides were washed
for 5 min in PBST before incubation in a diaminobenzidine (DAB) solution for 10 min
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(0.05 % DAB, 0.02 % ammonium nickel sulfate in PBST). H2O2 (10 %) was added to a
final concentration of 0.006 %, and slides were incubated for 1.5 min. Afterwards, they
were washed three times with PBS and counterstained with nuclear fast red solution for
50 s. Subsequently, the slides were given in PBS and demineralized water, processed in
an ascending alcohol series and mounted with DePex. All stained slides were evaluated
with a BH2 microscope (Olympus, Hamburg, Germany) mounted with a CCD-camera for
digital imaging.
5.2.4 Calcein-AM efflux assay
The exact assay procedure is described in chapter 4.2.3.
5.2.5 Chemosensitivity assay
The procedure is described in detail in chapter 3.2.6.
5.2.6 Intracerebral tumor cell implantation
The breeding of the used NMRI(nu/nu) nude mice is reported in chapter 3.2.7.
The intracerebral model has been described at Altenschöpfer (1998). In brief: the
parietal bone of anaesthetized nude mice was drilled with a 1-mm-diameter bit 3 mm
to the right-hand side of the sagittal line and 3 mm rostral of the coronal line. Human
lung cancer cells (5·104 and 1 · 105 cells in case of NCI-H460 and DMS 114 cell line,
respectively) suspended in 5 µl of serum-free RPMI 1640 culture medium (NCI-H460 cell
line) or Eagle’s minimum essential medium (DMS 114 cell line) were injected 3 mm deep
into the brain tissue, and the wound was closed with a surgical clamp.
5.2.7 Treatment of intracerebrally growing lung cancer
In the intracerebral model, the 7- to 9-week old nude mice were assigned to 5 groups
(n = 6-8). For each experiment only animals of the same sex were used. In the co-
application studies of valspodar and vinblastine mice were assigned to 5 groups of 6 to
8 animals. The control groups received either 0.9 % NaCl solution (vehicle of cytostatic
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drug, group 5), complex vehicle of valspodar (group 4) or valspodar alone (50 mg/kg, p.o.,
group 3). Two additional groups were treated either with a combination of valspodar and
the cytostatic drug (50 mg/kg valspodar, p.o.; 0.8 mg/kg vinblastine, i.p.; group 1) or
with the cytostatic drug alone (0.8 mg/kg vinblastine, i.p., group 2). Solutions were
administered in a volume of 0.1 ml/20 g body weight. Valspodar and its vehicle were
given orally every 5 days 4 h before the intraperitoneal injection of vinblastine and its
vehicle. The survival rate was calculated by a Kaplan-Meyer analysis.
In case of co-application of valspodar and paclitaxel the treatment of mice, which
were assigned in groups according to the co-application of valspodar and vinblastine, was
as follows: valspodar (50 mg/kg) and vehicle were administered orally 4 h before the
intravenous injection of two doses of paclitaxel and its vehicle, i.e., 3 mg/kg on day 8 and
another 2 mg/kg on day 15 after tumor implantation. Animals were killed at day 20, and
brains were fixed in Bouin’s solution for histological examination. Serial 5 µm coronal
sections were prepared every 150 µm from the paraffine embedded brains starting and
ending 1.5 mm rostral and caudal to the region of tumor cell implantation. The sections
were stained according to the HE-staining procedure described in detail in chapter 3.2.3.
5.3 Results
5.3.1 Prerequisites of an intracerebral in vivo model for the p-gp
modulation in the nude mouse brain
The orthotopic brain tumor model is suitable for studies on the p-gp modulation at the
BBB (see also chapter 7). Furthermore, it is used for treatment experiments of primary
and secondary brain tumors. Selected tumor cell lines for these tests have to comply with
the following requirements. To observe a p-gp modulatory effect only at the BBB, the
cells have to be negative for the MDR1 phenotype. As a second prerequisite, the cells
should be chemosensitive in the presence of low concentrations of cytostatic drugs. In
addition, the cells have to be tumorigenic in the brains of nude mice.
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5.3.1.1 Investigations on the MDR phenotype of human lung cancer cell lines
The MDR phenotype of the selected lung cancer cell lines NCI-H460 and DMS 114 was
examined in three ways. The existence of p-gp encoding mRNA was detected by PCR.
The p-gp expression was demonstrated with immunohistochemical methods, and the func-
tionality of an eventually expressed p-gp was determined by the calcein-AM efflux assay.
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Figure 5.1: Determination of p-gp encoding mRNA in NCI-H460 and DMS 114 cells. mRNA
encoding for the MDR1 phenotype was only detected in NCI-H460 cells (ethidium-
bromide stained RT-PCR gel after 34 cycles. β-Actin served as a control.)
The results of the RT-PCR for the MDR1 encoding mRNA are shown in Fig. 5.1.
mRNA encoding for p-gp was detected in PCR products of the NCI-H460 cells. DMS 114
cells possessed no p-gp encoding gene, because no PCR product of 167 base pairs was
observed. β-Actin served as a control for proper RT-PCR procedure.
The expression of p-gp was examined with an avidin-biotin-method on paraffine sec-
tions as well as on fixed cells. No typical p-gp staining was observed on any examined
slide. Hence, although NCI-H460 cells have MDR1 encoding mRNA, p-gp is not expressed
at the protein level. In case of the DMS 114 cell line, the negative MDR phenotype of
the cells determined in the RT-PCR experiment was confirmed.
Fig. 5.2 shows the results of the calcein-AM efflux assay that was used to investigate the
cell lines regarding p-gp activity. Both NCI-H460 and DMS 114 cells took up calcein-AM
very well leading to high fluorescence intensities. Therefore, no active p-gp was expressed
in the two cell lines despite the genetic disposition of NCI-H460 cells. However, NCI-
H460 cells could presumably become MDR resistant by the addition of p-gp inducers like
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Figure 5.2: Comparison NCI-H460 (dashed line), DMS 114 (dotted line) and p-gp overexpress-
ing Kb-V1/VBL (solid line) cells with respect to their p-gp activity. Both NCI-H460
and DMS 114 cells show higher fluorescence intensities compared to Kb-V1/VBL
cells indicating an inactive p-gp or the lack of p-gp.
vinblastine.
In conclusion, the selected cell lines do not exhibit a MDR1 phenotype. Therefore, the
study of p-gp modulation exclusively at the BBB is possible using NCI-H460 or DMS 114
cells in an orthotopic brain tumor model.
5.3.1.2 Chemosensitivity of human lung cancer cell lines
With respect to a successful treatment experiment the selected tumor cell lines have to be
sensitive against chemotherapeutic agents. For our treatment studies the cytostatic drugs
paclitaxel and vinblastine were chosen due to their applicability in treatment experiments
in nude mice (Fellner et al. 2002, Spruss et al. 1995). Fig. 5.3 and Fig. 5.4 illustrate the
chemosensitivity of DMS 114 and NCI-H460 cells against the two cytostatic drugs. Both
substances are very potent cytostatics and thus, cytocidal effects were achieved in low
concentrations. For example, 5 nM paclitaxel had a transiently cytocidal effect on DMS
114 cells, i.e. not all cells died and cells began to recover after 100 hours. In contrast, a
concentration of 1 nM vinblastine was already sufficient for a permanent cytocidal effect.
In general, the NCI-H460 cells were less sensitive to the selected cytostatic drugs than the
DMS 114 cells (see also chapter 3.3.4). Concentrations of 30 nM paclitaxel and 50 nM
vinblastine, respectively, were necessary to achieve cytocidal effects.
102 In vivo models of human lung cancer brain metastases
Figure 5.3: Chemosensitivity of DMS 114 cells against paclitaxel (a) and vinblastine (b)
Figure 5.4: Chemosensitivity of NCI-H460 cells against paclitaxel (a) and vinblastine (b)
5.3 Results 103
Hence, NCI-H460 as well as DMS 114 cells were sensitive against low concentrations of
the chemotherapeutic drugs paclitaxel and vinblastine.
5.3.1.3 Intracerebral in vivo growth
To investigate the tumorigenicity of the selected tumor cells three different tumor cell
quantities were injected into the brain of nude mice to determine the optimal cell concen-
tration. After three to four weeks, the intracerebral tumor growth was controlled. Fig.
5.5 and Fig. 5.6 illustrate an intracerebrally grown DMS 114 tumor. In this case 100,000
cells were injected.
The appearance of the brain tumor is similar to that of the subcutaneously grown
tumor (see chapter 3.3.5). Here as well, the cells have mostly one prominent nucleolus.
Multinucleated cells are observed, too. The tumor is not well-delimited against the brain
tissue. The infiltration into other brain areas is clearly visible.
In case of NCI-H460 tumors the characteristics of the subcutaneously grown tumor are
similar to those of the intracerebral tumor (Fig. 5.7 and Fig. 5.8). The cells with scanty
cytoplasm have round to oval nuclei with irregularly formed prominent nucleoli. Mitotic
50µm
Figure 5.5: MG-staining of an intracerebrally grown DMS 114 tumor. The diffuse tumor infil-
trates other brain regions (indicated by arrows).
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Figure 5.6: MG-staining of an intracerebrally grown DMS 114 tumor. The anisometrically
formed cells are occasionally multinucleated (indicated by arrow 1). The irregular
formed nuclei are of different size and have several prominent nucleoli (indicated
by arrow 2).
100µm
Figure 5.7: MG-staining of an intracerebrally grown NCI-H460 tumor. Many blood vessels
(indicated by arrows) are observed in this well-delimited tumor.
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Figure 5.8: MG-staining of an intracerebrally grown NCI-H460 tumor. The cells have round
to oval nuclei with several irregularly shaped nucleoli. Mitotic activity (arrow 1)
and the vascularization of the tissue (arrows 2 and 3) is marked by arrows.
activity is not as high as seen in the subcutaneously grown tumor. The tumor tissue is
well vascularized, but infiltration of the vessels is not observed. After three weeks nearly
all mice were dead because the tumor grew very rapidly and aggressively in the brain.
A tumor was detectable in all examined brains. Thus, both cell lines were tumorigenic
in the nude mouse brain.
In summary, the selected lung cancer cell lines NCI-H460 and DMS 114 fulfill all
three prerequisites. They are suitable to establish an orthotopic tumor model simulating
brain metastases of lung cancer. Furthermore, the cell lines are sensitive to the selected
chemotherapeutic agents. Since NCI-H460 and DMS 114 cells do not express a MDR1
phenotype, the effect of a specific p-gp modulation at the BBB could be examined in a
treatment experiment.
5.3.2 Treatment experiments
The results of Fellner et al. (see page 94) showed that valspodar pretreatment increased
the brain levels of administered paclitaxel to concentrations which were sufficient to pro-
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duce a therapeutic effect on a paclitaxel sensitive transplanted tumor. Therefore, the
adaptation of this successful approach to the treatment of brain metastases was investi-
gated.
5.3.2.1 Combination of valspodar with cytostatic drugs in vitro
First, the efficacy of valspodar co-administered to certain cytostatic drugs was investigated
in vitro. MDR resistant Kb-V1 cells (Kb-V1/VBL, see chapter 4.4) were incubated with
paclitaxel or vinblastine in combination with various concentrations of valspodar. The
cytostatic drugs as well as the modulator valspodar were given at concentrations that did
not affect the growth of the Kb-V1/VBL cells when the compounds were administered as
single drugs. The results of the chemosensitivity assay are illustrated in Fig. 5.9.
Figure 5.9: Chemosensitivity of p-gp expressing MDR resistant Kb-V1/VBL cells against vin-
blastine (a) and paclitaxel (b) in combination with different concentrations of val-
spodar. The chemosensitivity of the cells is increased by valspodar.
The co-incubation of paclitaxel or vinblastine with valspodar led to a transient inhi-
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bition of the Kb-V1/VBL cell proliferation due to the blockade of the p-gp activity in
a valspodar concentration dependent manner. A valspodar concentration of 1 µM even
fully restored the paclitaxel sensitivity of the Kb-V1/VBL cells as indicated by the com-
plete growth inhibition. Using vinblastine as cytostatic drug the cell proliferation was at
least transiently inhibited. The co-application of valspodar led to enhanced toxicity of
the co-administered cytostatic drug. This proves the ability of valspodar to inhibit p-gp
activity.
5.3.2.2 Co-application of valspodar with vinblastine for the treatment of
NCI-H460 lung cancer in the brains of nude mice
NCI-H460 human lung cancer cells were intracerebrally implanted into nude mice. This
procedure resulted in aggressively growing intracerebral neoplasms (see chapter 3 and
5.3.1.3). Every five days nude mice received 0.8 mg/kg of vinblastine intraperitoneally
with (group 1) or without (group 2) 50 mg/kg valspodar. Valspodar was given orally 4 h
before the vinblastine injection. In the literature, valspodar is described as a cytotoxic
agent with an anticancer effect independent from the modulatory action on MDR (Kreis
et al. 2001). Therefore, it was given to another group of mice that served as a control
(group 3). The valspodar vehicle was also administered to mice as a control (group 4)
because cremophor RH40, a derivative of cremophor EL, is an ingredient of the vehicle.
50mg/kg valspodar,
0,8 mg/kg vinblastine,
every 5 days
0,8 mg/kg vinblastine,
every 5 days
control
(50 mg/kg valspodar,
vehicle or
NaCl solution 0.9 %
every 5 days)
tumor implantation
determination of survival rates
1 d 1 d 1 d
Figure 5.10: Application scheme for the treatment of NCI-H460 brain metastases in nude mice
with vinblastine co-administered with valspodar. Each group consists of 6 to 8
nude mice.
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For cremophor EL a modulating effect on p-gp is described in literature (Chervinsky et al.
1993, Woodcock et al. 1990). In addition, mice received 0.9 % sodium chloride solution,
the vehicle of vinblastine, to represent the "untreated" control (group 5). The survival
plot was determined according to Kaplan-Meyer.
Survival did not significantly differ within the five groups (Fig. 5.11). Until day 15
the combination treatment seemed to exhibit an advantage compared to the other groups
because no mouse died in group 1 until this day. In contrast, in the other groups at least
2 mice had died by day 15 indicated by a survival rate of 80% at best. On day 20 all
living animals were very weak and apathetic, and the experiment was aborted. In group
1 where mice received the combination of vinblastine and valspodar, 2 of 8 mice (25 %)
were still living. In the control groups 3 and 4, all animals had died. However, 1 animal
remained alive in the vinblastine group 2 (16.7 %) as well as in the untreated group 5
Figure 5.11: Kaplan-Meyer survival plot for the treatment of intracerebrally grown NCI-H460
lung cancer in nude mice with vinblastine and valspodar. The animals (n = 6
- 8) were treated every 5 days starting on day 1. Group 1 received vinblastine
(0.8 mg/kg, i.p.) and valspodar (50 mg/kg, p.o., 4 h before vinblastine), group 2
vinblastine alone and the groups 3 to 5 served as control groups and received
either valspodar, valspodar vehicle or sodium chloride solution, respectively. No
significant differences within the five groups were observed.
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(16.7 %). In this model no significant increase in survival time was achieved by systemic
treatment with vinblastine and even the co-application of valspodar had no significant
effect on the life span of the nude mice.
Up to day 5 the mice put on weight slightly (data not shown). Two to 3 days after the
2nd treatment a clear decrease in body weight was observed in the treated groups 1 and
2 and also in the control groups 3 to 5 on day 10 after the 3rd treatment. There are no
differences between the vinblastine/valspodar group and mice, which received vinblastine
alone. There are at least three reasons for the obvious body weight reduction. The first
one is the increased toxicity of vinblastine caused by the co-administration of valspodar;
this is well known from clinical studies (Bates et al. 2001). Another reason for the de-
crease in body weight in the vinblastine treated groups is the narrow therapeutic index
of vinblastine and the corresponding systemic toxicity. The third reason is the aggressive
and rapid growth of the NCI-H460 cell line (see chapter 3).
The experiment was repeated and this time the brains were supposed to be ana-
Figure 5.12: Tolerance experiment for the vinblastine/valspodar combination. Mice received
50 mg/kg valspodar p.o. 4 h before i.p. injection of 0.8 mg/kg vinblastine.
Decrease in body weight is an indicator of systemic toxicity. The combination of
vinblastine and valspodar was only tolerated by 2 mice (a,f).
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lyzed by a morphometrical method described at Fellner (2001). Unfortunately, the mice
treated with vinblastine and valspodar already died 2 days after the 1st treatment. There-
fore, the experiment was not repeated. The intraperitoneal administration of vinblastine
0.8 mg/kg, every 5 days, to 5 tumor-free female nude mice was well tolerated. The appli-
cation of the vinblastine/valspodar combination was tested in healthy mice as well and in
contrast to the result described above most of the mice did not withstand the treatment.
Fig. 5.12 shows the body weights of 8 male nude mice, which received 50 mg/kg valspodar
orally, and 4 h later 0.8 mg/kg vinblastine intraperitoneally.
Two days after the 1st treatment 2 mice died (b,g), another 2 mice (c,d) died 4 days after
the 1st treatment. Again 3 days after the 2nd treatment 2 mice (e,h) died. Only 2 mice
(a,f) sustained the combination treatment with vinblastine and valspodar. Subsequently
performed HPLC investigations of the used vinblastine solutions proved that incorrect
preparation of the vinblastine solutions can be excluded as a possible cause of the fatalities.
5.3.2.3 Co-application of valspodar with paclitaxel for the treatment of DMS
114 lung cancer in the brain of nude mice
In a second study nude mice with intracerebrally grown DMS 114 tumors were treated
with a combination of paclitaxel and valspodar. The animals were treated with 3 mg/kg
of paclitaxel intravenously on day 8 after tumor cell implantation and with 2 mg/kg of
50mg/kg valspodar,
3 mg/kg paclitaxel
50 mg/kg valspodar,
2 mg/kg paclitaxel
3 mg/kg paclitaxel
2 mg/kg paclitaxel
control
(50 mg/kg valspodar,
vehicle or
NaCl solution 0.9 %
on day 8 and 15)
tumor implantation
brain preparation (n = 4 – 6)
8 d 8 d
7 d 7 d
5 d 5 d
Figure 5.13: Application scheme for the treatment of DMS 114 brain metastases with paclitaxel
co-administered with valspodar. Each group consists of 6 to 8 nude mice.
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paclitaxel on day 15, with (group 1) and without (group 2) orally administered 50 mg/kg
of valspodar 4 h before each paclitaxel dose. The control groups received either 50 mg/kg
of valspodar (group 3), the valspodar vehicle (group 4) or 0.9 % sodium chloride solution
(group 5), the vehicle of paclitaxel (cp. chapter 5.3.2.2). The mice were killed 20 days
after implantation and the tumor volume in each brain was determined morphometrically.
In each group 4 brains were used for the morphometric analysis. After the HE-staining
of the brains of group 1, a tumor of enormous size was detected in one brain. Paclitaxel
and valspodar had been administered to mice in group 1. In theory, the brains of group 1
should possess small or no tumors due to a therapeutical benefit of the valspodar pretreat-
ment. Thereupon, only the brains of the mice assigned to the control group 4 (valspodar
vehicle) were examined as the morphometric examination is very time consuming. As-
suming a globular or ellipsoidal tumor growth, the tumor volumes were estimated from
the HE-stained sections.
Figure 5.14: Mean estimated tumor volumes of treated group 1 (50 mg/kg valspodar p.o.,
4 h before 3 and 2 mg/kg paclitaxel i.v., respectively) and untreated group 4
(valspodar vehicle). There is no significant difference within the two groups.
Paclitaxel administration even in combination with valspodar, did not have a
tumor reducing effect on intracerebrally grown DMS 114 tumors.
Fig. 5.14 presents the estimated tumor area for the paclitaxel/valspodar treated group 1
and the control group 4. In this study, there were no statistically significant differences
between the mean tumor volumes within the two examined groups. Only 3 of the 4
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examined brains per group could be used for the volume estimation. In group 4, one
brain was incorrectly prepared, so only part of the brain which did not contain any tumor
was available for evaluation. In group 1 no tumor was detected in one brain. It cannot
be excluded that the injection of the tumor cells had failed in this animal as the tumor
volume of another DMS 114 brain tumor was assessed to 39 mm3. Hence, no therapeutic
benefit could be achieved in this tumor model by systemic treatment with paclitaxel even
in combination with valspodar.
Figure 5.15: Decrease in body weight is an indicator of systemic toxicity. The arrows indicate
drug administration. The animals (n = 6 - 8) were treated on day 8 (3 mg/kg
paclitaxel i.v.) and on day 15 (2 mg/kg paclitaxel i.v.). Group 1 received pa-
clitaxel and valspodar (50 mg/kg, p.o., 4 h before paclitaxel), group 2 paclitaxel
alone and the groups 3 to 5 served as control groups and received either valspodar,
valspodar vehicle or sodium chloride solution, respectively.
The changes in body weight are depicted in Fig. 5.15. Particularly in mice treated
with the paclitaxel/valspodar combination (group 1) the body weight was reduced after
each treatment. The body weight of mice assigned to the control groups 3 to 5 remained
relatively constant over a long period of time and decreased at the end of the experiment
due to the tumor burden. The body weight reduction of animals which received pacli-
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taxel alone, was lower than in case of the paclitaxel/valspodar treated mice. Thus, the
co-application of valspodar increases the toxicity of paclitaxel. This finding is in good
agreement with results of clinical trials (Advani et al. 2001).
5.3.3 Discussion
In both studies no therapeutic effect of valspodar co-administration on the growth of
brain tumors was observed. The dosage of valspodar (50 mg/kg) was sufficient to inhibit
p-gp activity in the mouse. Lemaire et al. (1996) investigated the brain-to-blood partition
coefficient of valspodar in rats 2 h after the intravenous administration of radioactively
labelled valspodar in doses of 0.1 to 30 mg/kg. A valspodar dosage of 10 mg/kg achieved a
saturation effect of the p-gp inhibition at the BBB. As the oral bioavailability of valspodar
reached 53 % (Covelli 1998), a concentration of 20 mg/kg should already be sufficient for
a complete p-gp inhibition at the BBB.
The ineffectiveness of the co-application of vinblastine and valspodar is discussed in
the literature. Lyubimov et al. (1996) and Drion et al. (1996) described that the increase
in vinblastine concentration achieved by co-administration of valspodar, was lower in the
brain than in liver and kidney. Similarly, in our study the vinblastine concentrations in
the brain were too low to achieve an antitumor effect. The intolerance of the combination
treatment in mice could be explained by the narrow therapeutic index of vinblastine.
Alterations of the pharmacokinetic parameters of vinblastine caused by the combination
with valspodar have profound consequences on the safety of the treatment. In other stu-
dies, the co-application was only tolerated with acceptable toxicities in case of a vinblastine
dose reduction (van Asperen et al. 1996, Bates et al. 2004). But with the optimized dosage
only a slight benefit was observed in both studies, because the vinblastine concentration
was too low after the dose reduction to have an effect on the tumor growth.
In the literature, studies with the combination of paclitaxel and valspodar are described
as well. By co-application of the p-gp modulator increased paclitaxel brain levels were
achieved (Fellner et al. 2002, Kemper et al. 2003) and toxicity remained acceptable due
to paclitaxel dose reduction (Fracasso et al. 2000). Moreover, Fellner (2001) determined
a paclitaxel concentration of 146 nmol/g in the nude mouse brain 24 h after the intra-
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venous injection of 4 mg/kg of paclitaxel when the animals were pretreated with 50 mg/kg
valspodar p.o. (4 h before paclitaxel injection). The in vitro chemosensitivity of DMS
114 against paclitaxel was tested within the scope this thesis (see chapter 5.3.1.2). A
paclitaxel concentration of 5 nM (equivalent to 5 nmol/g) had a cytocidal effect on the
in vitro growth of DMS 114 cells. Hence, the paclitaxel brain levels detected by Fell-
ner should be intrinsically high enough to achieve a therapeutic effect on the DMS 114
brain tumors in nude mice. However, under the conditions described by Fellner et al. the
treatment of DMS 114 brain metastases failed. It is conceivable that the chemosensitivity
of the selected DMS 114 tumor against paclitaxel in vivo is reduced compared to the
chemosensitivity in vitro.
Furthermore, the injected number of tumor cells plays a decisive role for the success of a
treatment experiment. In preliminary tests with different cell numbers (30,000 to 300,000
DMS 114 cells) tumors of sufficient size grew after an injection of 30,000 and 100,000
tumor cells, respectively. As in the treatment experiment the investigated tumors were
partly too big in size for a morphometric analysis, the preliminary tests were repeated
with 10,000 and 30,000 cells, respectively (4 mice per group). After 22 days the brains
were collected and the prepared sections were analyzed. Only in 5 of 8 brains tumors were
detectable. Since the mice received no treatment, probably the injection of the tumor cells
was incorrect. In one brain, no injection channel was detected and in another case, the
tumor had grown between the skull and the dura mater. The detected tumors differed
in size independent of the injected tumor cell number. Thus, the procedure of the tumor
cell injection is complicated and it is difficult to produce tumors of a sufficient size (10 -
15 mm3) especially in case of the DMS 114 cell line.
In case of the NCI-H460 cell line, the cell injection is important as well. Additionally,
the tumor growth is aggressive and rapid both in vitro and in vivo. Since the cells
possess the mRNA encoding for p-gp (see chapter 5.3.1.1), it is possible that the cells
became chemoresistant during therapy due to the continuous contact with the p-gp inducer
vinblastine. Thus, this cell line is unsuited for the brain metastases model studying effects
of p-gp inhibition at the BBB, because of its rapid growth, the high chemoresistance and
the existence of p-gp encoding mRNA.
For further treatment studies with the DMS 114 tumor, the model should be improved.
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The application scheme could be optimized by reduction of the valspodar concentration.
Then the paclitaxel dose can be increased as analogously described for a combination with
vinblastine (Bates et al. 2004). Moreover, the tumor cells should be stably transfected
to express fluorescent proteins like GFP and EGFP (Yang et al. 2000, Hoffman 2002).
The intracerebral tumor growth may then be controlled in the living animal and similar
to the subcutaneous tumor model only mice which developed a solid brain tumor can be
selected for the experiments.
5.4 Summary
In this chapter the suitability of the lung cancer cell lines NCI-H460 and DMS 114 for
the intracerebral in vivo model and the treatment of these tumors were examined. The
NCI-H460 and DMS 114 cell lines were tumorigenic in the brain of nude mice and were
used to simulate brain metastases of lung cancer. Furthermore, no MDR1-phenotype was
exhibited despite the detection of MDR1 encoding mRNA in NCI-H460 cells. There-
fore, the cell lines were suited for experiments on the selective p-gp modulation at the
BBB. Also, the lung cancer cells were sensitive against low concentrations of the selected
cytostatic drugs vinblastine and paclitaxel.
Whereas the combination of the potent p-gp modulator valspodar with the chemothe-
rapeutic agents vinblastine or paclitaxel resulted in a restoration of the chemosensitivity
of p-gp expressing Kb-V1/VBL cells in vitro, no therapeutic benefit was observed in the
treatment experiments of the simulated NCI-H460 and DMS 114 brain metastases in the
intracerebral in vivo model.
The highly aggressive and rapid growth of the intracerebral NCI-H460 tumors could not
be affected by the treatment with vinblastine. Furthermore, the increase in vinblastine
brain concentration caused by the co-administration of valspodar seemed to be extremely
low. Although the vinblastine concentrations in brains of mice which received additionally
valspodar were not determined within these experiments, other studies indicated only a
slight increase in vinblastine brain levels after valspodar pretreatment (Lyubimov et al.
1996, Drion et al. 1996). Additionally, vinblastine has a narrow therapeutic index. The
neurotoxic side effects of vinblastine were too serious to allow for a continuation of the
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experiments. Therefore, the NCI-H460 cell line is unsuited for treatment experiments
using the intracerebral in vivo model.
The DMS 114 cell line seemed to be less chemosensitive against paclitaxel in vivo com-
pared to the in vivo tests. Moreover, the tumorigenicity of the cells was heavily dependent
upon the injected number of cells. Hence, the control of the intracerebral tumor growth is
indispensable. This may be achieved by transfection of the tumor cells with the fluores-
cent proteins GFP or EGFP. Furthermore, the use of newly developed p-gp modulators
such as elacridar, tariquidar (see chapter 6 and 7) or zosuquidar (Kemper et al. 2004b)
is recommended, as according to literature these compounds do not alter the pharma-
cokinetic parameters of co-administered substances. Using these new 3rd generation p-gp
modulators, the paclitaxel concentration could be increased leading to an improvement
of the therapy of DMS 114 brain tumors in the intracerebral tumor model.
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Chapter 6
Characterization of the 3rd generation
p-gp inhibitors elacridar and tariquidar1
6.1 Introduction
Inhibiting P-glycoprotein 170 (p-gp, ABCB1) as a way of reversing multidrug resistance
(MDR) has been extensively studied for more than two decades (Thomas and Coley
2003). A broad range of substances that interact with p-gp and block p-gp mediated drug
efflux have been reported. These compounds include calcium channel blockers, calmodulin
inhibitors, steroidal derivatives, antibiotics, cardiovascular drugs and cyclosporins (Ford
1996, Krishna and Mayer 2000). The calcium channel antagonist verapamil has been one
of the best studied compounds in clinic (Dalton et al. 1989, Miller et al. 1991). However,
these compounds were developed for other pharmacological purposes than the reversal of
MDR, they are very weak and non-specific p-gp modulators, and p-gp substrates. The
use of high doses of these 1st generation modulators was necessary because of their low
binding affinity resulting in unacceptable toxicity (Ferry et al. 1996).
The development of more selective and potent inhibitors led to the 2nd generation
of p-gp modulators such as biricodar (VX-710, Germann et al. (1997b)) and the non-
immunosuppressive cyclosporin D analogue valspodar (SDZ PSC 833, Boesch et al. (1991)).
Although these substances were more potent and less toxic in comparison to the 1st
1Parts of this work were presented at the BBB Expertentreffen 2004 in Bad Herrenalb
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generation modulators, they retained some characteristics that limited their clinical use-
fulness. These compounds caused alterations of the pharmacokinetic parameters of the
co-administered cytotoxic drugs, whereby the toxicity of these cytotoxic agents increased.
This led to dose reductions and to limited success in cancer chemotherapy (Rowinsky
et al. 1998, Fischer et al. 1998).
Agents lacking the alteration of pharmacokinetic parameters when co-administered
with cytostatic drugs were developed by using structure-activity relationships and com-
binatorial chemistry (Robert and Jarry 2003). These so-called 3rd generation modulators
include zosuquidar (LY 335979, Dantzig et al. (1996)), laniquidar (R 101933, van Zuylen
et al. (2000)), ONT 093 (Newman et al. 2000), elacridar (GF 120918, Hyafil et al. (1993))
and tariquidar (XR 9576, Mistry et al. (2001)). The latter two are shown in Fig. 6.1.
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Figure 6.1: Structures of the acridone carboxamide derivative elacridar and the anthranilamide
derivative tariquidar. Both substances are 3rd generation p-gp modulators.
Elacridar and tariquidar are two of the most promising chemosensitizing inhibitors of
p-gp (Myer et al. 1999). According to the literature both substances are suitable for
combination therapy with cytostatic drugs (Ward and Azzarano 2004). The compounds
are no p-gp substrates, e.g. tariquidar inhibits p-gp function by binding at a site which
is distinct form the site of interaction of transported substances (Martin et al. 1999). In
the present study these inhibitors were characterized with respect to their spectroscopical
properties, their potential toxicity and their in vitro efficacy.
P-gp is not the only ATP-binding cassette (ABC) transporter that is associated with
MDR. Besides p-gp, the members of the MDR associated protein (MRP) family have
been extensively studied since 1992 (Cole et al. 1992). In 1998 another ABC transporter
called ABCG2 was identified independently by three different groups (Doyle et al. 1998,
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Allikmets et al. 1998, Miyake et al. 1999). ABCG2, that is also known as BCRP, MXR
or ABCP, consists of 6 transmembrane domains. Thus, it is a half transporter member of
the ABC superfamily. It probably requires dimerization in order to become a functional
full transporter molecule (Litman et al. 2001). The different transporters have in part
the same substrates. Doxorubicin efflux is mediated by all three ABC transporters. How-
ever, topotecan is transported by p-gp and ABCG2 (Bates et al. 2000). Therefore, it is
important to know if an inhibitory substance acts multispecificly on more than one ABC
transporter or if the modulator is selective for only one transport protein. Zosuquidar, for
example, specifically inhibits p-gp and does not affect MRP1 or ABCG2 (Shepard et al.
2003). The specificity of the two modulators elacridar and tariquidar was investigated in
this study, too.
6.2 Materials and methods
6.2.1 Drugs and chemicals
Starting materials and solvents for the synthesis of tariquidar were purchased from Lan-
caster Synthesis (Frankfurt, Germany), Sigma (München, Germany) and Merck (Darm-
stadt, Germany). Elacridar (GF 120918·HCl) was kindly provided by GlaxoSmithKline
(Research Triangle Park, North Carolina, Unites States). Valspodar (SDZ PSC 833) was
a gift from Novartis (Nürnberg, Germany). Fumitremorgin C was provided by the work
group of Susan Bates (NIH, Bethesda, Maryland, United States). Papaverine and the
solvents acetonitrile, ethanol and methanol were purchased from Merck. Mitoxantrone
was obtained from Sigma. The suppliers of the other cytostatic drugs are mentioned in
chapter 3. The PCR primers were ordered from MWG Biotech (Ebersberg, Germany).
Calcein-AM was purchased from Molecular Probes (Eugene, Oregon, United States). For
details concerning calcein-AM storage see chapter 4. PBS composition is specified in
chapter 3. The ingredients of the loading buffer are mentioned in chapter 4.
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6.2.2 Cell culture
All cell lines were purchased from the American Type Culture Collection (ATCC), Rock-
ville, MD, USA and cultured as monolayers in 75 cm2 flasks (Nunc, Wiesbaden, Germany).
The cells were maintained at 37 ℃/5 % CO2 in different culture media. MCF-7 cells
were cultivated in RPMI 1640 culture medium (Sigma) supplemented with 1.5 g/l of
sodium hydrogen carbonate and 10 % FCS, adjusted to pH 7.4. The cultivation of the
Kb-V1/VBL cells is described in chapter 3. Subculturing was carried out with 0.2 %
trypsin/EDTA (Viralex, Paa Laboratories, Pasching, Austria) in PBS once a week. The
chemoresistant variant of the MCF-7 cell line, MCF-7/Topo, was obtained by adding
increasing volumes of a topotecan solution within a period of about 40 days to achieve
a topotecan concentration of 500 ng/ml culture medium (11.9 µl of 10−3 M topotecan
in 70 % ethanol). After 3 passages the treated cells expressed sufficient quantities of
ABCG2.
6.2.3 Synthesis of tariquidar
General conditions. Melting points (Mp) were determined on a BÜCHI 510 electri-
cally heated copper block apparatus using an open capillary and are uncorrected. Silica
gel 60 (0.063 - 0.200 nm, Merck) was used for column chromatography, and thin layer
chromatography (TLC) was performed with silica gel plates (Merck F254). Elemental
analysis was carried out by the department of microanalysis of the faculty. Mass spec-
trometry analysis (MS) was performed on a Varian MAT 112 (PI-EIMS 70 eV). The peak
intensity is indicated relatively to the strongest signal in %. Nuclear Magnetic Resonance
(1H-NMR) spectra were recorded using a Bruker ARX-300 spectrometer with deuterated
chloroform or DMSO. The chemical shift δ is given in parts per million (ppm) with re-
ference to the chemical shift of the residual protic solvent compared to tetramethylsilane
(TMS, δ = 0 ppm).
Synthesis. The preparation of tariquidar was performed according to Dodic et al.
(1995), Roe et al. (1999) and Sharp et al. (1998) with slight modifications. A solu-
tion of 4-nitrophenethyl bromide 1 (10.5 g, 43.4 mmol), 6,7-dimethoxy-1,2,3,4-tetrahydro-
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isoquinoline hydrochloride 2 (10.9 g, 47.5 mmol) and potassium carbonate (13.9 g, 100
mmol) in 100 ml DMF was heated at 100 ℃ for 6 h. The mixture was filtered and evapo-
rated, the residue was taken up in water and extracted with dichloromethane (3 x 30 ml).
The organic layer was dried over sodium sulphate and the solvents were removed under
reduced pressure. The resulting solid was recrystallized from ethanol to give 10.52 g of
6,7-dimethoxy-2-[2-(4-nitrophenyl)ethyl]-1,2,3,4-tetrahydroisoquinoline 3 as orange crys-
tals (mp 115 ℃, yield: 65.3 %). This product was hydrogenated in ethanol (200 ml) at
room temperature at a pressure of 5 bar in the presence of Pd/C (10 %, 1 g). After com-
pletion of hydrogenation the catalyst was filtered off and the solution was concentrated
to give 8.16 g of 4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenylamine 4
as a creamy solid (mp 125 ℃, yield: 85.2 %).
1H-NMR ([D6]DMSO) of compound 4. δ[ppm] = 2.52-2.74 (m, 8H, CH2), 3.51 (s,
2H, NCH2C), 3.69 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 4.83 (br, 2H, NH2), 6.45-6.51 (m,
2H, AA’BB’), 6.63 (s, 1H, Ar-H), 6.65 (s, 1H, Ar-H), 6.85-6.91 (m, 2H, AA’BB’)
For the next step 2-amino-4,5-dimethoxybenzoic acid 5 (2.37 g, 12 mmol) and HOBt
(1.84 g, 12 mmol) were dissolved in DMF (120 ml) for 10 min at room temperature.
Compound 4 (3.75 g, 12 mmol) and DCC (2.48 g, 12 mmol) were successively added, and
the reaction mixture was stirred at room temperature overnight. Subsequently, the solu-
tion was filtered and concentrated under reduced pressure. The residue was treated with
sodium hydroxide solution (2 N) and extracted with dichloromethane (3 x 30 ml). The or-
ganic layers were separated, washed with water (3 x 30 ml) and brine (3 x 30 ml), dried over
sodium sulphate and evaporated. The product was purified by column chromatography
on silica gel using a mixture of dichloromethane and methanol (90:10, v/v) for elution,
followed by recrystallization from isopropyl alcohol. Another column chromatography
(elution with dichloromethane and methanol, 97:3, v/v) and recrystallization from ethyl
acetate with petroleum ether gave 3.67 g of 2-amino-N-4-[2-(6,7-dimethoxy-3,4-dihydro-
1H-isoquinolin-2-yl)-ethyl]phenyl-4,5-dimethoxy benzamide 6 (mp 180 ℃, yield: 62:3 %)
as a yellow solid.
Quinoline-3-carboxylic acid 7 (1.1 g, 6.38 mmol), compound 6 (3.14 g, 6.38 mmol) and
HOBt (0.98 g, 6.38 mmol) were dissolved in dichloromethane at room temperature. DCC
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(1.32 g, 6.38 mmol) was added, and the reaction mixture was stirred at room temperature
over night. After filtration the solution was washed with a saturated solution of sodium
hydrogen carbonate (3 x 30 ml), water (3 x 30 ml) and brine (3 x 30 ml). The solution was
dried over sodium sulphate and the solvent was evaporated. The product was purified by
column chromatography on silica gel by elution with a mixture of dichloromethane and
methanol (97:3, v/v) followed by recrystallization from chloroform to give 1.5 g of tari-
quidar (quinoline-3-carboxylic acid (2-4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-
yl)ethyl]phenylcarbamoyl-4,5-dimethoxyphenyl)amide 8.
Yield: 1.5 g (2.72 mmol, 36 %, creamy solid)
Mp: decomposition at 260 ℃
1H-NMR ([D6]DMSO):δ[ppm] = 2.62 (m, 8H, CH2), 3.55 (s, 2H, NCH2C), 3.69 (s, 3H,
OCH3), 3.70 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 6.63 (s, 1H, Ar-H),
6.65 (s, 1H, Ar-H), 7.23-7.29 (m, 2H, Ar-H), 7.52 (s, 1H, Ar-H), 7.57-7.62 (m, 2H, Ar-H),
7.69-7.76 (m, 1H, Ar-H), 7.88-7.96 (m, 1H, Ar-H), 8.05-8.18 (m, 2H, Ar-H), 8.26 (s, 1H,
Ar-H), 8.88 (d, 4J = 2.2, 1H, COCCHC), 9.34 (d, 4J = 2.2, 1H, COCCHN), 10.33 (s, 1H,
NH), 12.30 (s, 1H, NH)
MS (PI-EIMS 70 eV): m/z (%) = 646 ([M·+], 6), 335 ([M-NH-C6H4-CH2-CH2-C9H8N
(OCH3)]+, 25), 206 ([CH2-C9H8N(OCH3)]+, 100), 164 ([CO-C6H2(OCH3)]+, 58)
Analysis:
calculated C: 70.57 H: 5.92 N: 8.66
found C: 69.78 H: 6.01 N: 8.87
C38H38N4O6 (646.74)
6.2.4 Spectroscopic methods
Absorption spectra were recorded on a Cary 100 conc UV visible spectrophotometer (Var-
ian, Darmstadt, Germany). The fluorescence spectra were measured on a Perkin Elmer
LS50B luminescence spectrophotometer (Wiesbaden, Germany). Solutions of the p-gp
modulators were prepared with concentrations from 0.1 to 10 µM in ethanol, methanol
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or phosphate buffer, pH 7.4, by dilution of a 1 mM stock solution (DMSO).
To determine the water solubility of the p-gp modulators, a Kontron UV-VIS spec-
trophotometer was used. Stock solutions (1 mM) made in DMSO were diluted in loading
buffer to achieve concentrations in the range from 0.1 nM to 30 µM. The solutions were
measured at a wavelength of 600 nm in polystyrene cuvettes. An optical density higher
than 0.05 indicates insolubility of the tested compound.
6.2.5 Chemosensitivity assay
The chemosensitivity assay was performed according to the procedure developed by Bern-
hardt et al. (1992). Details are given in chapter 3.2.6.
6.2.6 Calcein-AM efflux assay
The calcein-AM efflux assay is described in detail in chapter 4.
6.2.7 RT-PCR
The RT-PCR was performed as described in chapter 5.2.2. The following primer sequences
were used to detect the ABCG2 gene.
Table 6.1: Primer sequences used for RT-PCR
Primer Sequence bp
β-actin sense 5’-CGGGATCCCCAACTGGGAC-3’ 304
antisense 5’-GGAATTCTGGCGTGAGGGA-3’
ABCG2 sense 5’-TTCCAAGCAGGATAAGCCACT-3’ 589
antisense 5’-AGCCACCATCATAAGGGTAAA-3’
6.2.8 ABCG2 assay
The assay was performed according to de Bruin et al. (1999), Lee et al. (1994), Maliepaard
et al. (1999) and Robey et al. (2001a) with modifications. In brief: ABCG2 expressing
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MCF-7/Topo cells were used for this assay. Cells that were passaged 3 or 4 days before
the assay was carried out, were trypsinized and washed with PBS at 25 ℃. A number of
1 ·106 cells per ml was adjusted with culture medium. Mitoxantrone was added to the cell
suspensions to achieve a concentration of 20 µM (6.67 µl of 3 mM stock solution in 70 %
ethanol). After short vortexing, test compounds were added in different concentrations.
The cell solutions were vortexed again and incubated for 30 min at 37 ℃/5 % CO2.
According to the literature an incubation period of 30 min is sufficient for complete
uptake of mitoxantrone in cells. Subsequently, the cells were washed with ice cold PBS
at 4 ℃ and resuspended in culture medium. Then, the samples were incubated for 1 h at
37 ℃/5 % CO2. After an incubation period of 1 h an equilibrium had developed between
mitoxantrone inside the cells and in the surrounding medium, i.e. no further mitoxantrone
efflux can be determined. The medium was removed by centrifugation, and the cell pellet
was rinsed once with ice cold PBS, resuspended in 0.5 ml of PBS per 1 · 106 cells and
placed on ice in the dark. A FACS Calibur™ (Becton Dickinson, Heidelberg, Germany)
was used to analyze the samples. A minimum of 10,000 events was collected per sample
and the events were gated according to forward scatter and sideward scatter to exclude
clumps and debris. The photomultiplier settings were as follows: E-1 for FSC, 200 for
SSC, 450 for FL1-H and 700 for FL4-H. FL4-H histograms were analyzed by the WinMDI
2.8 software.
To determine the mitoxantrone efflux two control samples were prepared. The first
control sample was used for the determination of the 100 % mitoxantrone uptake. There-
fore, fumitremorgin C (2 µl of 3 mM stock solution in DMSO) was added to a sample
containing 1 · 106 cells per ml and mitoxantrone (20 µM). After short vortexing, the con-
trol sample was incubated for 30 min at 37 ℃/5 % CO2 and washed with ice cold PBS at
4 ℃. The cells of this control sample were then resuspended in ice cold PBS and placed
on ice in the dark until measurement to avoid mitoxantrone efflux. In the second con-
trol sample (1 · 106 cells per ml) cells were loaded with mitoxantrone (20 µM) during an
incubation period of 30 min at 37 ℃/5 % CO2. After a washing step, the cells of the sec-
ond control sample were resuspended in culture medium and incubated for 1 h at 37 ℃/
5 % CO2 to determine the residual mitoxantrone fluorescence after mitoxantrone was ef-
fluxed. Subsequently, the cells were washed, resuspended in ice cold PBS and measured
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at a flow cytometer according to the aforementioned settings. The difference between the
fluorescence intensities of the second control sample and the 100 % mitoxantrone uptake
value determined with the first control sample represents the 100 % mitoxantrone efflux.
All other samples were related to the 100 % efflux value resulting in mitoxantrone efflux
expressed in [%] depending on the added test compound concentration.
6.3 Results and discussion
The two newly developed p-gp modulators elacridar and tariquidar were characterized
regarding their in vitro efficacy to inhibit p-gp mediated drug efflux as well as their
potential cytotoxicity. Furthermore, the inhibitory effect of compound 4 on p-gp was
examined to identify structure activity relationships. Compound 4 is a common structural
part of the two modulators. The selectivity to other multidrug transporters responsible
for MDR was investigated, too. As tariquidar could not be procured, the modulator was
synthesized in our department. The spectroscopical characteristics that were important
for analytical detection were also determined.
6.3.1 Synthesis of tariquidar
The 3rd generation p-gp modulator tariquidar (XR 9576) was developed by Roe et al.
(1999) by evaluation of a series of commercially available compounds which contained
features common to known p-gp modulators such as verapamil, S 9788 (Dhainaut et al.
1992), CP 100356 (Kajiji et al. 1994), biricodar, elacridar and zosuquidar. These struc-
tural characteristics include a tertiary amine, a dimethoxyphenyl group and an amide
group (Wang et al. 2003), and seemed to be important for p-gp inhibition (see chapter
6.3.4). In our department tariquidar was synthesized as depicted in Fig. 6.2.
126 Characterization of the 3rd generation p-gp inhibitors elacridar and tariquidar
+
O2N
Br
HN
OCH3
OCH3
O2N
OCH3
OCH3
N
2H N
OCH3
OCH3
N
i ii
1 2 3 4
OCH
H3CO
H3CO NH2
O
3
OCH3
N
+
2H N
OCH3
OCH3
N H3CO
H3CO NH2
OH
O
iii
4 5 6
+
OCH
H3CO
H3CO NH2
O
3
OCH3
N H3CO
H3CO
N
H
N
OCH3
OCH3
NH
N
O
O
iv
6 7 8
O
OH
N
Figure 6.2: Strategy of tariquidar 8 synthesis reported by Dodic et al. (1995) and Roe et al.
(1999). The following reagents were used: i) K2CO3, DMF, 100℃; ii) Pd/C, 5 bar;
iii) HOBt, DCC, DMF; iv) HOBt, DCC, CH2Cl2
The commercially available bromide derivative 1 was allowed to react with isoquinoline
2 according to a nucleophilic substitution in the presence of potassium carbonate in
DMF. The subsequent hydrogenation of the nitro compound 3 was carried out according
to standard procedures using palladium on charcoal (10 % Pd/C) at 5 bar hydrogen
pressure. In the next step the resulting amine 4 was coupled to the anthranilic acid 5
using HOBt and DCC as coupling reagents to yield the intermediate 2-aminobenzamide
6. The same reagents were used in the last step. Here, reaction of 6 by activation of the
carboxylic acid 7 with HOBt led to the anthranilamide derivative tariquidar 8.
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6.3.2 Spectroscopic characterization
After the in vitro characterization of the two selected modulators, pharmacokinetic inves-
tigations were planned. To be able to detect the modulators by HPLC using a fluores-
cence or UV/VIS detector, the spectroscopical characteristics of the substances have to be
known. Moreover, this information is necessary for the in vitro investigation of the p-gp
modulation in the calcein-AM efflux assay and the MDR transporter selectivity using the
ABCG2 assay, that the modulators do not show fluorescence signals interfering with the
respective fluorescence agents calcein and mitoxantrone. For this reason, fluorescence and
UV spectra were recorded and the respective maxima were determined.
Figure 6.3: (a) Excitation (λem = 492 nm) and emission (λex = 418 nm) spectrum of elacridar
in phosphate buffer pH 7.4. (b) Excitation (λem = 367 nm) and emission (λex =
308 nm) spectrum of tariquidar in phosphate buffer pH 7.4.
Fig. 6.3 shows representative fluorescence spectra of elacridar and tariquidar. The
fluorescence spectra were measured in three different solvents: loading buffer, ethanol
and methanol. The excitation and emission maxima were determined as presented in
table 6.2.
The excitation and emission maxima corresponded well for the solvents ethanol and
methanol. The fluorescence spectra obtained in loading buffer (pH 7.4) differed in the po-
sitions of the maxima, compared to spectra in ethanol and methanol. Tariquidar emitted
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Table 6.2: Excitation and emission maxima of elacridar and tariquidar in different solvents.
solvent buffer, pH 7.4 ethanol methanol
λex [nm] 417 407 405
elacridar
λem [nm] 492 469 475
λex [nm] 308 318 316
tariquidar
λem [nm] 366 360 359
at shorter wave lengths than elacridar. This was expected because the elacridar struc-
ture includes an acridine system which is responsible for the fluorescence at higher wave
lengths.
Representative UV spectra of elacridar and tariquidar are depicted in Fig. 6.4. The UV
spectra were measured in three different solvents: loading buffer, ethanol and methanol.
The excitation and emission maxima were determined as presented in table 6.3.
Figure 6.4: (a) UV spectrum of elacridar (100 nM in phosphate buffer, pH 7.4) (b) UV spectrum
of tariquidar (100 nM in phosphate buffer, pH 7.4)
The excitation and emission maxima corresponded well for all examined solvents. The
UV maxima of tariquidar were determined at shorter wave lengths compared to the max-
ima of elacridar. Furthermore, an additional maximum was observed in the elacridar
UV spectra at a wave length of about 410 nm due the acridine system of the elacridar
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Table 6.3: UV maxima of elacridar and tariquidar in different solvents.
solvent buffer pH 7.4 ethanol methanol
226 nm 225 nm 228 nm
elacridar 260 nm 258 nm 258 nm
413 nm 410 nm 408 nm
222 nm 220 nm 223 nm
tariquidar
247 nm 245 nm 244 nm
structure and the resulting light yellow color of substance and prepared solutions.
The solubility of a compound is another important criterion for analytical exami-
nations. The modulators were dissolved in different solvents at various concentrations
from 1 nM to 30 µM and measured at 600 nm in an UV/VIS-spectrophotometer (data
not shown). Aqueous loading buffer, methanol and acetonitrile were used as solvents.
Elacridar and tariquidar are readily soluble in the three examined solvents within the
tested concentration range. However, aqueous solutions with modulator concentrations
higher than 30 µM are not recommended for the use in in vitro experiments. At this
concentration the measured optical density of the aqueous solutions slightly increased
indicating insolubility at modulator concentrations higher than 30 µM. This was not ob-
served in ethanol and methanol solutions.
In conclusion, the two examined modulators are detectable with both fluorescence
and UV spectroscopy. The fluorescence of elacridar and tariquidar has no influence on
the assays that are used for the investigation of the selectivity and the in vitro efficacy
(see 6.3.4 and 6.3.5). In the ABCG2 assay an excitation wavelength of 635 nm is used
and calcein is excited at 488 nm in the case of the calcein-AM efflux assay. At both
wavelengths the two modulators are not excited. Elacridar and tariquidar are easily
soluble in different solvents such as methanol and acetonitrile. In aqueous solutions the
modulator concentrations should be kept below 1·10−4 M to avoid solubility problems.
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6.3.3 Cytotoxicity of the p-gp modulators elacridar and tariqui-
dar
To test the cytotoxicity of an anticancer drug depending on the presence of a p-gp in-
hibitor the latter can only be used in concentrations that do not affect the cell proliferation.
Hence, the in vitro cytotoxicity was investigated to obtain an indication for these modu-
lator concentrations. Kb-V1/VBL and MCF-7/Topo cells were used in chemosensitivity
assays for the p-gp modulator characterization. According to the chemosensitivity assay
procedure the cells were incubated for up to 168 hours with elacridar and tariquidar us-
ing concentrations from 5 to 500 nM (Kb-V1/VBL) and 0.1 to 10 µM (MCF-7/Topo),
respectively. Fig. 6.5 and Fig. 6.6 present the results for the in vitro cytotoxicityof the
two modulators.
Figure 6.5: Impact of different concentrations of elacridar (a) and tariquidar (b) on the growth
of Kb-V1/VBL cells. The incubation with the modulators has no effect on the cell
proliferation.
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Figure 6.6: Impact of different concentrations of elacridar (a) and tariquidar (b) on the growth
of MCF-7/Topo cells. Addition of high elacridar concentrations (10 µM) results in
a cytocidal effect. The cytotoxicity of tariquidar is obvious at a concentration of
10 µM, at which the cell growth is inhibited by 40 %.
The growth of the Kb-V1/VBL cells was not influenced by long term incubation with
elacridar and tariquidar at the examined modulator concentrations. Even 500 nM of
modulator, a concentration 10-fold higher than that required for a complete reversal of
drug resistance, had no effect on the Kb-V1/VBL cells. By contrast, the MCF-7/Topo
cell line showed sensitivity to the new modulators at high concentrations, particularly to
elacridar. At a concentration of 10 µM elacridar had a cytocidal effect.5 µM of elacridar
were sufficient to induce a cytostatic effect and to reduce the cell proliferation by 50 %.
Tariquidar did not affect the growth of MCF- 7/Topo cells to such an extent. Tariquidar
concentrations higher than 5 µM were necessary to influence the cell proliferation, e.g. at
a concentration of 10 µM, a growth inhibition by 40 % was observed. The IC50 values
determined in the ABCG2 assay were 5 (elacridar) and 2 (tariquidar) times lower than
the concentrations that caused growth inhibition.
Thus, the achieved potentiation of the cytostatic effects of anticancer drugs by co-
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application of MDR modulators in the respective long term incubation studies may be
attributed to inhibition of p-gp or ABCG2 function since the cytotoxicity of the modula-
tors is irrelevant at the concentrations used in the corresponding assays.
6.3.4 In vitro efficacy of p-gp inhibitors
The Kb-V1/VBL cell line which was used to investigate the p-gp inhibitors, exhibited
an acquired MDR phenotype as a result of p-gp overexpression (see chapter 4). The in
vitro efficacy of elacridar, tariquidar and valspodar was examined in two different test
series. The ability of the modulators to potentiate the cytotoxicity of several drugs was
evaluated in the chemosensitivity assay. The impact of the modulators on the p-gp efflux
activity was investigated in the calcein-AM efflux assay.
6.3.4.1 Determination of the inhibition of the p-gp mediated efflux by the
chemosensitivity assay
Over the whole incubation period of up to 150 hours Kb-V1/VBL cells were exposed to
cytostatic drugs that are known p-gp substrates. The drugs were used at low concen-
trations that did not affect the growth of Kb-V1/VBL cells. Additionally, the cells were
incubated with combinations of drugs and 3 different concentrations of the modulators
elacridar, tariquidar and valspodar, respectively. The modulators had no cytotoxic effects
in the used concentrations. The ability of elacridar and tariquidar to reverse resistance of
the Kb-V1/VBL cells to various cytostatic agents is shown in Figs. 6.7 to 6.10.
The resistance to all examined drugs was completely reversed by the addition of the
new modulators elacridar and tariquidar at a concentration of 50 nM, indicated by the
cytocidal effect. The two modulators produced significant reversal of resistance at con-
centrations of 10 nM in the case of doxorubicin (Fig. 6.7) and topotecan (Fig. 6.9).
The potentiation of the cytotoxic effect of topotecan was delayed when compared to
the other cytostatic drugs, which showed cytocidal effects 50 hours after addition of 50 nM
of the modulators. The potency of elacridar was comparable with that of tariquidar with
respect to the reversal of resistance against the cytostatic drugs.
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Figure 6.7: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of Kb-V1/VBL cells against doxorubicin (300 nM). The chemore-
sistance of the cells is fully reversed after addition of 50 nM of modulator.
Figure 6.8: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of Kb-V1/VBL cells against vinblastine (10 nM). The chemore-
sistance of the cells is completely abrogated after addition of 50 nM of modulator.
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Figure 6.9: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of Kb-V1/VBL cells against topotecan (50 nM). The chemore-
sistance of the cells is completely abrogated after addition of 50 nM of modulator.
Fig. 6.10 and Fig. 6.11 compare the effect of paclitaxel on Kb-V1/VBL cells in combina-
tion with either the 3rd generation modulators or the 2nd generation modulator valspodar.
Almost complete reversal of resistance to paclitaxel was achieved by the addition of 1 µM
valspodar. A cytostatic but no cytocidal effect was observed at this valspodar concen-
tration. In contrast, already an addition of 50 nM of elacridar and tariquidar sufficed to
restore the paclitaxel resistance completely in case of the new modulators elacridar and
tariquidar.
In case of vinblastine (Fig. 6.8) and paclitaxel (Fig. 6.10) it was noticeable that the
useful concentration range of the modulators was very narrow. The co-incubation of
10 nM of elacridar or tariquidar with vinblastine had nearly no influence on the growth of
Kb-V1/VBL cells, whereas an addition of 50 nM of p-gp inhibitor led already to a clear
cytocidal effect of about 40 %.
6.3 Results and discussion 135
Figure 6.10: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of Kb-V1/VBL cells against paclitaxel (30 nM). The chemore-
sistance is fully reversed by the addition of 50 nM of modulators.
Figure 6.11: Impact of different concentrations of valspodar on the chemosensitivity of Kb-
V1/VBL cells against paclitaxel (30 nM). Addition of valspodar (c) leads to a
cytostatic inhibition of the Kb-V1/VBL cell proliferation.
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The results show that elacridar and tariquidar are highly active p-gp modulators. Both
compounds were very potent by fully reversing resistance to various agents associated with
the MDR phenotype in the multidrug resistant Kb-V1/VBL cell line. The new modulators
were considerably more potent than valspodar. Importantly, they did not affect the
activity of cisplatin as presented in Fig. 6.12. This was expected as cisplatin is not a p-gp
substrate and hence, the inhibition of the p-gp mediated efflux in the Kb-V1/VBL cells
by the new modulators elacridar and tariquidar should not lead to an improvement of the
chemosensitivity of the Kb-V1/VBL cells against cisplatin. Moreover, the lack of additive
toxicity shown in Fig. 6.12 supports the conclusion that at the used concentrations the
modulators do not act as cytotoxic drugs.
Figure 6.12: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of Kb-V1/VBL cells against cisplatin (100 nM). Addition of the
modulators does not enhance the effect of the non p-gp substrate cisplatin.
6.3.4.2 Determination of the p-gp activity by the calcein-AM efflux assay
The p-gp inhibitory potency (IC50 values) of the new modulators was determined in the
calcein-AM efflux assay. If p-gp function is blocked by an added test compound, calcein-
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AM is hydrolyzed to calcein by esterases after penetration across the cell membrane.
Calcein is trapped inside the cells due to its hydrophilicity and its fluorescence is taken as a
measure of transport inhibition. The test compounds were used in different concentrations
with respect to the construction of concentration response curves. A sample incubated
without test compounds served as control and represented 100 % of calcein-AM efflux.
The geometric means were calculated from the fluorescence intensity histograms, related
to the control and plotted against the test compound concentration. The results of the
Figure 6.13: P-gp inhibition by the modulators elacridar (a), tariquidar (b) and valspodar
(c) in the calcein-AM efflux assay on Kb-V1/VBL cells. Increasing modulator
concentrations lead to an enhanced efflux inhibition.
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calcein-AM efflux assay for the p-gp modulators elacridar, tariquidar and valspodar are
presented in Fig. 6.13.
The addition of increasing concentrations of modulators led to sigmoidal concentration
response curves. The IC50 values were calculated using the Hill equation (see table 6.4).
Table 6.4: IC50 values of the p-gp modulators elacridar, tariquidar and valspodar calculated
from the inhibition curves described in Fig. 6.13. The IC50 value of valspodar is
about 80 times higher than the values of elacridar and tariquidar.
modulator elacridar tariquidar valspodar
IC50 value 20.5 ± 1.7 nM 26.5 ± 2.5 nM 1.62 ± 0.3 µM
The shape and the slope of the concentration response curves of elacridar and tariquidar
modulation were similar. Moreover, the slopes of the curves were steeper compared to
the curve obtained by valspodar modulation. It is obvious that compared to valspodar
the 3rd generation p-gp modulators inhibited calcein-AM efflux completely at very low
concentrations. According to the IC50 values tariquidar and elacridar are 60 and 80 times
more potent p-gp inhibitors than valspodar. Therefore, elacridar and tariquidar appeared
to be very potent p-gp modulators.
The structures of elacridar and tariquidar are in part identical. The common part,
compound 4 (see page 126 and Fig. 6.15), was also tested in the calcein-AM efflux assay to
Figure 6.14: Impact of compound 4 on the p-gp mediated calcein-AM efflux. Increasing con-
centrations lead to enhanced efflux inhibition.
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clarify the contribution of this partial structure to the high p-gp inhibitory potency of the
modulators. Fig. 6.14 shows the sigmoidal concentration-response curve of compound 4
as an inhibitor of the calcein-AM efflux.
The IC50 value of compound 4 (42.7 ± 13.2 µM) was about 5 times lower than the
IC50 value of the 1st generation modulator verapamil, which was determined to be 248 µM
(see chapter 4.5.2). Additionally, in preliminary investigations, both papaverine and com-
pound 2 were tested in the calcein-AM efflux assay. Papaverine was chosen because of its
structural similarity to compound 4 (Fig. 6.15). The distance between the ring system
and the phenyl ring structure is similar in both compounds as demonstrated by super-
imposition of the structures in Fig. 6.16.2 Papaverine produced a 25 % inhibition of the
calcein-AM efflux at a concentration of 100 µM. In contrast, compound 2 lacking the
phenyl ring did not inhibit the calcein-AM efflux. Thus, both ring systems arranged in a
critical distance appear to be crucial for the potent p-gp modulating activity of elacridar
and tariquidar.
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Figure 6.15: Structures of compounds 2 and 4 and papaverine. Compounds 2 and 4 are
building blocks for the synthesis of tariquidar.
2Both substances were fitted and minimized by means of multifit tool implemented in Sybyl 6.9.2 (Tri-
pos Inc., ST. Louis, Missouri, USA). Gasteiger-Hückel-charges were applied at all atoms. For compound
4 the Tripos Force Field is 15.28 kcal/mol and for papaverine 19.59 kcal/mol, respectively. The analy-
sis was performed by Hendrik Preuß(Institute of Pharmaceutical Chemistry, University of Regensburg,
Germany).
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Figure 6.16: Superimposition of compound 4 (green) and papaverine (orange) indicates that
both substances are structurally similar.
The results of the chemosensitivity assay were confirmed with the calcein-AM efflux
assay. The new substances elacridar and tariquidar are highly potent p-gp modulators,
that are able to inhibit the p-gp mediated efflux directly.
6.3.5 Selectivity of the 3rd generation modulators
P-gp is a member of a large superfamily of ABC efflux transporters which contribute to the
"impermeability" of the blood-brain barrier (BBB) to numerous drugs. Apart from p-gp
the members of the MRP family, MRP1 and MRP2, and the ABCG2 transporter are to be
mentioned. To increase the concentration of cytostatic drugs, which are substrates of one
or more efflux transporters, inside the human body, multispecific modulators should be
administered to block several transporters at the same time. Therefore, the selectivity of
the modulators elacridar and tariquidar was investigated. In chapter 6.3.4 the inhibition
of the p-gp function by these modulators was described. In another study the ability of
elacridar and tariquidar to inhibit the function of the ABCG2 transporter was examined.
Again, chemosensitivity assays were used to investigate the potency of the modulators
to intensify the effect of cytostatic ABCG2 substrates. The modulation of the ABCG2
function by elacridar and tariquidar was investigated with an optimized flow cytometry
assay.
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Figure 6.17: Determination of mRNA encoding ABCG2 in wildtype MCF-7 cells and chemore-
sistant MCF-7/100ng and MCF-7/500ng subclones. The intensity of the ABCG2
bond (589 bp) is higher with increasing topotecan concentrations indicating an in-
tensified ABCG2 expression (ethidiumbromide stained agarose gel after RT-PCR
(34 cycles); β-actin served as a control).
In both assays, MCF-7 cells, which possess mRNA encoding ABCG2, were used. These
cells expressed functional ABCG2 protein when incubated with increasing concentrations
of topotecan up to 500 ng/ml (see Fig. 6.17). The cell line is designated as MCF-7/Topo.
6.3.5.1 Determination of the ABCG2 mediated efflux using the ABCG2 assay
In the literature various test systems are described to determine the functionality of
ABCG2 and the potency of different modulating substances. For this purpose, fluorescent
dyes such as Lysotracker Green (Litman et al. 2000) and BODIPY-prazosin (Robey et al.
2001a) or the cytostatic drug mitoxantrone (Robey et al. 2001b) were used as fluorescent
ABCG2 substrates. In preliminary experiments, mitoxantrone proved to be suitable. The
VIS spectrum of mitoxantrone (Fig. 6.18 b) indicated that mitoxantrone is excitable using
a red diode laser (λex = 635 nm) due to the maxima at wavelengths of 609 and 660 nm.
The emitted red fluorescence of mitoxantrone is detectable in channel 4 (FL4-H; λem =
661 ± 16 nm) of a flow cytometer.
MCF-7/Topo cells were incubated with mitoxantrone and different concentrations of
test substances. After mitoxantrone uptake for 30 minutes, the added substances were re-
moved and the cells were incubated for an additional hour, so that efflux of mitoxantrone
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Figure 6.18: Structure of the blue colored chemotherapeutic agent mitoxantrone (a). It is
excitable at 635 nm as deduced from the spectrum (b). Mitoxantrone has maxima
at 609 and 660 nm.
could take place. The residual mitoxantrone was measured by flow cytometry and the mi-
toxantrone efflux was calculated from the geometric means of FL4-H histograms. For this
purpose, two additional control samples were prepared. One control sample represented
Figure 6.19: Impact of elacridar (a) and tariquidar (b) on the ABCG2 mediated mitoxantrone
efflux. Increasing modulator concentrations result in maximum efflux inhibition
by about 40 %.
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the 100 % mitoxantrone uptake and contained the known ABCG2 inhibitor fumitremor-
gin C (Rabindran et al. 1998) apart from mitoxantrone. The mitoxantrone fluorescence
of this control sample was determined after an incubation for 30 minutes, when mitox-
antrone uptake by the cells was finished. The second control sample contained only
mitoxantrone and was incubated after the uptake incubation for one further hour in fresh
culture medium to allow mitoxantrone efflux. This fluorescence intensity of the residual
mitoxantrone in the second control sample is subtracted from the 100 % mitoxantrone
uptake value to obtain the 100 % mitoxantrone efflux value. The samples which contain
test substances were related to this 100 % efflux value. Fig. 6.19 presents the results of
the ABCG2 assay for the 3rd generation modulators elacridar and tariquidar.
Both efflux inhibition curves obtained for the ABCG2 modulation by elacridar and
tariquidar showed a sigmoidal and concentration dependent curve. The mitoxantrone
efflux was inhibited by about 40 % in both cases. Complete efflux inhibition was not
achieved. This can be explained by passive diffusion of mitoxantrone and mitoxantrone
efflux that is mediated by transporters other than ABCG2. The following IC50 values
were calculated from the curves (table 6.5).
Table 6.5: IC50 values of elacridar and tariquidar for the modulation of the ABCG2 transporter
in MCF-7/Topo cells.
modulator elacridar tariquidar
IC50 value 0.86 ± 0.23 µM 4.76 ± 2.33 µM
Elacridar as well as tariquidar inhibit the ABCG2 mediated mitoxantrone efflux in
MCF-7/Topo cells with IC50 values lower than 5 µM. Elacridar was a more potent ABCG2
inhibitor than tariquidar. In both cases, the obtained IC50 values were higher than the IC50
values in the calcein-AM efflux assay for the p-gp modulation (see page 138). An elacridar
concentration 80 times lower than the concentration required for a 50 % inhibition of
ABCG2, is sufficient to obtain a half maximum blockade of p-gp function. The IC50 value
of tariquidar for the ABCG2 transporter modulation is 180 times higher than that for the
modulation of the p-gp mediated efflux. Thus, both modulators inhibit predominantly
the p-gp mediated efflux. These results are in agreement with the characterization of
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elacridar and tariquidar as multispecific modulators in the literature (Han and Zhang
2004, de Bruin et al. 1999, Robey et al. 2004). Because of the great discrepancy between
the IC50 values for p-gp and ABCG2 modulation in case of tariquidar, it is improbable,
that tariquidar concentrations necessary for the inhibition of ABCG2 mediated efflux
were achieved in vivo. Therefore, the modulation of the ABCG2 transporter caused by
tariquidar seems to be negligible for in vivo pharmacokinetic and treatment studies.
The 2nd generation p-gp modulator valspodar was tested as well. However, no influence
on the mitoxantrone efflux was observed (data not shown). Therefore, valspodar is a
specific p-gp modulator and inactive on the ABCG2 transporter.
6.3.5.2 Determination of the inhibition of the ABCG2 mediated efflux using
the chemosensitivity assay
The results of the ABCG2 assay were reexamined with the chemosensitivity assay. The
ability of elacridar and tariquidar to intensify the effect of cytostatic drugs which are
ABCG2 substrates on MCF-7/Topo cells was examined within this assay. These cytostatic
drugs particularly include camptothecins and anthracyclines. MCF-7/Topo cells were
incubated with topotecan and doxorubicin at concentrations that did not affect the cell
growth. In addition, various concentrations of elacridar and tariquidar were added, which
themselves have no influence on the cell proliferation. Furthermore, paclitaxel, a cytostatic
agent that is only transported by p-gp, was included in the study as a negative control.
The results of the chemosensitivity tests are summarized in Figs. 6.20 to 6.22.
The effects of both doxorubicin (Fig. 6.20) and topotecan (Fig. 6.21) were enhanced by
the co-administration of elacridar and tariquidar. Under the test conditions an inhibition
of the cell growth by 80 % was achieved. However, the addition of the modulators did
not completely abrogate the drug resistance of MCF-7/Topo cells if administered at a
concentration of 1 µM in case of elacridar and 5 µM for tariquidar, respectively.
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Figure 6.20: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of MCF-7/Topo cells against doxorubicine (50 nM).
Figure 6.21: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of MCF-7/Topo cells against topotecan (100 nM).
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Figure 6.22: Impact of different concentrations of elacridar (a) and tariquidar (b) on the
chemosensitivity of MCF-7/Topo cells against paclitaxel (1 nM). Addition of the
modulators has no influence on the effect of the non ABCG2 substrate paclitaxel.
As expected, the combination of paclitaxel and the modulators had no effect on the
cell growth (Fig. 6.22). MCF-7/Topo cells only expressed the ABCG2 transporter and no
p-gp. Because paclitaxel is a selective p-gp substrate, no potentiation of the cytostatic
effect of paclitaxel was achieved by combination with elacridar or tariquidar.
It is obvious that higher concentrations were necessary to reverse drug resistance of the
MCF-7/Topo cells compared to the experiments with the p-gp expressing Kb-V1/VBL
cell line. Hence, the chemosensitivity results confirmed the findings of the ABCG2 assay.
In summary, elacridar and tariquidar are modulators of p-gp and ABCG2 mediated drug
efflux. Elacridar is more potent on blocking ABCG2 function than tariquidar. In con-
trast, the potency of the p-gp inhibition is similar for both substances. As the common
structural part, 2-[2-[4-aminophenyl)ethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline
(compound 4), seems to be necessary for modulation of p-gp, the residual structural
moiety appears to be important for the modulation of the ABCG2 transporter.
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6.4 Summary and conclusion
The 3rd generation p-gp modulators elacridar and tariquidar were examined and cha-
racterized with regard to their in vitro efficacy and their selectivity to other multidrug
transporters. Both substances showed higher p-gp inhibitory potency than any other
reported modulator with IC50 values of 20.5 nM in case of elacridar and 26.5 nM for
tariquidar, respectively. These data are in agreement with the literature. Mistry et al.
(2001) observed complete reversal of drug resistance in a multidrug resistant small lung
cancer cell line with tariquidar concentrations of 25 to 80 nM. Elacridar in concentrations
from 7 to 91 nM was reported to sensitize p-gp expressing human sarcoma cells to various
cytostatic drugs (Traunecker et al. 1999). The new modulators were about 80 times more
efficient when compared to the 2nd generation p-gp modulator valspodar.
In addition to p-gp modulation, the specificity of elacridar and tariquidar was inves-
tigated concerning the ABCG2 transporter. Both modulators proved to be unspecific
inhibitors. Elacridar as well as tariquidar inhibited the ABCG2 mediated efflux of several
cytotoxic agents such as mitoxantrone or doxorubicin in addition to the aforementioned
p-gp activity modulation. However, despite the similar specificity concerning p-gp and
ABCG2, the affinity of the two modulators for the ABCG2 efflux pump is different.
Whereas the IC50 values for inhibition of p-gp are very similar the effect of tariquidar
on the ABCG2 transporter was not marked compared to the effect caused by elacridar.
There is only little information on the selectivity of the described modulators to MRP,
a third relevant ABC transporter responsible for MDR. Some work groups are concerned
with this aspect. Germann et al. (1997a), Evers et al. (2000) and Tang et al. (2002)
reported that elacridar has no effect on MRP1 as well as on MRP2 function. In case of
tariquidar, the affinity to MRP transporters has to be evaluated.
The building block 4 was identified as an important structural part for the high in
vitro efficacy of elacridar and tariquidar. Because of the different activity in the ABCG2
assay, the acridine structure of elacridar appears to be necessary for inhibition of ABCG2.
Further investigations on the structure activity relationships are required as a basis for
the development of another modulator generation. Such studies may contribute to the
understanding of the mode of action of ABC transporters and lead to the discovery of
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active substances that are not recognized by multidrug transporters.
Elacridar and tariquidar are suited for fluorescence and UV spectroscopic detection.
These characteristics are important for in vivo distribution experiments of the two mod-
ulators. Ward and Azzarano (2004) demonstrated that elacridar did not inhibit human
cytochrome P450 enzymes. This leads to the assumption that elacridar and possibly
tariquidar, lack the ability to alter pharmacokinetic parameters of co-administered cyto-
static drugs. Thereby, these new modulators will be more suitable for clinical trials in
comparison to 2nd generation p-gp modulators (see 6.1). Examinations were carried out
by various groups, e.g Bardelmeijer et al. (2000), to investigate the effect of elacridar on
the AUC of co-administered cytostatic drugs such as paclitaxel. Bardelmeijer observed
that elacridar does not interfere with the elimination of paclitaxel.
In summary, due to the presented results of the in vivo experiments the new p-gp
modulators are clearly superior to the 2nd generation modulator valspodar. Therefore,
these promising compounds in combination with cytostatics appear to be suitable for
the clinical treatment of multidrug resistant tumors and to overcome barriers inside the
human body such as the BBB .
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Chapter 7
Effect of the p-gp modulators elacridar
and tariquidar on the distribution of
paclitaxel in nude mice3
7.1 Introduction
Paclitaxel (Taxol®, Fig. 7.1) is well established as an anticancer drug in the treatment
of various human malignancies (Kroger et al. 1999, Bunn and Kelly 2000, Nathan et al.
2000). It has also been used in the therapy of primary and secondary brain tumors (Glantz
et al. 1999). However, the efficacy of paclitaxel in the systemic treatment of these tumors
is variable and low. Although paclitaxel is very lipophilic, its access to the brain is limited
(Heimans et al. 1994). The brain, often regarded as a "sanctuary site" for cytotoxic drugs,
is protected by the blood-brain barrier (BBB), which restricts penetration of drugs into
the brain and the brain tumor tissue as well. The BBB consists of endothelial cells of
brain capillaries. In the luminal membrane of these endothelial cells the efflux transporter
p-glycoprotein 170 (p-gp) is expressed. Experiments with p-gp knockout mice used as a
reference model for complete p-gp inhibition have shown that p-gp limits the entry of
anticancer drugs such as paclitaxel into the brain (van Asperen et al. 1996). Moreover,
several studies done by Tanaka et al. (1994), Sawada et al. (1999) and Gallo et al. (2003)
3Parts of this work were presented at the BBB Expertentreffen 2004 in Bad Herrenalb
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Figure 7.1: Structure of the cytostatic drug paclitaxel
have shown that p-gp is also expressed in the neovasculature of brain tumors, although it
is postulated that the BBB is compromised in brain tumor tissue.
However, it is possible to enhance the concentration of p-gp substrates in the brain by
blocking the function of the p-gp mediated efflux transport. The p-gp mediated transport
is inhibited by certain substances, the so-called p-gp modulators. Experiments with male
Wistar rats treated with paclitaxel (8 mg/kg on day 4) demonstrated that addition of
the 2nd generation modulator valspodar (100 mg/kg/d over 5 d) led to an 8- to 20-fold
increase of paclitaxel in the brain (Donatsch 1996). Fellner et al. (2002) investigated the
impact of valspodar co-administration on the paclitaxel distribution in nude mice. They
determined a 6-fold increase of the paclitaxel concentration in the brain after pretreatment
with valspodar (50 mg/kg, 4 h before 8 mg/kg paclitaxel) compared to the paclitaxel
brain levels without valspodar co-application. However, the 2nd generation modulators
enhanced not only the concentrations of cytostatic drugs in the brain, but also in liver,
kidney and plasma. In addition, they interact with cytochrome P450 enzymes, leading to
alterations of pharmacokinetic parameters of cytostatic drug such as delayed elimination
(Wandel et al. 1999). Thus, the toxic side effects of chemotherapy increase, and cytostatic
drug doses have to be reduced, which in turn results in a lower amount of cytostatic drug
in the brain.
To avoid the aforementioned disadvantages new modulators were developed. These
were supposed to preferentially modulate p-gp in brain capillaries and lack the interac-
tion with cytochrome P450 enzymes. Two of these 3rd generation modulators, elacridar
(GF 120918, Hyafil et al. (1993)) and tariquidar (XR 9576, Mistry et al. (2001)) were
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characterized in chapter 6 as highly potent p-gp inhibitors. For elacridar, several studies
were carried out that demonstrated the p-gp modulating effect of elacridar at the BBB
(Edwards et al. 2002, Huisman et al. 2003). Moreover, combinations of these modulators
were well tolerated in phase I studies (Sparreboom et al. 1999, Stewart et al. 2000).
In the present study, the ability of these new p-gp modulators to increase the penetra-
tion of paclitaxel into the nude mice brain was examined. The effect of co-administration
of elacridar and tariquidar on the distribution of paclitaxel in different nude mice tissues
and plasma was investigated as well. For comparison, valspodar (SDZ PSC 833) was
included in the study. The impact of valspodar on paclitaxel distribution was already
determined by Stephan Fellner (Fellner 2001).
7.2 Material and methods
7.2.1 Drugs and chemicals
Elacridar (GF 120918·HCl) was kindly provided by GSK (Research Triangle Park, North
Carolina, United States). Tariquidar (free base) was synthesized at our department as
described in chapter 6. Paclitaxel (6 mg/ml) was obtained from the pharmacy of the Uni-
versity Hospital Regensburg as well as Ketamine (Ketanest®, WVD, Garbsen, Germany)
and xylazine (Rompun®, Bayer, Leverkusen, Germany). BSA was purchased from Serva
(Heidelberg, Germany).
7.2.2 Pharmacokinetic studies in nude mice
The breeding of the NMRI(nu/nu) mice is described in chapter 3.2.7.
Six to 8-week-old NMRI(nu/nu) mice were assigned to groups of three animals per
time point. For each experiment only animals of the same sex were used, male mice
in case of elacridar experiments and female mice for the tariquidar modulation studies.
Elacridar and tariquidar were dissolved in a vehicle that was used in previous studies
for valspodar application. This vehicle contained 52.2 g of chremophor RH40 (Caelo,
Hilden, Germany), 15 g of absolute ethanol (Merck), 0.1 g of D,L-α-tocopherol (Sigma),
7.5 g of propyl glycol (Merck) and 15 g of Labrafil M2125CS (Gattefosse, Weil am Rhein,
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Germany). The solution was treated with ultrasound and heated in a water bath to 37 ℃
to increase the solubility of the compounds. A volume of 0.1 ml was administered by
gavage per 10 g of body weight, resulting in a dosage of 5 or 50 mg of modulator per
kilogram of body weight. In the same way, the solvent was applied to the control animals.
For intravenous injection paclitaxel (6 mg/ml) was diluted with 0.9 % NaCl solution
to a paclitaxcel concentration of 1.6 mg/ml. The drug was injected via the retrobulbar
plexus in a volume of 0.1 ml per 20 g of body weight within approximately 10 s. Four
hours before the injection of paclitaxel either a dose of 50 mg/kg of modulator (modulator
group) or a corresponding volume of the vehicle (control) was orally administered to the
mice.
To minimize interferences with the analytical results by drug in the vasculature, ke-
tamine/xylazine-anesthetized mice were killed by cardiac puncture, 1.5, 3, 4.5 and 24
hours after intravenous paclitaxel injection. Heparin-plasma, brain, liver and kidneys were
collected. Tissues were homogenized in 4 % BSA solution within 5 minutes and shock-
frozen in liquid nitrogen. For homogenization, each organ was cut into small pieces. One
milliliter 4 % BSA solution was added per 150 mg tissue. Homogenization was carried
out with a Potter-Elvehjem homogenizer by 15 strokes. All samples, except for the brain
homogenates, were stored at -78 ℃. The brain homogenates were prepared for paclitaxel
analysis immediately after homogenization.
7.2.3 Sample preparation
Tissue extraction was performed by a modification of the method of Sparreboom et al.
(1995). Thawed tissue homogenate (1 - 2 ml) was pipetted into a glass centrifugation
tube with a ground joint. Samples less than 1 ml were filled up to 1 ml with 4 % BSA
solution. Tissue samples underwent diethyl ether extraction (4 ml per sample, 5 min) and
were subsequently centrifugated at 1000 rpm for 5 min at 4 ℃. The samples were frozen
by a cooling bath and the organic layer was decanted to another centrifugation tube. This
extraction procedure was repeated. The combined diethyl ether phases were evaporated
under nitrogen at 37 ℃. The residues were resuspended in 250 µl of citrate-phosphate-
dextrose (CPD) plasma (BRK, Regensburg, Germany) by ultrasonic treatment for 3 min
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and vortexing for 30 s, and were purified by solid-phase-extraction (SPE). Bond Elut
CN-E columns (Varian, Darmstadt, Germany) were conditioned with 2 ml of methanol
and 2 ml of NH4OAc buffer (0.01 M, pH 5.0) at 850 to 900 mbar. Samples were mixed with
300 µl of NH4OAc buffer (0.02, pH 5.0), and the mixtures were loaded on the SPE columns
at 700 to 800 mbar. Columns were washed with 2 ml of NH4OAc buffer (0.01 M, pH 5.0)
and 1 ml of 20 % methanol in NH4OAc buffer (0.01 M, pH 5.0). Samples were eluted
with 500 µl of a mixture of acetonitrile and triethylamine (1000:1) into an eppendorf cup
(1.5 ml, Eppendorf, Hamburg, Germany). The solvent was evaporated by a SpeedVac
Plus 110 A (Thermoquest, Egelsbach, Germany), and the residues were resuspended in
200 µl of mobile phase by vortexing for 30 s. The brain samples were additionally treated
with ultrasound for 3 min. All samples were centrifugated at 4000 rpm for 10 min at
4 ℃. The supernatant was either analyzed immediately, as in the case of brain samples,
or stored at -78 ℃.
Plasma samples consisted of 250 µl of thawed murine plasma. Samples less than 250 µl
were filled up to 250 µl with human CPD plasma. The plasma samples underwent only
SPE and were stored at -78 ℃.
7.2.4 Paclitaxel analysis
To each sample 10 µl of a 50 µM docetaxel solution were added as internal standard at
the beginning of the sample preparation. For docetaxel stock solutions Taxotere® (80 mg
doctaxel per 2 ml of polysorbate 80; Rhone-Poulenc Rorer, Anthony Cedex, France) was
diluted with absolute ethanol. HPLC analysis was carried out on a Merck Hitachi liquid
chromatograph (Merck, Darmstadt, Germany). A stainless steel (125 x 4 mm) analytical
column equipped with a guard column (4 x 4 mm), both packed with 5 µm LiChrospher
100 RP-18 material (Merck), was thermostated to 33 ℃. The mobile phase consisted of
acetonitrile, methanol, NH4OAc buffer (0.2 M, pH 5.0) at the ratio of 35:7.8:57.2 (vol/vol).
Ultraviolet detection was performed at 227 nm, and a washing gradient was applied after
each run (additional 35 % vol/vol acetonitrile). Injection volumes were either 50 or 100 µl.
For calibration, paclitaxel and docetaxel stock solutions in anhydrous ethanol, stored at
-20 ℃, were diluted with mobile phase (1:100) on the day of analysis.
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The method of analysis was validated for murine plasma, brain, liver, and kidney
samples (Fellner 2001). Correlation coefficients for paclitaxel calibration curves in the
concentration range 50 - 1000 nM were greater than 0.999. Recovery rates for paclitaxel
ranged from 50 to 85 %, depending on the paclitaxel concentration and the type of tissue.
The method’s accuracy for tissue samples was below 2 % for paclitaxel concentrations
between 0.667 and 6.67 nmol/g of tissue and better than 8 % for 0.133 nmol/g. The
precision for these determinations was better than 10 %.
7.2.5 Recovery and analysis of elacridar and tariquidar
Stock solutions of the modulators were freshly prepared in mobile phase before sample
analysis. For calibration, solutions were diluted with mobile phase (1:100). The modulator
and docetaxel (internal standard) solutions used for recovery studies were prepared in
absolute ethanol by 1:5 dilution of respective stock solutions.
Homogenized tissues (brain, liver, kidney) and plasma of untreated mice was used for
the recovery studies. Prior to diethyl ether extraction 10 µl of a 50 µM solution of the
internal standard docetaxel and 10 µl of 3 different concentrations of the modulators (10,
50, 100 µM) were added to blank tissue samples. The analyses of elacridar and tariquidar
were performed according to the paclitaxel analysis. The recoveries were determined by
comparison of recovery sample peak areas and standard peak areas obtained from directly
injected recovery stock solutions after dilution with mobile phase (1:100). For each tissue
as well as for murine plasma, 5 samples were analyzed. Additionally, for each recovery
concentration one blank tissue and plasma sample was prepared to determine interfering
peaks. The peak area of these interfering peaks was subtracted from the corresponding
sample areas.
7.3 Results 155
7.3 Results
The paclitaxel concentrations in brain, liver, kidney and plasma of nude mice were de-
termined according to Sparreboom et al. (1995) with slight modifications. The tissue
samples were homogenized by a Potter Elvehjem homogenizer and underwent ether ex-
traction and subsequent solid phase extraction. Plasma samples were prepared only by
solid phase extraction. Separation was performed on a RP-18 column. Docetaxel was
used as internal standard instead of 2’-methyl paclitaxel. The method for examining pa-
clitaxel was established and validated at our department by S. Fellner (Fellner 2001). This
method was also used for the determination of elacridar and tariquidar concentrations in
these tissues.
7.3.1 Study design
The pharmacokinetic experiments were carried out according to Fig. 7.2. Nude mice
received either elacridar or tariquidar at a dosage of 50 mg per kg of body weight. Pacli-
taxel was administered 4 hours after the p-gp modulators. Brain, liver, kidney and plasma
samples were collected after certain periods of time and prepared for HPLC analysis.
p.o.application of
p-gp modulator
(50 mg/kg)
p.o. application of
vehicle (solvent of
p-gp modulators)
1.5, 3, 4.5, 24 h
4 h4 h
paclitaxel administration (8 mg/kg, i.v.)
sample collection and homogenisation (n = 3)
Figure 7.2: Application scheme of the p-gp modulators elacridar and tariquidar, and the cy-
tostatic drug paclitaxel to nude mice. Each group consisted of 3 nude mice per
observation time after intravenous injection of paclitaxel.
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7.3.2 Determination of elacridar and tariquidar in nude mice tis-
sue
The HPLC chromatograms of mice brain tissues treated with modulator and paclitaxel
showed a peak in addition to the paclitaxel and the internal standard peaks. Since this
peak only occurred in samples of mice that received either elacridar or tariquidar, the
additional peak originated from the modulator. This phenomenon was verified by HPLC
analysis of elacridar and tariquidar solutions. Fig. 7.3 shows typical HPLC chromatograms
of tissue samples, that consist of either elacridar or tariquidar.
Figure 7.3: HPLC chromatograms of elacridar (a) and tariquidar (b) from mouse brain sam-
ples. HPLC conditions: LiChrospher 100 RP-18 (5 µm)(125 mm x 4 mm); acetoni-
trile/methanol/0.2 M NH4OAc, pH 5.0, 35:7.8:57.2; flow: 1 ml/min; UV detection
at 227 nm; 30 ℃.
Elacridar was detected at a retention time of about 10 min. Since the peaks of docetaxel
and tariquidar were not well separated, the composition of the mobile phase was changed
from that described by Fellner (2001). Thus, tariquidar had a retention time of about 14
min and was distinguishable and separated from the docetaxel signal, which was measured
at about 16 min. The separation efficiency was controlled in every analysis due to peak
resolution values of just 1.25 for tariquidar and docetaxel peaks. Interfering peaks from
tissue and plasma were observed at the same retention times as elacridar and tariquidar.
This was especially true for liver and kidney samples. To take these peaks into account,
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samples without modulator or blank samples of the different tissues were analyzed. The
areas of the interfering peaks at the retention times of the modulators were calculated
and subtracted from the determined areas for elacridar and tariquidar.
The recovery of elacridar and tariquidar from mouse brain, liver and kidney tissue
homogenates as well as from murine plasma, was determined for 3 different concentrations.
Docetaxel was used as internal standard to calculate the modulator content of the different
tissues directly from the samples that were prepared for paclitaxel analysis. The same
amount of docetaxel was given to all recovery samples (10 µl of 50 µM docetaxel solution
in absolute ethanol). The recovery samples were prepared similarly to the procedure
for the paclitaxel distribution samples. The recovery of elacridar and tariquidar in the
different organs is described in table 7.1 and 7.2.
Table 7.1: Recovery of elacridar and internal standard docetaxel after preparation of brain,
liver, kidney and plasma samples (mean values ± SEM). Prior to sample preparation
10 µl of 50 µM of a docetaxel solution were added. For each tissue as well as for
murine plasma, 5 samples were analyzed.
elacridar elacridar docetaxel (IS) recovery ratio
tissue
concentration recovery [%] recovery [%] elacridar/IS
667 pmol/g 16.47 ± 3.74 58.83 ± 3.88 0.284 ± 0.085
brain 3.33 nmol/g 13.93 ± 3.50 46.08 ± 4.28 0.299 ± 0.055
6.67 nmol/g 21.59 ± 3.56 45.59 ± 4.17 0.476 ± 0.081
667 pmol/g 35.44 ± 2.55 62.26 ± 5.22 0.571 ± 0.047
liver 3.33 nmol/g 22.25 ± 3.58 61.69 ± 3.02 0.358 ± 0.048
6.67 nmol/g 23.51 ± 4.95 69.55 ± 4.08 0.336 ± 0.057
667 pmol/g 21.68 ± 5.53 66.32 ± 2.56 0.329 ± 0.092
kidney 3.33 nmol/g 18.39 ± 3.18 59.48 ± 2.10 0.309 ± 0.053
6.67 nmol/g 20.75 ± 4.85 62.10 ± 2.21 0.334 ± 0.078
667 pmol/g 10.32 ± 4.40 76.51 ± 3.63 0.134 ± 0.054
plasma 3.33 nmol/g 10.36 ± 2.04 80.55 ± 3.05 0.129 ± 0.025
6.67 nmol/g 11.47 ± 5.77 85.24 ± 3.58 0.134 ± 0.065
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Table 7.2: Recovery of tariquidar and internal standard docetaxel after preparation of brain,
liver, kidney and plasma samples (mean values ± SEM). Prior to sample preparation
10 µl of 50 µM of a docetaxel solution were added. For each tissue as well as for
murine plasma, 5 samples were analyzed.
tariquidar tariquidar docetaxel (IS) recovery ratio
tissue
concentration recovery [%] recovery [%] tariquidar/IS
667 pmol/g 18.09 ± 2.73 58.83 ± 3.88 0.310 ± 0.062
brain 3.33 nmol/g 13.82 ± 3.65 46.08 ± 4.28 0.299 ± 0.056
6.67 nmol/g 18.85 ± 2.94 45.59 ± 4.17 0.415 ± 0.064
667 pmol/g 32.39 ± 3.04 62.26 ± 5.22 0.523 ± 0.061
liver 3.33 nmol/g 18.89 ± 2.56 61.69 ± 3.02 0.304 ± 0.032
6.67 nmol/g 17.48 ± 4.11 69.55 ± 4.08 0.250 ± 0.048
667 pmol/g 32.92 ± 6.43 66.32 ± 2.56 0.438 ± 0.113
kidney 3.33 nmol/g 17.78 ± 1.57 59.48 ± 2.10 0.299 ± 0.025
6.67 nmol/g 21.86 ± 3.55 62.10 ± 2.21 0.352 ± 0.056
667 pmol/g 9.78 ± 4.86 76.51 ± 3.63 0.128 ± 0.063
plasma 3.33 nmol/g 12.17 ± 2.65 80.55 ± 3.05 0.151 ± 0.032
6.67 nmol/g 13.37 ± 5.92 85.24 ± 3.58 0.156 ± 0.067
Interestingly, the recovery of the p-gp modulators was much lower compared to the re-
covery of paclitaxel which had been examined by S. Fellner (Fellner 2001). The elacridar
recovery was very low. The values ranged between 10 and 35 % depending on the elacridar
concentration and the tissue. The recovery from plasma was the lowest. In brain, liver
and kidney a 20 % recovery was determined. The recovery was similar for elacridar and
tariquidar. Tariquidar recovery was calculated from 9 to 32 %. In plasma, recovery of
tariquidar was lower as well when compared to the other tissues. The average recovery
of tariquidar in brain, liver and kidney was 20 %. The recovery of the internal standard
docetaxel was about three times greater in brain, liver and kidney compared to the re-
covery of elacridar and tariquidar in these tissues. In plasma a six times higher recovery
was found in case of docetaxel compared to elacridar and tariquidar recovery values, i.e.
docetaxel and the two modulators were not extracted to the same extent. For calculation
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of the modulator concentrations in the different tissues, the unequal recovery has to be
considered.
Correlation coefficients for modulator calibration curves in the concentration range 5
to 5000 nM were higher than 0.99. The method’s accuracy was determined for kidney
samples (see table 7.3). The accuracy was below 19 % for tariquidar concentrations and
14 % for elacridar concentrations between 0.667 and 6.67 nmol/g of tissue. The precision
for these calculations was better than 24 % in case of elacridar and 15 % for tariquidar,
respectively.
Table 7.3: Determination of known elacridar and tariquidar concentrations by quanitfication
with calibration curves in murine kidney homogenates. Five samples were analyzed
per modulator concentration.
modulator determined elacridar determined tariquidar
concentration [nmol/g] concentration [nmol/g] concentration [nmol/g]
0.667 0.758 ± 0.206 0.791 ± 0.118
3.33 3.60 ± 0.44 3.54 ± 0.25
6.67 6.72 ± 1.62 7.14 ± 1.06
Elacridar and tariquidar levels in different tissues of the nude mice could only be
estimated due to the low recovery of the two modulators particularly from murine plasma,
and the high variations determined in accuracy and precision calculations.
7.3.3 Distribution of elacridar and tariquidar in nude mice
Based on the recovery data, elacridar and tariquidar concentrations in brain, liver, kidney
and plasma were calculated from the HPLC chromatograms of the paclitaxel distribution.
Fig. 7.4 and 7.5 presents the modulator levels in the different tissues.
The modulators were detectable in all examined tissues as well as in plasma. Elacridar
was quantified in liver and kidney even after 24 hours (Fig. 7.4). The highest elacridar
levels were 120 nmol/g after 4.5 hours in liver and kidney. The levels decreased after
4.5 hours to 3.7 nmol/g in liver and 5.5 nmol/g in kidney. After 3 hours approximately
3 times more elacridar was found in brain than in plasma. The maximum concentration
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Figure 7.4: Concentrations of p-gp modulator elacridar in brain (N), liver (•), kidney (¥) and
plasma (H) of nude mice (mean values ± SEM).
Figure 7.5: Concentrations of p-gp modulator tariquidar in brain (N), liver (•), kidney (¥) and
plasma (H) of nude mice (mean values ± SEM).
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in brain was 51.5 nmol elacridar per g tissue. In chapter 6, the IC50 value for elacridar was
determined to be 20.5 nM. Compared to this value, the elacridar levels in the brain were
500 to 2500 times higher than those required for p-gp inhibition. In case of tariquidar (Fig.
7.5) the modulator was identified in all examined samples during the entire experiment.
The highest tariquidar concentrations were measured in liver with a maximum amount
of 198 nmol per g of tissue after 3 hours. This is about 40 % higher than the achieved
elacridar concentration. Only half of the tariquidar concentration determined in liver
was measured in kidney. The tariquidar level in plasma was two-fold higher than in
brain. In contrast, the distribution of elacridar was several fold higher in brain tissue
compared to plasma. The tariquidar concentrations decreased after 3 hours in all tissues
as well as in plasma. The tariquidar brain concentrations were determined to be at least
2.7 nmol/g and at most 8.8 nmol/g. It is important to note that even the lowest tariquidar
concentrations measured in these experiments were 100 times higher than those necessary
for p-gp modulation (IC50 value of 26.5 nM determined in chapter 6). While brain and
plasma concentrations of elacridar declined to undetectable levels within 24 hours after
paclitaxel administration, the tariquidar levels in plasma and brain remained relatively
constant during the 24 hour study period. Obviously, tariquidar has a longer lasting effect
than elacridar.
7.3.4 Pharmacokinetic study on the paclitaxel distribution in nude
mice
In this study, the influence of the p-gp modulators elacridar and tariquidar on the pa-
clitaxel distribution in brain, liver, kidney and plasma of nude mice was investigated.
The analyzed paclitaxel concentrations after elacridar or tariquidar administration were
compared to the results obtained in the valspodar study carried out by S. Fellner. The
paclitaxel distribution in the different tissues is summarized in Figs. 7.6 to 7.9.
In liver (Fig. 7.6), paclitaxel levels were very high (> 15 nmol/g) after 1.5 hours. The
values decreased to similar paclitaxel levels in all four groups. No statistically significant
differences were determined between the different p-gp modulator groups and the control
group.
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Figure 7.6: Effect of p-gp modulator co-administration (50 mg/kg, p.o.) on paclitaxel levels
in liver (mean values ± SEM). Paclitaxel was given intravenously at a dosage
of 8 mg/kg. Valspodar (¥), elacridar (N) and tariquidar (H) were used as p-gp
modulators; untreated mice served as a control (◦).
Figure 7.7: Effect of p-gp modulator co-administration (50 mg/kg, p.o.) on paclitaxel levels
in kidney (mean values ± SEM). Paclitaxel was given intravenously at a dosage
of 8 mg/kg. Valspodar (¥), elacridar (N) and tariquidar (H) were used as p-gp
modulators; untreated mice served as a control (◦).
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In contrast to the drug levels determined in liver, in the kidney the highest concen-
tration of paclitaxel was found in mice that received valspodar (Fig. 7.7). In fact, 1.5
hours after injection the paclitaxel levels were high in all examined groups with values
up to 15.5 nmol paclitaxel per g of tissue. Then in elacridar and tariquidar treated mice,
the paclitaxel content in kidney decreased to achieve concentrations similar to those in
the untreated control group. In contrast, co-administration of valspodar led to a slight
increase in the paclitaxel concentration after 3 hours compared to the values obtained
after 1.5 hours. Paclitaxel levels were 7-fold higher after 4.5 hours than after 24 hours.
However, this paclitaxel content was still significantly different from the concentrations in
the other groups. The paclitaxel concentrations determined in kidney were slightly lower
in comparison to the levels measured in liver.
Figure 7.8: Effect of p-gp modulator co-administration (50 mg/kg, p.o.) on paclitaxel levels
in plasma (mean values ± SEM). Paclitaxel was given intravenously at a dosage
of 8 mg/kg. Valspodar (¥), elacridar (N) and tariquidar (H) were used as p-gp
modulators; untreated mice served as a control (◦).
The paclitaxel concentration time profile in plasma (Fig. 7.8) followed a similar pattern
as observed in kidney. Relative to the control group the paclitaxel level in plasma of mice
that received valspodar increased by 2.5-fold after 1.5 hours and 10-fold after 3 hours. In
mice pretreated with elacridar or tariquidar the paclitaxel concentrations were similar to
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those in plasma of the control mice and decreased during the experiment to values lower
than 0.2 nmol/g after 24 hours. By contrast, in the plasma of valspodar treated mice, no
decrease in the paclitaxel concentration was observed.
Figure 7.9: Effect of p-gp modulator co-administration (50 mg/kg, p.o.) on paclitaxel levels
in brain (mean values ± SEM). Paclitaxel was given intravenously at a dosage
of 8 mg/kg. Valspodar (¥), elacridar (N) and tariquidar (H) were used as p-gp
modulators; untreated mice served as a control (◦).
The concentration of paclitaxel in the brains of nude mice was also measured (Fig. 7.9).
The administration of paclitaxel alone resulted in low levels of the drug in the brain. The
concentrations were near the limit of quantitation (0.1 nmol/g). Brain levels were up to
57 times lower (1.5 and 3 hours after injection) compared to those in liver and kidney.
Co-administration of valspodar substantially increased the paclitaxel concentration in the
brain. Although the levels were 5- to 8.5-fold higher than in the control group the new
p-gp modulators elacridar and tariquidar were not able to induce the same increase in
the concentration of paclitaxel in the brain as that achieved by valspodar administration.
Co-application of elacridar and tariquidar led only to an increase by 4.9 to 7 fold and
4.7 to 6.6 fold, respectively. Despite this slight increase, brain paclitaxel levels observed
after pretreatment with elacridar and tariquidar remained significantly different from the
control levels. Thus, the brain was the only examined tissue, where administration of
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elacridar and tariquidar resulted in different paclitaxel concentrations compared to the
control levels. Furthermore, in contrast to liver, kidney and plasma, where paclitaxel
concentrations strongly declined after 24 hours, the paclitaxel levels in the brain remained
relatively constant within 24 hours.
The different impact of valspodar, elacridar and tariquidar co-administration on the
paclitaxel levels in the brain compared to plasma is presented as concentration ratios
determined at different points in time in Fig. 7.10. Irrespective of the administered
modulator, more paclitaxel was found in plasma than in brain 1.5 hours after paclitaxel
injection. However, additional 1.5 hours later, the brain/plasma ratio had changed in
case of elacridar or tariquidar co-application: 2.5 and 1.5 times higher paclitaxel levels
were detected in brain than in plasma. This effect lasted for 4.5 hours, and was more
pronounced with tariquidar (ratio 4.5) than with elacridar (ratio 1.2). The brain/plasma
ratios of paclitaxel after valspodar co-administration were 2- to 15-fold lower than in the
presence of the new p-gp modulators, indicating that p-gp inhibition by valspodar does
Figure 7.10: Brain-plasma ratio of paclitaxel after co-administration of valspodar (black bar;
not determined at 4.5 h), elacridar (light grey bar) and tariquidar (dark grey bar).
Three hours after paclitaxel injection more paclitaxel is found in brain than in
plasma if elacridar or tariquidar were co-administered.
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not lead to a specific accumulation of paclitaxel in the brain of nude mice.
As the measured elacridar concentrations in the brain were at least 50 times higher than
the IC50 value (ca. 20 nM) determined for p-gp inhibition in vitro, in another experiment
the dosage of the modulator was reduced to 5 mg/kg. This dosage should be sufficient
by far to achieve the elacridar concentration required for p-gp inhibition. The effect of
5 mg/kg elacridar on the distribution of paclitaxel in different tissues and plasma of nude
mice compared to untreated mice is summarized in Fig. 7.11.
In liver, kidney and plasma of mice treated with elacridar at reduced dosage, the
paclitaxel concentrations were not significantly different from the control values. As ex-
pected, the paclitaxel levels in liver, kidney and plasma obtained after co-administration
Figure 7.11: Effect of elacridar co-administration (5 mg/kg, p.o.) on paclitaxel levels in brain
(a), liver (b), kidney (c) and plasma (d) of nude mice (black bar; mean values
± SEM). Paclitaxel was intravenously given at a dosage of 8 mg/kg. Untreated
mice served as a control (light grey bar).
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of 5 mg/kg of elacridar were comparable to those after a dosage of 50 mg/kg. However,
the reduced dose of elacridar did not result in an increase of the paclitaxel concentration
in brain. All measured paclitaxel levels in the brain were near the limit of quantitation. In
all tissue and plasma samples a decrease in the paclitaxel concentration was determined
during the 4.5 hour study period. Only little information is available on the absorption
of the lipophilic elacridar and its distribution into adipose tissue. Due to the lack of in-
creased paclitaxel levels in the brain after p.o. administration of 5 mg/kg elacridar, it may
be speculated, that the modulator is only partly absorbed and distributed preferentially
to adipose tissue. This would explain why a higher dosage is required to inhibit the p-gp
at the BBB.
7.4 Discussion
The 3rd generation p-gp modulators elacridar and tariquidar proved to be highly potent
p-gp inhibitors in vitro (see chapter 6). Now, their efficacy was investigated in vivo by
quantification of the paclitaxel levels in different tissues of nude mice depending on the
co-application of the MDR modulators. Fortunately, the two modulators were detectable
in the HPLC chromatograms which were recorded for paclitaxel analysis. The recovery
of elacridar and tariquidar was determined afterwards, the calculated modulator distribu-
tion in the different tissues could be estimated although sample preparation and HPLC
method were developed for the detection and quantification of paclitaxel. The high SEM
values in the determination of accuracy and precision were explainable by the following
facts. Interfering peaks that were observed particularly in liver and kidney and could only
be estimated in control samples might influence the results especially at low modulator
concentrations. Since the tariquidar peak was detected close to the peak of the internal
standard the separation of both peaks was impaired at higher modulator concentrations.
The peak area that is attributed to interfering peaks is negligible at modulator concentra-
tions greater than 2.5 µM. At high elacridar concentrations the pronounced tailing of the
peak hampered the exact quantification of elacridar. The asymmetry factor of elacridar
peaks at high modulator concentrations was close to the acceptable value of 2.5. Factors
higher than 3 result in unprecisely defined peak areas because the point at which the
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peak reaches the base line is not well identifiable (Meyer 1992). To determine the con-
centrations of elacridar and tariquidar correctly, a new method has to be developed. Due
to the low recovery, particularly from plasma, the procedure of the sample preparation
should be adapted to the modulators. The preparation of modulator samples according
to a different method failed due to the small tissue homogenate volume especially in case
of brain samples.
Another problem was the poor solubility of elacridar and particularly tariquidar in
the vehicle if dosed at 50 mg/kg. Different solvents mentioned in literature such as
hydroxypropylmethyl cellulose (HMPC) and tween 80 solutions (Mistry et al. 2001) were
tested, but proved to be unsuited, and therefore the modulators were administered in
suspension. Thus, the exact dose of soluble modulator that was given to each mouse
remained unknown. By improving the solubility of these compounds, the ideal modulator
concentration could be determined.
Despite the problems associated with the exact determination of the modulator con-
centrations, high elacridar and tariquidar levels were analyzed particularly in liver and
kidney. Even in the nude mouse brain, the modulator levels were at least 10 to 50 times
higher than those required for p-gp inhibition in vitro (see IC50 values in the calcein-AM
efflux assay). Elacridar and tariquidar were able to significantly increase the paclitaxel
concentrations up to 0.3 nmol/g after 24 hours in the brain compared to the control.
However, the increase ín brain paclitaxel levels caused by the new modulators was not
as high as in case of valspodar administration (about 0.5 nmol/g after 24 hours), indi-
cating an incomplete inhibition of p-gp. This observation should not necessarily lead to
the conclusion that elacridar and tariquidar are weaker p-gp modulators in vivo. For the
evaluation of the efficacy of a p-gp inhibitor with respect to the increase in brain concen-
trations of a co-administered drug it is also necessary to take into account the influence
of the inhibitor on the drug plasma level. Kemper et al. (2003) examined to what extent
increased plasma levels contribute to higher brain levels. They determined the paclitaxel
concentrations in the brains of p-gp knockout mice after administration of valspodar. The
paclitaxel brain levels were even higher as in untreated knockout mice, suggesting that
increased plasma levels due to reduced excretion also account for higher brain levels in
wild type mice receiving valspodar. Since the plasma levels of paclitaxel measured by
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S. Fellner were markedly increased after valspodar administration compared to the con-
trol, the increased levels in the brain might have partly resulted from the high plasma
levels in the valspodar group. In case of the new modulators, no marked elevations of
the paclitaxel levels in plasma were observed compared to the control. Thus, the elevated
paclitaxel concentrations in brain of elacridar and tariquidar treated mice only resulted
from the inhibition of p-gp at the BBB. The potency of elacridar found in this study is
in line with previous reports on its effects on the brain penetration of docetaxel (Kemper
et al. 2004c) and morphine (Letrent et al. 1998).
Another important conclusion can be drawn from the experiment with reduced elacridar
dosage. In this case there was no increase in paclitaxel levels at all compared to the control
samples. Thus, a relatively high modulator dose is required to show marked elevated
paclitaxel levels in the brain. In case of valspodar a further increase in dosage is not
reasonable. In experiments done by Kemper et al. (2003) a single dose of 25 mg/kg was
found to be sufficient to achieve maximum inhibition of p-gp and other enzymes involved
in metabolic elimination of paclitaxel. In addition, higher valspodar doses did not lead to
enhanced paclitaxel levels, but could result in toxic side effects if valspodar plasma levels
were higher than 3.5 µM. In contrast, elacridar can be administered at high concentrations
up to 1 g orally without any toxic side effects to patients (Kruijtzer et al. 2002).
Paclitaxel was specifically accumulated in brain in case of elacridar and tariquidar co-
administration. The favorable brain/plasma concentration ratios indicate a preferential
modulation of p-gp at the BBB and lower systemic toxicity for the combination of pacli-
taxel with the new modulators. Several clinical studies in which paclitaxel was combined
with a presumed selective and potent p-gp modulator, have shown that dose reductions of
the cytostatic were not necessary (Boniface et al. 2002). The fact that no increase in the
paclitaxel levels in liver and kidney was measured after co-administration of elacridar and
tariquidar, confirmed the suitability of these substances for the combination treatment
with cytostatic drugs. By contrast, valspodar caused considerably elevated paclitaxel
concentrations in plasma due to substantial reduction of paclitaxel clearance (p-gp inhi-
bition in kidneys). The increased systemic exposure to paclitaxel led to enhanced toxic
effects such as bone marrow suppression and neurotoxicity. Hence, it can be concluded
that 3rd generation p-gp modulators are not more efficient in inhibiting p-gp in vivo, but
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these substances are much more suitable for a well tolerated combination chemotherapy
compared to 2nd generation modulators such as valspodar.
7.5 Summary and perspective
The combination of paclitaxel with the newly developed p-gp modulators elacridar or
tariquidar led to encouraging results. The compounds were able to increase the brain
paclitaxel levels. Thereby, the modulator concentrations in plasma remained lower than
1 nM. These concentrations were well tolerated in patients without any significant side
effects (Malingre et al. 2001). Furthermore, elacridar and tariquidar presumably do not
enhance the systemic side effects of co-administered cytostatic drugs. Hence, dose reduc-
tions of cytostatic drugs are unnecessary and it should be possible to achieve therapeutic
benefits in cancer chemotherapy.
The poor solubility of the two examined modulators has to be improved. Moreover,
as suggested by the experiments with reduced elacridar dosage the absorption and the
distribution into the different compartments has to be optimized. In particular, the
modulator accumulation in lipophilic compartments such as adipose tissue should be
avoided. Furthermore, it should be investigated whether adjustments of the dosage of
the p-gp modulators could help to increase the accumulation and retention of cytostatic
drugs in the brain. First experiences concerning this aspect were reported by Kemper
et al. (2003). They were able to achieve paclitaxel levels in the brain of wild type mice
close to paclitaxel concentrations found in p-gp knockout mice after co-administration of
elacridar in two doses of 50 mg/kg at 2 and 8 hours after paclitaxel application. Thus,
it is possible to increase cytostatic drugs levels in the brain by repeated dosage of p-
gp modulators. Even the order of modulator administration, e.g. before and/or after
cytostatic drug application, influences the modulator efficacy. Additional experiments
have to be carried out to find the ideal regimen for combination therapies.
Improvements of the aforementioned physicochemical and pharmacokinetic parameters
may contribute to the optimization of the treatment of brain tumors with combinations
of cytostatics and the new p-gp modulators. In conclusion, cancer chemotherapy in com-
bination with elacridar, tariquidar or other optimized p-gp inhibitors could lead to an
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antitumoral efficacy comparable to that described for valspodar by Fellner et al. (2002)
on brain tumors, but with less systemic toxicity.
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Chapter 8
The transferrin receptor - a possible
loophole at the blood-brain barrier
8.1 Introduction
Overcoming the blood-brain barrier (BBB) is a major challenge in the chemotherapy of
primary and secondary brain tumors. Research effort is devoted to the inhibition of drug
transporters and efflux pumps located at the BBB such as p-glycoprotein 170 or the mul-
tidrug resistance related proteins with variable success (Fellner et al. 2002, Kemper et al.
2004b). An alternative approach to selectively increase the brain concentration of cyto-
static drugs that normally do not accumulate within the brain, would be to take advantage
of a specific transport system present at the BBB. A multiplicity of receptor mediated
transport systems responsible for the delivery of peptides and proteins is located at the
BBB including receptors for insulin and transferrin (Friden 1993). The transferrin recep-
tor (TfR, CD71) was discovered in 1981 (Trowbridge and Omary 1981). It is expressed
in all nucleated cells in the body, but due to the high levels of oxidative metabolism in
neuronal cells and the resulting significant requirement of iron the receptor is present in
unusually high number on brain capillary endothelial cells (Jefferies et al. 1984). The
human TfR is a transmembrane glycoprotein composed of two disulfide-bonded subunits,
each of an apparent molecular mass of 95 kDa (Schneider et al. 1982, Trowbridge 1995).
TfR mediates the endocytosis of iron into cells with the help of transferrin as iron carrier
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(Li and Qian 2002). In addition, transcytosis of iron mediated by the transferrin/TfR sys-
tem was observed in vitro and in vivo by different work groups. In vitro, Descamps et al.
(1996) figured out by pulse-chase and double labelling experiments that in bovine brain
capillary endothelial cell cultures the majority of transferrin bound iron was transcytosed
to the abluminal side of the cells. Broadwell et al. (1996) and Bickel et al. (1994) used
electron microscopic techniques to show that horseradish peroxidase or colloidal gold con-
jugates of monoclonal antibodies (MAb) targeted to TfR cross the BBB in vivo. Possible
transendothelial pathways through the BBB are depicted in Fig. 8.1.
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Figure 8.1: Possible transendothelial pathways through the BBB followed by blood-borne
transferrin and MAbs directed to the TfR (adapted from Broadwell et al. (1996)).
After internalization of the receptor-ligand complex, the formed endocytic vesicle
fuses with an endosome, where iron or MAbs dissociate from the receptor. The
receptor is recycled to the cell surface. Free iron, apo-transferrin and MAbs are
transported to the abluminal membrane for exocytosis. MAbs can also be directed
with the receptor to the Golgi complex, where dissociation takes place. The re-
ceptor is recycled to the cell surface, whereas MAbs are packaged in a vesicle for
migration to the abluminal membrane where they are released by exocytosis.
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The first step of TfR-mediated transcytosis of iron across the BBB (Fig. 8.1) is the
binding of the transferrin-iron complex (ferro-transferrin) to TfR on the luminal surface of
the brain capillary endothelial cells (1). Subsequently, the occupied receptor internalizes
into an endocytic vesicle (2), that fuses with an endosome (3). Because of the acid pH
inside the endosome the iron dissociates from the transferrin/TfR complex (3). The ferric
ions and the iron free apo-transferrin are packaged into export vesicles for migration to the
abluminal membrane (4), where exocytosis (5) takes place (Broadwell et al. 1996, Friden
1996). The TfR is recycled to the cell surface (6,7). In non brain tissues the endothelium
is sufficiently leaky for passive diffusion of ferro-transferrin. Due to the preferential ex-
pression of TfR at the BBB compared to non brain tissues, the TfR mediated transport
can be used as a specific drug targeting system across the BBB to increase drug levels in
the brain (Friden 1993, Huwyler et al. 1996).
The use of covalently linked compounds to transferrin is limited by the high concen-
tration of transferrin in the blood that leads to competition for binding to the receptor
(Friden 1996). Therefore, MAbs directed to the TfR have been introduced into research.
Friden et al. (1996) have demonstrated the selective brain distribution of a MAb targeted
to the human and monkey TfR after intravenous injection in Cynomolgus monkeys. The
MAbs were found almost exclusively in brain parenchyma rather than in capillaries, in-
dicating transcytosis of the MAbs across the BBB. A second endothelial pathway for the
transcytosis of MAbs directed to TfR is described in literature (Fig. 8.1; Broadwell et al.
(1996)). If no dissociation of MAb from TfR takes place in the endosome, the residual
MAb/TfR complex is directed within a transfer vesicle (10) to the inner saccule of the
Golgi complex (11). The MAb is separated from the TfR by enzymes of the Golgi complex
and packaged in transporting vesicles arising from the inner Golgi saccule for exocytosis
to the abluminal membrane (9,12), while the free TfR is again inserted into the luminal
membrane (13,14). For in vitro and in vivo studies the MAb OX26 (Jefferies et al. 1984)
directed to the rat TfR is well established as a drug targeting vector. This antibody
has been shown to bind to an extracellular epitope of the receptor, different from the
transferrin binding site (Pardridge 1995). However, only 2 or 3 biotinylated drugs can be
attached to an OX26 conjugate indicating the low carrying capacity of the OX26 MAb
(Huwyler et al. 1996). An answer to this problem is the usage of drug incorporated li-
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posomes loaded with MAb (immunoliposomes), where more than 10,000 small molecules
may be entrapped in a single 100 nm liposome. The immunoliposomes should be steri-
cally stabilized by insertion of poly(ethylene glycol) (PEG) derivatized lipids within the
bilayer of conventional liposomes (Allen 1994). This stabilization leads to a substantial
improvement of blood circulation half life (several days in contrast to minutes for con-
ventional liposomes) in humans (Gabizon 2001). Furthermore, the PEG chains enhance
the antibody antigen binding as they act as linkers between antibody and liposome, and
thus, the antibody is not shielded by the steric barrier of PEG. Schnyder et al. (2004) have
investigated a new coupling procedure for the preparation of pegylated immunoliposomes,
that is useful for drug targeting to the brain (Fig. 8.2).
biotin
biotin
biotin
SA
SA
SA
Figure 8.2: Structure of an immunoliposome (adopted from Schnyder et al. (2004)).
Streptavidin(SA)-conjugated MAbs are coupled to biotinylated PEG liposomes.
A biotinylated PEG-phospholipid was used for a non-covalent attachment of streptavi-
din-conjugated OX26 MAb to sterically stabilized liposomes. The prepared immunolipo-
some has a particle size of 150 nm and contains approximately 5500 strands of 2000 Da
PEG and 30 strands of the biotinylated PEG lipid. Biotinylation had no influence on
the in vivo pharmacokinetics of the liposomes (Laverman et al. 2000). The use of strept-
avidin instead of avidin reduced the amount of non-specific binding and thus, the systemic
clearance in vivo. The lower isoelectric point of streptavidin (pI 5-6; Kang and Pardridge
(1994)) compared to avidin contributes to this effect. As streptavidin can be conjugated
to a great variety of MAbs, the presented immunoliposomes represent a delivery system
that is easily adapted to special drug targeting problems in vivo.
8.2 Materials and methods 177
The well known endocytosis mediated by TfR could be used for the targeting of cyto-
static drugs directly to brain tumor cells. Wen et al. (1995) reported that human brain
tumors preferentially express TfR rather than normal brain tissue. In treatment studies
of human brain tumors implanted in rats a second MAb targeted to the human TfR has
to be introduced into the immunoliposome delivery system to transport the incorporated
cytostatic drug straight to its target. Further studies demonstrated that therapy with
repeated administration of TfR specific MAbs did not result in a down regulation of TfR
in tumor cells (Wu and Pardridge 1998).
Therefore, by means of the presented immunoliposome delivery system the concentra-
tion of cytostatic drugs could be increased in the brain to sufficient levels for brain tumor
therapy. Furthermore, this system can be used to by-pass the efflux pump p-glycoprotein
170 (p- gp) and thus even deliver drugs to the brain, that normally cannot enter the brain
due to their high affinity to p-gp (Huwyler et al. 2002). In this chapter the establishment
of a tumor model is described that is suitable for the investigation of primary brain tumor
therapy with immunoliposome delivery systems that use the TfR mediated transport to
overcome the BBB.
8.2 Materials and methods
8.2.1 Cell cultivation
The human glioblastoma cell lines were purchased from the American Type Culture Col-
lection (ATCC, Rockville, MD, USA) and were maintained as "monolayer cultures" in
75 cm2 flasks (Nunc, Wiesbaden, Germany). The cells were cultured at 37 ℃/5 % CO2 in
different culture media. U-87 MG and U-373 MG cells were cultivated in Eagle’s minimum
essential medium (EMEM, Sigma, München, Germany), supplemented with 110 mg/l
sodium pyruvate, 3.7 g/l sodium hydrogen carbonate and 5 % FCS. For U-118 MG cells,
Dulbecco’s modified eagle medium (DMEM, Sigma) was used, containing 110 mg/l sodium
pyruvate, 2.2 g/l sodium hydrogen carbonate and 5 % FCS. All culture media were ad-
justed to pH 7.4. Subculturing was carried out with 0.2 % trypsin/EDTA (Viralex, Paa
Laboratories) in PBS once a week. The human B-cell line RAJI was kindly provided by
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the work group of R. Knüchel (Institute of Pathology, University of Regensburg). These
cells were maintained as suspension culture in RPMI 1640 culture medium (Sigma) sup-
plemented with 1.5 g/l sodium hydrogen carbonate and 10 % FCS, and subcultured once
a week.
8.2.2 Transferrin receptor determination by flow cytometry
The in vitro determination of the transferrin receptor (CD71) was performed according to
Krieg et al. (2000) and Brockhoff et al. (1994) with modifications. Cells were harvested
and washed with PBS. Subsequently, the cells were adjusted to 1·106 cells per 1 ml
with PBS, and the samples were centrifugated again at 1100 rpm for 5 min at room
temperature. Three different kinds of samples were prepared for the determination of
autofluorescence, total staining and unspecific binding of the antibody (negative control).
Each sample, except the one for the determination of the autofluorescence, was prepared
in triplicate. The cell pellets (autofluorescence and negative control) were resuspended
in 50 µl of PBS. The primary mouse anti-human CD71 antibody (M 0734, clone Ber-T9,
DAKO, Hamburg, Germany) was used in a dilution of 1:50 (50 µl) to label cell pellets for
the total staining. All samples were incubated for 1 h at room temperature. Afterwards,
the cells were washed twice with PBS. 50 µl of PBS were given to the autofluorescence
sample. All residual cell pellets were resuspended in 50 µl of fluorescein isothiocyanate
(FITC)-coupled rabbit anti-mouse antibody (F 0261, DAKO, Hamburg, Germany). The
secondary antibody was diluted 1:20 with PBS. After an incubation period of 1 h at room
temperature in the dark, the samples were washed once with PBS, resuspended in 250 to
400 µl of PBS and placed on ice in the dark until analysis. The FITC fluorescence was
detected after excitation at 488 nm in the FL1-H (530 ± 30 nm) band pass filter using a
FACS Calibur™ (Becton Dickinson, Heidelberg, Germany). The photomultiplier settings
were as follows: E-1 for FSC, 200 for SSC and 450 for FL1-H. A threshold of 450 was set up
for FL1-H. The samples were gated on forward scatter versus sideward scatter to exclude
clumps and debris and a minimum of 10,000 gated events was collected per sample. FL1-H
histograms were analyzed by the WinMDI 2.8 software. Mean fluorescence intensity
of negative control cells was subtracted from the fluorescence intensities of anti-CD71
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labelled cells. Membrane expression of CD71 was quantified in molecules of equivalent
soluble fluorescence (MESF) using Quantum™ 26 beads (Bangs Laboratories, Fishers, IN,
USA). As FITC fluorescence intensity is strongly dependent on pH values, all samples as
well as the microbead populations were prepared in PBS adjusted to pH 7.2. RAJI cells
served as a positive control of transferrin receptor expression (Trowbridge 1995).
8.2.3 Immunohistochemistry
Frozen sections were used to detect transferrin receptors in tumor tissue and nude mouse
brain. Subcutaneously grown glioblastomas were excised when the tumor growth reached
an area of about 150 mm2 in nude mice (see chapter 3). The tumor tissue was embedded
in frozen tissue matrix (Tissue-Tek® O.C.T.™ Compound, Sakura Finetek, Giessen, Ger-
many) to ensure freezing without trapped air and stored in liquid nitrogen. The sections
were cut on a freezing microtome (FrigocutE 2800, Reichert-Jung, Nussloch-Heidelberg,
Germany) with a thickness of 5 to 8 µm, and two sections each were mounted on Super-
frost Plus (Fisher Scientific, Pittsburgh, PA) glass slides. The sections were immersed
immediately in acetone for 15 min to fix the sections on the slides. After fixation, the
slides were rinsed for 5 min with phosphate-buffered saline (PBS), pH 7.4, and subjected
to immunostaining.
Endogenous peroxidase was blocked by incubation in PBS containing 3 % H2O2 and
10 % methanol for 30 min, followed by two incubations in PBS with 0.04 % Triton-X-100
(PBST) for 5 min. Nonspecific binding was prevented by incubation for 30 min in 10 %
natural donkey serum (NDS, Sigma, München, Germany), 2.5 % skimmed milk powder
(Milupa, Friedrichsdorf, Germany), and 0.3 % Triton-X-100 in PBS. Subsequently, cells
were washed three times with PBST. Primary mouse anti-human CD71 antibody (M 0734,
clone Ber-T9, anti-human CD71, DAKO, Hamburg, Germany) was diluted 1:5 with wash-
ing buffer consisting of 10 ml of milk powder solution (2.5 % skimmed milk powder in
PBST), 100 µl 1 % NDS, and 0.3 % Triton-X-100. After incubation with the primary
antibody for 48 h at 4 ℃, the slides were washed three times with PBST and treated
with biotinylated donkey anti-mouse antibody as secondary antibody (1:100, Dianova,
Hamburg, Germany) for 2 hours at room temperature. All incubations with antibody
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were performed in humid chambers. Afterwards, slides were washed three times in PBST
and incubated for 1 hour with horseradish-conjugated avidin-biotin complex (Vectastain
Elite Kit ABC, Vectorlabs, Burlingame, United Kingdom) in PBST. Slides were washed
for 5 min in PBST before incubation in a diaminobenzidine (DAB) solution for 10 min
(0.05 % DAB, 0.02 % ammonium nickel sulfate in PBST). H2O2 (10 %) was added to a
final concentration of 0.006 %, and slides were incubated for 1.5 min. Afterwards, they
were washed three times in PBS and counterstained with Harris’ haematoxylin. Then
the slides were placed in PBS and demineralized water, processed in an ascending alcohol
series and mounted in DePex. All stained sections were evaluated with a BH2 microscope
(Olympus, Hamburg, Germany) mounted with a CCD-camera for digital imaging.
8.2.4 Chemosensitivity assay
The chemosensitivity assay was performed according to the procedure described by Bern-
hardt et al. (1992). Details are given in chapter 3.2.6.
8.2.5 In vivo experiments
Rowett(rnu/rnu) nude rats and NMRI(nu/nu) mice obtained from the nude mice labo-
ratory of the department were used for the in vivo growth studies. The animals were
allowed to take water and food, a combined breed and maintenance nutrition (Altromin),
ad libitum. The water was supplemented with 1.33 g/l of potassium sorbate, 2 g/l of
chloramphenicol and 1 g/l of hydrochloric acid yielding a pH value of 2.5. The animals
were housed under specified pathogen free conditions at a 12 h light/dark cycle at a tem-
perature of 25 ℃ and a relative humidity of 70 %. At an age of 6 weeks the rats were
used for studies.
The subcutaneous tumor model is discussed in chapter 3.
The intracerebral model has been described by Altenschöpfer (1998). In brief: the
parietal bone of anaesthetized nude rats was drilled with a 1-mm-diameter bit 3 mm to
the right-hand side of the sagittal line and 3 mm rostral of the coronal line. The rats
were anesthesized with sevoflurane (Abbott, Wiesbaden, Germany). Human glioblastoma
cells (3·105 cells) suspended in 5 µl of serum-free EMEM were injected 5 mm deep into
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the brain tissue, and the wound was closed with a surgical clamp. The body weight was
observed to assess the tumor burden and the rats were killed when 20 % weight reduction
occurred.
For histological staining of the tumor bearing brains, the nude rat brains were removed
and fixed for at least three days in Bouin’s solution. The tissues were embedded in
paraffin by a standard procedure in a Histokinette (Shandon, Frankfurt/Main, Germany),
cut by a Microtome Leitz 1516 (Leitz, Wetzlar, Germany) in sections with a thickness
of 6 µm and put on object slides prepared with poly-L-lysin. Prior to each staining
procedure, the sections were deparaffinized with xylol and various ethanol solutions with
descending concentrations. The sections were stained according to the Masson-Goldner
(MG) procedure which is described in detail in chapter 3.2.3. All stained sections were
evaluated with a BH2 microscope (Olympus, Hamburg, Germany) mounted with a CCD-
camera for digital imaging.
8.3 Results and discussion
The aim of the study was the examination of several human brain tumor cell lines with re-
spect to their suitability for a targeted treatment with an immunoliposome based delivery
system. The selected cell lines have to fullfill to the following requirements. The tumor
cells should express sufficient quantities of TfR to target the immunoliposomes directly to
the tumor cells after they have crossed the BBB. This was investigated in vitro and the
TfR expression was confirmed in vivo in tumors growing subcutaneously in nude mice.
As a second prerequisite, the cells have to be chemosensitive to low concentrations of
the cytostatic drug that is incorporated in the immunoliposome. In addition, the tumor
cells have to be tumorigenic in the brains of nude rats. These animals were used for the
experiments, because of the possibility to overcome the BBB by means of transcytosis
mediated by the OX-26 antibody which is targeted to the rat TfR.
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8.3.1 Transferrin receptor content in tumor cells
8.3.1.1 TfR content of various tumor cell lines
The TfR content of several tumor cell lines that include brain and lung cancers was deter-
mined in vitro by an indirect immunofluorescence detection procedure at a flow cytome-
ter. The FITC fluorescence intensity was quantified in molecules of equivalent solubility
(MESF) by means of four fluorescent standard microbead populations of approximately
7 to 9 µ in diameter. The beads matched both the excitation and emission spectra of
FITC labelled antibodies. Each microbead population had a different level of fluores-
cence intensity that referred to a certain MESF value. This means that microbeads with
a MESF value of 10,000 exhibit the same fluorescence intensity as a solution containing
10,000 FITC molecules. A calibration curve was obtained by plotting the fluorescence
intensities (relative channel number) of the single bead populations against the corre-
sponding MESF values of the 4 populations. The single bead populations were recorded
at the same settings as the analyzed samples (Fig. 8.3). Using this calibration curve, the
MESF value of every sample was determined and measurements performed on different
days could be compared with each other.
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Figure 8.3: (a) fluorescence intensity at FL1-H channel of a mixture consisting of 4 microbead
populations. (b) calibration curve of MESF calculated from microbead fluorescence
intensities. RCN (relative channel number) is equivalent to FL1-H channel number.
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The secondary antibody used for the indirect determination of TfR was labelled with
FITC. Since the ratio of fluorescent dye and antibody ranges between 1 and 3, the fluo-
rescence intensity of the different tumor cells can not be transformed directly in antibody
binding capacity values or TfR densities. Direct quantification of receptor densities with
fluorescent antibodies is only possible at fluorescent dye/antibody ratios of 1 as in case of
phycoerythrin (PE) labelling. In consideration of the FITC/antibody ratio only a range
for the TfR density of the different cell lines could be estimated. The TfR density ranges
of selected glioblastoma and lung cancer cell lines are summarized in table 8.1. The TfR
densities of the lung cancer cell lines were determined as these tumor entities metastasize
preferentially to the brain. The human B-cell line RAJI served as a positive control for
TfR expression.
Table 8.1: MESF values of different cell lines and their corresponding TfR density. Measure-
ments were taken on day 5 after last passage (n= 3-6).
transferrin receptor
cell line MESF [·103] density [·103]
min. max.
U-87 MG 347.91 ± 51.96 139 - 348
U-118 MG 714.07 ± 224.46 286 - 714
U-373 MG 540.36 ± 26.83 216 - 540
RAJI 158.50 ± 3.37 64 - 159
NCI-H460 266.06 ± 3.05 106 - 266
DMS 53 61.82 ± 1.21 25 - 62
DMS 114 75.86 ± 1.42 30 - 76
The highest TfR densities were detected on U-87 MG, U-118 MG and U-373 MG glioma
cells with levels 2 to 4 times higher compared to those of the RAJI control cells. The
examined lung cancer cell lines exhibited lower TfR densities than the brain tumor cells,
particularly the small cell lung cancer cells DMS 53 and DMS 114. In these cell lines
TfR densities under 100,000 were determined. In contrast, in NCI-H460 non-small cell
lung cancer cells TfR is expressed at a level similar to that in U-87 MG cells. The TfR
184 The transferrin receptor - a possible loophole at the blood-brain-barrier
density in the U-118 MG cells was the highest among the analyzed cell lines. However, the
expression of TfR seemed to be unequal, since the standard deviation of the calculated
MESF value was extremely high. Lower standard deviation combined with high TfR
density was found in U-373 MG cells. Therefore, the U-373 MG cell line is the most
suitable one among the examined brain tumor cell lines, for a TfR targeted treatment
regarding the TfR density in vitro.
8.3.1.2 Growth depended TfR expression
The TfR is essential for cell growth as it mediates the transport of iron into the cell, which
is necessary for metabolic processes. Several work groups identified a close relationship
between TfR expression and cell proliferation (Trowbridge et al. 1984, Gambari et al. 1986,
Chan et al. 1994). Therefore, we investigated the TfR content of various glioblastoma
cell lines in different proliferation stages by indirect immunofluorescence detection using
FITC labelled antibodies. RAJI cells are described as TfR expressing cells in literature
(Laskey et al. 1988) and were used as a positive control. The human glioblastoma cell
lines U-87 MG, U-118 MG and U-373 MG were examined 3, 5 and 7 days after passaging
to simulate subconfluent and postconfluent growth. The measured fluorescence intensities
of the single cell lines plotted against the growth time are depicted in Fig. 8.4.
In all cell lines a FITC fluorescence intensity that correlates with TfR expression was
detected at all time points. For the control cell line RAJI (black bars) the highest flu-
orescence intensities were measured after 3 days. Subsequently, the intensity strongly
decreased to values 7 times lower than those measured after 3 days in culture. This indi-
cated that the growth of the RAJI cells is almost complete after 3 days. Thus, there is
no need for further TfR expression. In case of the U-87 MG cells (right-hatched bars) the
determined fluorescence intensity reached maximum values on day 3 as well. Indeed, the
intensities measured on the other two days slowly declined compared to day 3, but the
decrease was not as distinct as observed in the RAJI cells. In contrast, the fluorescence in-
tensity of U-118 MG cells (cross-hatched bars) increased up to day 5. After 2 further days
of incubation only half of the fluorescence intensity was measured compared to day 5. The
fluorescence intensity of U-373 MG cells (left-hatched bars) remained relatively constant
over the examination period in consideration of the SEM values. The detected intensity
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Figure 8.4: Growth dependent TfR expression in different glioblastoma cell lines U-87 MG
(right-hatched bars), U-118 MG (cross-hatched bars) and U-373 MG (left-hatched
bars). RAJI cell line (black bars) serves as control for measurable TfR expression.
(mean values ± SEM)
values were similar to those measured in U-87 MG cells, but U-373 MG cells showed no
decrease in fluorescence intensity. This indicated a relatively constant cell growth in vitro.
In view of the suitability for the mentioned tumor model, the brain tumor cell line should
have a constant TfR expression over a longer period of time. This requirement is best
fulfilled by the U-373 MG cells as they showed the most constant TfR expression.
8.3.2 Transferrin receptor expression in tumor tissue
To ensure the relevance of the in vitro data to the in vivo situation, the TfR expression was
also analyzed in tumors growing subcutaneously in athymic mice. Immunohistochemical
methods were used to detect TfR in solid U-87 MG, U-118 MG and U-373 MG tumors.
The sections were counterstained with Harris’ haematoxylin to stain nuclei blue for a
better contrast to the light brown staining of the TfR. TfR as a transmembrane cell
surface receptor is located at the cell membrane. The main part of the receptor is present
at the extracellular site and only a small region is found at the cytoplasmic site of the cell
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5µm
Figure 8.5: Section of subcutaneously grown U-87 MG glioblastoma immunostained with
mouse MAb to the human TfR shows positive TfR staining at the cell membrane
(clone Ber-T9 (1:5), avidine-biotin-peroxidase staining on frozen sections, hema-
toxylin counterstaining.)
5 µm
Figure 8.6: Tumor tissue section of subcutaneously grown U-118 MG glioblastoma demon-
strates positive TfR staining at the cell membrane with mouse MAb to the hu-
man TfR (clone Ber-T9 (1:5), avidine-biotin-peroxidase staining on frozen sections,
hematoxylin counterstaining.)
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Figure 8.7: Frozen section of subcutaneously grown U-373 MG tumor. Despite the poor qual-
ity of the frozen section, positive TfR staining is detectable at the membrane of
the tumor cells (clone Ber-T9 (1:5), avidine-biotin-peroxidase staining on frozen
sections, hematoxylin counterstaining.)
membrane. The described TfR localization was found in all immunostained sections of
the three tumor types (Figs. 8.5 to 8.7). The tumor cells demonstrated a specific positive
staining of the cell membrane, but not of the cytoplasm. This is clearly visible in sections
of U-87 MG and U-118 MG tumors (Fig. 8.5 and Fig. 8.6). Many blue stained nuclei were
visible that were enclosed by the light brown stained cell membrane. Occasionally sections
of cells without visible nuclei were observed that were intensely stained at the membrane
rather than at the cytoplasm indicating the specific staining of TfR which is a transmem-
brane protein. In immunostained sections of U-373 MG tumors the TfR staining was
difficult to determine because of the poor quality of the frozen tumor sections. However,
the tumor section depicted in Fig. 8.7 presents the aforementioned characteristics for a
positive TfR staining.
The immunohistochemical staining was very weak and not sensitive enough to stain
internalized TfR inside the cells. Furthermore, differences in TfR expression level as
determined by flow cytometry were not detected between the single cell lines. Hence, this
method could only be used to visualize of TfR expression and not for the quantitative
distribution of the receptor.
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8.3.3 In vitro chemosensitivity against anthracyclins
Immunoliposomes that are targeted to brain tumors can include a cytostatic drug concen-
tration of 0.2 to 0.5 µM (Huwyler et al. 2002). Hence, for an effective treatment of brain
tumors, the cancer cells have to be sensitive to the incorporated cytostatic drug at least at
these concentrations. Cytostatic agents like the anthracyclins doxorubicin and daunoru-
bicin (see Fig. 8.8) are well suited for the incorporation into immunoliposomes. However,
since both substances are substrates of the p-gp, these compounds cannot reach the brain
and consequently, the brain tumors. Masking of such compounds by incorporation in
immunoliposomes leads to an enhanced accumulation in the brain, which is a prerequi-
site for a successful chemotherapy. The three selected glioblastoma cell lines U-87 MG,
U-118 MG and U-373 MG were examined with respect to their chemosensitivity against
various concentrations of doxorubicin and daunorubicin ranging from 0.1 to 1 µM. For
this purpose the tumor cells were exposed to the cytostatic drugs over a period of 150
hours and the cell proliferation was determined. The results shown in Figs. 8.9 to 8.11
demonstrated a marked effect of the selected cytostatic drugs on the cell proliferation of
the glioblastoma cells.
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Figure 8.8: Structures of the anthracyclins doxorubicin and daunorubicin. Both chemothera-
peutics are easily incorporated in immunoliposomes at concentrations from 0.2 to
0.5 µM.
Long term incubation with doxorubicin and daunorubicin had similar effects on the
growth of the three tumor cell lines at all experimental concentrations. Doxorubicin was
slightly more potent compared to daunorubicin except for U-118 MG cells. Addition of
only 200 nM doxorubicin led to complete decay of U-87 MG cells (Fig. 8.9 a). In case
of daunorubicin a concentration of 300 nM was needed to produce the same effect (Fig.
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8.9 b). Lower concentrations of both compounds resulted in cell growth inhibition of
at least 80 %. To reach complete disintegration of U-118 MG cells, significantly higher
concentrations were required (Fig. 8.10). Here, a doxorubicin concentration of 1 µM was
necessary for a cytocidal effect (50 % of the cells were killed after 150 hours). Daunorubicin
was more effective in inhibiting the proliferation of U-118 MG cells as the addition of
300 nM daunorubicin led to killing of the tumor cell population. If the cytostatic agents
were used at lower concentrations, a cytostatic effect on the cell growth was observed.
However, doxorubicin added at a concentration of 100 nM inhibited the growth of U-118
MG cells only by 40 %, which was the weakest effect measured in this study. The U-118
MG cell line was the only cell line of the selected ones, where daunorubicin was more
active than doxorubicin. The most sensitive glioblastoma cell line was the U-373 MG cell
line (Fig. 8.11). Cytocidal effects were observed after incubation with 100 nM doxorubicin
and 200 nM daunorubicin. But even 100 nM daunorubicin had a cytostatic effect on the
cells and inhibited the cell proliferation by 95 %.
Figure 8.9: Chemosensitivity of U-87 MG cells against the anthracyclins doxorubicin (a) and
daunorubicin (b) at concentrations of 100 nM (◦), 200 nM (2), 300 nM (4), 500 nM
(5) and 1 µM (3). Proliferation of untreated cells served as control (•).
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Figure 8.10: Chemosensitivity of U-118 MG cells against the anthracyclins doxorubicin (a)
and daunorubicin (b) at concentrations of 100 nM (◦), 200 nM (2), 300 nM (4),
500 nM (5) and 1 µM (3). Proliferation of untreated cells served as control (•).
Figure 8.11: Chemosensitivity of U-373 MG cells against the anthracyclins doxorubicin (a)
and daunorubicin (b) at concentrations of 100 nM (◦), 200 nM (2), 300 nM (4),
500 nM (5) and 1 µM (3). Proliferation of untreated cells served as control (•).
8.3 Results and discussion 191
When considering the loading capacity of the immunoliposomes, a tumor cell line used
for the tumor model has to be chemosensitive to a cytostatic drug concentration of at
least 200 nM. U-118 MG cells were indeed chemosensitive against the two chemother-
apeutics. However, it is debatable, if the observed growth inhibition of 40 % in case
of doxorubicin and 60 % for daunorubicin, is sufficient to provide a therapeutic benefit.
U-87 MG cells were more sensitive compared to U-118 MG cells, particularly regarding
their chemosensitivity against doxorubicin. Here a cytocidal effect was demonstrated at
200 nM doxorubicin. In contrast, incubation of U-373 MG cells with the same drug con-
centration led to complete cell disintegration in both cases. Provided that the U-373 MG
glioblastoma has the same chemosensitivity in vitro and in vivo, this cell line is preferred
for the therapy with anthracyclins loaded immunoliposomes.
8.3.4 Growth of human glioblastomas in the nude rat brain
It is indispensable that brain tumor cell lines are tumorigenic in the laboratory animal in
order to study the effect of a brain targeted immunoliposome based chemotherapy in vivo.
Another criterion to assess the suitability of a tumor cell line for the use in an animal model
is the tumor burden, which results from the intracerebral tumor growth. The OX-26 is a
MAb directed to the rat TfR and it was chosen as a vector for targeting immunoliposomes
to the brain. Thus, the planned animal tumor model has to be established in nude rats.
The three brain tumor cell lines U-87 MG, U-118 MG and U-373 MG were injected into the
brains of three nude rats per cell line. The tumor appearance and growth were examined
after 4 to 5 weeks by histological staining techniques. Additionally, the body weight of
the animals was monitored during the experiment to evaluate the tumor burden.
Fig. 8.12 and Fig. 8.13 illustrate histological sections of an intracerebrally grown U-87
MG tumor. The big, cell-rich tumor is well confined from the normal brain tissue. Many
blood vessels, that are not infiltrated by the tumor cells, are observed in the tumor tissue.
Besides tumor areas with high content of connective tissue, necrotic areas are also detected
within the tumor tissue. The tumor consists of inhomogeneous formed cells with mostly
one round to oval nucleus and several pleomorphic nucleoli. Mitotic activity is visible as
well.
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Figure 8.12: MG-stained section of intracerebrally grown U-87 MG glioblastoma in the nude
rat. The well-confined tumor is of enormous size and has necrotic areas (indicated
by arrow 1). Blood vessels are observed as well (indicated by arrow 2).
10µm
Figure 8.13: MG-stained section of intracerebrally grown U-87 MG glioblastoma in the nude
rat. The inhomogeneous formed tumor cells have round to oval nuclei with irreg-
ular formed nucleoli. Mitotic activity is observed (indicated by arrows).
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The appearance of the intracerebrally grown U-118 MG tumor (Fig. 8.14 and Fig.
8.15) is quite different to that of the U-87 MG tumor. U-118 MG tumors are significantly
smaller and the cell density is lower. The high amount of connective tissue indicated
by the intensive green color, is an important characteristic of this tumor. The tumor
cells with indistinct cytoplasm infiltrate the normal brain tissue. The fusiform cells have
readily identifiable oval nuclei with several prominent nucleoli.
In Fig. 8.16 and Fig. 8.17 histological U-373 MG tumor sections of the injection area in
the brain are presented. The tumor is spread along the puncture channel, but only slight
infiltration of the normal brain tissue is observed. The homogenous tumor consists of
fusiform cells with oval nuclei, which are of different size and have mostly one prominent
nucleolus. The cell density is comparable to that of the U-87 MG tumor.
50µm
Figure 8.14: MG-stained section of intracerebrally grown U-118 MG glioblastoma in the nude
rat. The tumor is characteristically green stained, because of the high content of
connective tissue.
194 The transferrin receptor - a possible loophole at the blood-brain-barrier
20µm
Figure 8.15: MG-stained section of intracerebrally grown U-118 MG glioblastoma in the nude
rat. The fusiform cells with indistinct cytoplasm have readily identifiable oval
nuclei with several prominent nucleoli. The high content of connective tissue and
necrotic areas are marked by arrows.
100µm
Figure 8.16: MG-stained section of intracerebrally grown U-373 MG glioblastoma in the nude
rat. The cell rich tumor slightly infiltrates normal brain tissue (indicated by
arrows).
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20µm
Figure 8.17: MG-stained section of intracerebrally grown U-87 MG glioblastoma in the nude
rat. The tumor cells appear homogenous and fusiform with different sized nuclei.
Infiltration of normal brain tissue is indicated by arrow.
All controlled rats developed brain tumors, which led to a loss of body weight of up to
20 % within 3 to 4 weeks after tumor cell injection. The changes of body weight depicted
in Fig. 8.18, indicate that the developed tumors are tolerated by the rats. Negative values
reflect an increasing tumor burden in the rat brain.
Rats bearing U-373 MG tumors were the only ones that put on weight during the first 3
weeks. However, a clear decrease in body weight was observed 4 weeks after the injection
of U-373 MG cell into the brain. At this time rats bearing U-87 MG or U-118 MG tumors
appeared lethargic and lost so much strength, that the experiment had to be stopped.
The intracerebrally growing tumors should enfeeble the experimental animals only
to such an extent that they can withstand subsequent chemotherapy. Therefore, no
detraction of the animals should be observable over a longer period. This is true in
case of U-373 MG glioblastoma, as the development of the brain tumor had no influence
on growth, behavior and general condition of the rats in the first 3 to 4 weeks of the
experiment.
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Figure 8.18: Change of mean body weight as an indicator for tumor aggressiveness. Negative
values reflect an increasing tumor burden in the rat brain.
8.3.5 Discussion
The three human glioblastoma cell lines U-87 MG, U-118 MG and U-373 MG were exam-
ined with respect to the following characteristics. The TfR density and the TfR expression
in various stages of growth were determined in vitro as well as the TfR expression in sub-
cutaneously grown tumors. Furthermore, the chemosensitivity of the cell lines against the
anthracyclins doxorubicin and daunorubicin was investigated. In addition, the tumori-
genicity of the human brain tumors in the nude rat brain was studied. These examinations
indicate, which of the tested cell lines is most suitable for a brain tumor model in nude rats.
By means of that model, treatment experiments with brain targeted immunoliposomes
should be carried out.
The TfR density of the U-118 MG cells was very high, and TfR was detected in
subcutaneously grown tumor tissue as well. However, the TfR expression in this cell line
did not remain constant during cultivation. Furthermore, the anthracyclins doxorubicin
and daunorubicin used at a concentration of 200 nM, led to an inhibition of the proli-
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feration by only 60 and 80 %, respectively. However, this anticancer drug concentration is
required as immunoliposomes can be loaded with a cytostatic drug concentration from 200
to 500 nM. U-118 MG cells were tumorigenic in the brain of nude rats, but the resulting
tumor enfeebled the rats. It is debatable, if rats bearing U-118 MG tumors will sustain the
additional burden of chemotherapy. As the body weight of tumor bearing rats significantly
decreased, the distinction between weight reduction as a result of tumor aggressiveness
or because of the toxicity of administered cytostatic drugs will be impossible. Thus, the
U-118 MG cells are unsuited as a brain tumor model.
The U-87 MG cell line was used in former studies to demonstrate imaging of intra-
cerebrally grown U-87 MG tumors in rat brains with a conjugate of peptide radiophar-
maceuticals and the OX-26 MAb targeted to the TfR (Kurihara and Pardridge 1999).
In the present study the suitability of this tumor for treatment experiments in rats was
studied. The determined TfR density was half that of U-118 MG cells. In contrast, the
TfR expression did not change significantly during cultivation. U-87 MG cells have a
TfR density twice as high compared to RAJI cells, which served as a positive control for
TfR expression. Hence, the lower TfR expression of U-87 MG cells compared to U-118
MG cells should be sufficient for the targeted therapy. In addition, TfR was discovered
in subcutaneously grown tumor tissue. Moreover, the U-87 MG cell line was sufficiently
sensitive against the selected cytostatic drugs. Doxorubicin is preferred over daunorubicin
because of the complete disintegration of the cells by incubation with 200 nM doxoru-
bicin. Assuming that chemosensitivity of the cells is similar in vitro and in vivo, U-87
MG tumors might be successfully treated with doxorubicin loaded immunoliposomes. Un-
fortunately, U-87 MG cells injected into nude rat brain developed very large tumors of
about half the size of the rat’s brain. Tumors of this size are not treatable any more. The
enormous extensions of these tumors led to a marked reduction of body weight of U-87
MG tumor bearing rats by 20 %. It becomes obvious from these results, that the U-87
MG glioblastoma is unsuited for the establishment of a brain tumor model.
The last examined human brain cancer cell line was the U-373 MG cell line. The
determined TfR density was similar to that in U-118 MG cells, but changes in TfR
expression in U-373 MG cells during cultivation were not as distinct as in U-118 MG
cells. The evidence of TfR in vivo was hampered by the poor quality of the tumor
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tissue section. However, slight positive staining of TfR was detected. The U-373 MG
cell line was most sensitive against doxorubicin and daunorubicin. The incubation of
U-373 MG cells with cytostatic drugs at a concentration of 200 nM led to a complete
disintegration of the cell culture in both cases. Cell death of the whole population is
desired in in vivo therapy experiments. Furthermore, the U-373 cells are tumorigenic in
the nude rat brain and developed solid tumors of a tolerable size. Up to 3 weeks after the
tumor cell injection the body weight was not affected. These results demonstrate, that
a nude rat brain tumor model could be established using the U-373 MG cells to study
the effect of an immunoliposome based, brain targeted chemotherapy on brain tumors.
The suitability of the U-373 MG cell line was proven by the work group of Martell et al.
(1993). Martell et al. demonstrated, that U-373 MG cells were extremely sensitive to
TfR targeted immunotoxins, indicating an successful drug targeting to these tumor cells
by using TfR as a vector. Therefore, U-373 MG has most promising prerequisites for a
successful therapy with the TfR targeted immunoliposomes.
8.4 Perspectives
As described in this chapter the human brain tumor cell line U-373 MG proved to be
suitable for the establishment of a tumor model in the nude rat brain. The therapeutic
effects of a brain targeted immunoliposome based drug delivery system can be evaluated
by using this model. Further investigations have to focus on the toxicity of unloaded
immunoliposomes at the U-373 MG cell line as well as on the chemosensitivity of U-373
MG cells against incorporated anthracyclins. Afterwards, in vivo experiments in nude rats
must show, if drug delivery systems targeted to the TfR at both the BBB and the brain
tumor, can improve the treatment of brain tumors and lower the negative side effects of
chemotherapy.
Because of the possibility to easily exchange the coupled MAb of the immunoliposomes
the presented drug delivery system can be targeted to other specific transport systems
that are located in certain organs or are highly expressed in tumor cells like insulin or
EGFP receptors (Friden 1996, Zhang et al. 2004).
The principle of the TfR mediated transcytosis which is the basis of the introduced drug
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delivery system is used by other work groups to increase the concentration of different
compounds in tumor cells or in the brain. In vitro studies were carried out to improve the
cellular delivery of antisense oligonucleotides to U-87 MG cells (Walker et al. 1995). Zhu
et al. (2004) demonstrated the TfR mediated transcytosis of adenoviral vectors in Caco-2
cells. Such vectors could be used in lung, urogenital and brain disorders. In vivo studies of
noninvasive gene targeting to the brain mediated by TfR at the BBB in rodents were also
reported (Shi and Pardridge 2000). Bickel et al. (2001) reviewed the possibility of delivery
of neuropeptides and proteins to the brain with the use of a chimeric peptide strategy.
Pharmacological effects were observed in the brain after the systemic administration of
relatively low doses of chimeric neuropeptide.
Therefore, the TfR as a drug delivery vehicle using the naturally occurring TfR me-
diated transcytosis pathway is a promising model for the targeted delivery to so-called
"sanctuary sites" in the human body such as the brain. Furthermore, the use of TfR
targeted compounds or immunoliposomes may lead to a better tolerated cancer therapy
with less negative side effects.
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Chapter 9
Summary
The treatment of malignant brain tumors is a major challenge for modern oncology. Only
minor success has been achieved by the application of current treatments including surgery
and radiotherapy. By means of chemotherapy, in contrast to surgery, the whole brain is
treated theoretically, but the brain concentrations of chemotherapeutic agents are usually
very low due to the existence of the blood-brain barrier (BBB). At the BBB special efflux
transport proteins, members of the ABC family, are present, which are transporting a
broad variety of compounds including most of the lipophilic cytostatic drugs such as
paclitaxel. The most common ABC transporter at the BBB is the p-glycoprotein 170
(p-gp, MDR1). Inhibitors, which block the ABC transporter mediated efflux, should
increase the concentrations of chemotherapeutic agents in the brain.
This work is based on the results of previous studies done by P. Altenschöpfer and
S. Fellner, who established a nude mouse model to study the treatment of human pri-
mary brain tumors (Altenschöpfer 1998) and demonstrated a therapeutic benefit by com-
bining the cytostatic agent paclitaxel with the p-gp inhibitor valspodar against U-118
MG glioblastoma (Fellner 2001). The main goal of this thesis was the adaptation of the
combination strategy to the therapy of brain metastases of lung cancer, occurring at a
much higher incidence than malignant primary brain tumors. To refine the combinatorial
approach, the new p-gp modulators elacridar and tariquidar were included in the studies.
First, three human lung cancer cell lines were characterized with respect to in vitro
growth, chromosome distribution, chemosensitivity against clinically established cyto-
static drugs, being p-gp substrates. Then, tumorigenicity was determined after subcuta-
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neous injection of the human lung cancer cells into nude mice. The NCI-H460 non-small
cell lung cancer cells and the DMS 114 small cell lung cancer cells proved to be parti-
cularly suited for the establishment of a subcutaneous tumor model. NCI-H460 cells are
very aggressive becoming obvious by the abundant abnormal mitotic figures. These cells
grow very rapidly (minimal doubling time: 9 hours) in vitro. In contrast, DMS 114 cells
grew markedly slower (minimal doubling time: 28 hours), but were more sensitive to
chemotherapeutic agents compared to the NCI-H460 cells.
Additionally, a flow cytometric assay for the assessment of p-gp activity in living cells
and for the determination of the inhibitory activity of p-gp modulators was established,
using the p-gp substrate calcein-AM.
Subsequently, the selected human lung cancer cells (NCI-H460 and DMS 114) were
examined with regard to the establishment of an intracerebral tumor model in nude mice
to simulate brain metastases. The presence of a MDR1 phenotype was also investigated.
Both, the NCI-H460 and the DMS 114 cells, were tumorigenic in the brains of nude mice.
Tumorigenicity of the DMS 114 cells strongly depended on the number of injected cells.
Moreover, no functional MDR1 protein was detected, despite the identification of mRNA,
encoding for p-gp in NCI-H460 cells. Hence, in case of a therapeutical benefit due to
a co-administration of a p-gp inhibitor with an antitumor agent in vivo, the effect is
attributable to the modulation of the p-gp mediated efflux of the chemotherapeutic at
the BBB. Two different therapeutic experiments were performed. As a model of non-
small cell lung cancer metastases, intacerebrally implanted human NCI-H460 cells were
treated with a combination of valspodar and vinblastine (50 mg/kg of valspodar p.o.;
0.8 mg/kg of vinblastine i.p., every 5 day). Brain metastases of small cell lung cancer
were simulated by the intracerebral injection of DMS 114 cells. These tumors were treated
with a combination of valspodar and paclitaxel (50 mg/kg of valspodar p.o.; 3 mg/kg of
paclitaxel i.v. on day 8, and 2 mg/kg on day 15). Although the combination of the p-gp
modulator with the aforementioned chemotherapeutic agents resulted in a recovery of the
chemosensitivity of p-gp overexpressing Kb-V1/VBL cells in vitro, no therapeutic benefit
was observed in the intracerebral tumor models. The high aggressiveness of NCI-H460
cells together with the rapid cell proliferation may be the reason for the negative in vivo
result. Furthermore, the increase in the vinblastine concentration in the brain, resulting
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from the p-gp inhibition by valspodar seemed to be extremely low. In case of intracranial
DMS 114 tumors chemosensitivity of DMS 114 cells against paclitaxel seemed to be lower
compared to the in vitro sensitivity, because, despite of paclitaxel concentrations sufficient
for a cytocidal effect in vitro, tumor growth was not affected in vivo.
Recently, new p-gp modulators had been developed, which were reported to be more
potent compared to valspodar and could therefore be superior to valspodar in a combina-
tion therapy approach to the treatment of secondary brain tumors. These new modulators
include the compounds elacridar and tariquidar. Both modulators were characterized with
respect to their activity to inhibit p-gp mediated efflux and their specificity against other
ABC proteins present at the BBB, particularly the ABCG2 transporter. Both compounds
showed an up to 80 times higher inhibitory activity against p-gp than valspodar with IC50
values of 20.5 nM for elacridar and 26.5 nM in case of tariquidar. Since elacridar and
tariquidar are structurally related, the common moiety 4-[2-(6,7-dimethoxy-3,4-dihydro-
1H-isoquinolin-2-yl)ethyl]phenylamine, designated as compound 4, was examined with
regard to its inhibitory activity, too. Compound 4 has an IC50 value of 42.7 µM, which
is 6 times lower compared to the IC50 value of the 1st generation p-gp modulator (R)-
verapamil (248 µM). Hence, it was assumed that this structural element is important
for the inhibition of p-gp mediated drug efflux. Elacridar and tariquidar are non-specific
modulators as both compounds were able to inhibit not only the p-gp mediated efflux
but also ABCG2 transport. However, they differed concerning the selectivity for the two
ABC transport proteins. The IC50 values of elacridar and tariquidar were similar in case
of p-gp inhibition. However, the IC50 value of elacridar concerning ABCG2 transport
inhibition (0.86 µM) was 5.5 times lower compared to the corresponding IC50 value of
tariquidar (4.76 µM).
After the in vitro characterization of the new modulators elacridar and tariquidar,
the two compounds were examined with respect to their effect on the paclitaxel distri-
bution in nude mice, particularly on the brain penetration of paclitaxel. The paclitaxel
levels were detected in liver, kidney, plasma and brain of nude mice 1.5, 3, 4.5 and 24
hours after the intravenous injection of paclitaxel by HPLC. One group of the animals
received either elacridar or tariquidar 4 hours before the paclitaxel administration. An-
imals, which served as control, received the vehicle of the modulator. The results were
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compared to the paclitaxel distribution determined by Fellner (2001) after valspodar co-
administration. In contrast to valspodar, elacridar and tariquidar were detectable in the
HPLC chromatograms. Therefore, the distribution of the two modulators was determined
as well. Due to the high SEM values in the determination of accuracy and precision of
the modulator recovery, the modulator distribution was only estimated. Compared to
the IC50 values for p-gp inhibition determined in vitro, 500 to 2500 times higher elacridar
concentrations were detected in the brain samples. In case of tariquidar at least 100 times
higher concentrations were determined in the brains of nude mice. Therefore, elacridar
and tariquidar reached tissue levels sufficient for p-gp modulation. In liver and kidney
the paclitaxel concentrations were similar in the control, the elacridar and the tariquidar
group, whereas in the valspodar group the paclitaxel concentrations were significantly
higher. In the plasma of valspodar treated mice the paclitaxel levels were about 10 times
higher than in the plasma of mice treated with tariquidar, elacridar or vehicle. Without
modulator the paclitaxel levels in the brain were close to the limit of quantification. The
paclitaxel concentrations in the brains of the valspodar group were 5 to 8.5 times higher
than in the control group, whereas in the elacridar and tariquidar groups an only 4-fold
increase compared to the control group was measured. Compared with valspodar, the
brain/plasma ratio of paclitaxel in mice treated with elacridar or tariquidar indicates a
more specific accumulation of paclitaxel in the brain. Although the increase in pacli-
taxel brain concentration in case of elacridar and tariquidar co-administration was not
as pronounced as in case of valspodar, a dose reduction of anticancer drugs, as in case
of valspodar paclitaxel co-administration, seems unnecessary with the new modulators,
due to the lack of p-gp modulation in liver and kidney, and the low cytostatic drugs
concentrations in plasma.
Another method to increase intracerebral drug concentrations is the utilization of the
transferrin receptor (TfR) mediated transcytosis at the BBB for drug delivery to the brain.
To be able to perform treatment studies with cytostatic drug loaded immunoliposomes
targeted to the transferrin receptor both at the BBB and in tumor cells, a tumor model
of primary brain tumors in the brain of nude rats was established. For this purpose, three
human glioblastoma cell lines were examined, but only the U-373 MG cells turned out
to be suited as an orthotopic tumor model. U-373 MG cells express a sufficient amount
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of TfR and were most sensitive to the cytostatic drugs doxorubicin and daunorubicin,
which are planned to be used in in vivo experiments. The developed U-373 MG tumors
in brains of nude rats three weeks after cell implantation were of sufficient size and were
well tolerated by the animals.
In summary, the administration of p-gp modulators of the 3rd generation in combination
with anticancer drugs is a promising strategy for the treatment of primary and secondary
brain tumors. Approaches exploiting specific transcytotic pathways at the BBB might also
enhance the concentrations of cytostatic drugs in the brain, a prerequisite for a successful
therapy of malignant brain tumors.
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List of abbreviations
ABC ATP-binding cassette
ABCP ABC transporter highly expressed in placenta
ADP adenosine-5’diphosphate
AM acetoxymethyl ester
AMT absorption mediated transcytosis
ATCC American Type Culture Collection
ATP adenosine-5’ triphosphate
AUC area under the concentration/time curve
BBB blood-brain barrier
BCB blood-cerebrospinal fluid barrier
BCEC brain capillary endothelial cells
BCRP breast cancer resistant protein
bp base pairs
BSA bovine serum albumin
cDNA copy DNA
CNS central nervous system
CPD citrate-phosphate-dextrose
CSF cerebrospinal fluid
CVO circumventricular organs
Da dalton
DCC 1,3-dicyclohexylcarbodiimide
DEPC diethyl pyrocarbonate
DMF N,N-dimethylformamide
DMEM Dulbecco’s Modified Eagle Medium
DMS Dartmouth Medical School
DMSO dimethyl sulfoxide
DNA desoxyribonucleic acid
DTT dithiothreitol
EDTA ethylenediaminetetraacetic acid
EGFP enhanced green fluorescent protein
EMEM Eagles Minimum Essential Medium
FCS fetal calf serum
FITC fluorescein-5-isothiocyanate
GFAP glial fibrillary acidic protein
GFP green fluorescent protein
GLUT glucose transporter
h hour
HE haematoxyline-eosin
HOBt 1-hydroxybenzotriazole
HPLC high performance liquid chromatography
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HUGO Human Genome Organisation
IC50 concentration of inhibitor required to give a 50 % inhibition of activity
i.p. intraperitoneal
i.v. intravenous
λ wave length
LAT large neutral amino acid transporter
LDL low density lipoprotein
log Po/w logarithm of the partition coefficient octanol/water
MAb monoclonal antibody
MDR multidrug resistance
MESF molecules of equivalent soluble fluorescence
MG Masson-Goldner
min minute
Mp melting point
mRNA messenger RNA
MRP multidrug resistance-associated protein
MS mass spectrometry
MSD membrane spanning domains
MW molecular weight
MXR mitoxantrone resistance
NAD nicotinamide adenine dinucleotide
NADH 1,4-dihydronicotinamide adenine dinucleotide
NBD nucleotide binding domain
NCI National Cancer Institute
N-SCLC non small cell lung cancer
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin
PEG polyethylene glycol
p-gp p-glycoprotein 170
pH negative logarithm of the hydrogen ion concentration
p.o. per os
RMT receptor mediated transcytosis
RNA ribonucleic acid
RP reversed phase
RPMI Roswell Park Memorial Institute
RT-PCR reverse transcription-polymerase chain reaction
s second
SCLC small cell lung cancer
SEM standard error of the mean
SPE solid phase extraction
TfR transferrin receptor
TMD transmembrane domain
Topo topotecan
UV ultra violet
VBL vinblastine
VP verapamil
WHO World health organization
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